

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	30	FEB 26	MEDLINE reloaded with enhancements
NEWS	31	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	32	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	33	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	34	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:15:39 ON 02 MAR 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:15:53 ON 02 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 FEB 2007 HIGHEST RN 923894-67-1

DICTIONARY FILE UPDATES: 28 FEB 2007 HIGHEST RN 923894-67-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s telmisartan

L1 8 TELMISARTAN

=> d 8

L1 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2007 ACS on STN

RN 144701-48-4 REGISTRY

ED Entered STN: 02 Dec 1992

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]- (9CI)

OTHER NAMES:

CN 4'-[[4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl]-2-biphenylcarboxylic acid

CN BIBR 277

CN BIBR 277SE  
 CN Micardis  
 CN Pritor  
 CN Telmisartan  
 MF C33 H30 N4 O2  
 CI COM  
 SR CA  
 LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA,  
 CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM,  
 DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE,  
 MRCK\*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SCISEARCH,  
 SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: WHO



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

598 REFERENCES IN FILE CA (1907 TO DATE)  
 9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 600 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus uspatful medline  
 COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	7.35	7.56

FILE 'CAPLUS' ENTERED AT 12:16:26 ON 02 MAR 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:16:26 ON 02 MAR 2007  
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:16:26 ON 02 MAR 2007

=> s l1 or telmisartan or pritor or micardis or bibr 277 or bibr 277se  
 L2 1943 L1 OR TELMISARTAN OR PRITOR OR MICARDIS OR BIBR 277 OR BIBR  
 277SE

=> s 12 and (diabetes or diabete or insuline resistance or hyperinsulinemia or  
glucose intolerance or insuline sensitivity )  
L3 761 L2 AND (DIABETES OR DIABETE OR INSULINE RESISTANCE OR HYPERINSUL  
INEMIA OR GLUCOSE INTOLERANCE OR INSULINE SENSITIVITY )

=> s 13 and pd<+2003  
<-----User Break----->

=> s 13 and pd<=2003  
L4 124 L3 AND PD<=2003

=> dup rem 14  
PROCESSING COMPLETED FOR L4  
L5 113 DUP REM L4 (11 DUPLICATES REMOVED)

=> focus  
PROCESSING COMPLETED FOR L5  
L6 113 FOCUS L5 1-

=> d ibib abs hitstr 1-113

L6 ANSWER 1 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:96709 CAPLUS  
DOCUMENT NUMBER: 138:163224  
TITLE: Effects of telmisartan on arterial stiffness  
in type 2 diabetes patients with essential  
hypertension  
AUTHOR(S): Asmar, Roland; Gosse, Phillipe; Topouchian, Jirar;  
N'tela, Gilbert; Dudley, Amanda; Shepherd, Gillian L.  
CORPORATE SOURCE: The Cardiovascular Institute, Paris, Fr.  
SOURCE: JRAAS (2002), 3(3), 176-180  
CODEN: JRAAAG; ISSN: 1470-3203  
PUBLISHER: JRAAS Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Arterial wall stiffness, an important independent risk factor for  
cardiovascular disease in patients with hypertension, is worsened by the  
coexistence of diabetes mellitus. This randomized, prospective,  
double-blind, crossover trial assessed the effects of telmisartan  
on arterial stiffness in patients with Type 2 diabetes with  
essential hypertension. After a two-week placebo wash out period, 28  
ambulatory patients received telmisartan (40 mg) or placebo for  
three weeks. Following a second two-week placebo wash out period,  
patients received the alternate treatment for a further three weeks.  
Augmentation index and central blood pressure (BP) were determined using the  
SphygmoCor device and pulse wave velocity (PWV) was measured using an  
automatic device, the Complior, at the beginning and the end of each  
period. Telmisartan significantly reduced the carotid-femoral  
PWV compared with placebo (mean adjusted treatment difference -0.95 m/s;  
95% CI: -1.67, -0.23 m/s; p = 0.013). Peripheral and central diastolic,  
systolic and pulse pressures were also significantly reduced with  
telmisartan compared with placebo. In conclusion,  
telmisartan reduces arterial stiffness and peripheral and central  
BPs as assessed by PWV and pulse contour anal. in hypertensive patients  
with Type 2 diabetes. These properties of telmisartan  
suggest that it may improve cardiovascular outcome in this patient  
population.


IT 144701-48-4, Telmisartan  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(telmisartan effect on arterial stiffness in type 2  
diabetes patients with essential hypertension)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-



benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:824351 CAPLUS

DOCUMENT NUMBER: 136:112467

TITLE: Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and type 2 diabetes mellitus

AUTHOR(S): Asmar, Roland

CORPORATE SOURCE: The Cardiovascular Institute, Paris, 75016, Fr.

SOURCE: JRAAS (2001), 2(Suppl. 2), S8-S11

CODEN: JRAAAG; ISSN: 1470-3203

PUBLISHER: JRAAS Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Arterial wall stiffness is an important independent risk factor for cardiovascular disease in hypertensive patients, which is further exacerbated by co-existent diabetes mellitus. Increased arterial stiffness is directly associated with an increase in pulse wave velocity (PWV) and indirectly with increased central and peripheral blood pressure. Following a two-week placebo run-in period, 27 patients with mild to moderate essential hypertension and Type 2 diabetes mellitus, were randomized to once daily treatment with either telmisartan 40 mg or placebo for three weeks, and after a two-week washout period, crossed-over to the alternative treatment for a further three weeks. Carotid/femoral and carotid/radial PWV were measured non-invasively using the automatic Complior device, and central parameters (central blood pressure, pulse contour anal., and augmentation index) were measured using the SphygmoCor system, at the start and end of each treatment period. Compared with placebo, treatment with telmisartan significantly reduced carotid/femoral PWV (mean adjusted treatment difference -0.95 m/s, 95% confidence intervals: -1.67, -0.23 m/s,  $p=0.013$ ), as well as peripheral and central diastolic, systolic and pulse pressure. In conclusion, the results of this study show that telmisartan is effective in reducing arterial stiffness in hypertensive patients with Type 2 diabetes mellitus, and may potentially have beneficial effects on cardiovascular outcomes, beyond blood-pressure lowering effects, in this patient group.


IT 144701-48-4, Telmisartan

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)  
(telmisartan effect on arterial distensibility and central  
blood pressure in patients with hypertension and type 2  
diabetes mellitus)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-  
benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:795609 CAPLUS

DOCUMENT NUMBER: 139:270158

TITLE: The telmisartan programme of research to  
show telmisartan end-organ protection  
(PROTECTION) programme

AUTHOR(S): Weber, Michael

CORPORATE SOURCE: State University of New York Downstate College of  
Medicine, New York, USA

SOURCE: Journal of Hypertension (2003), 21(Suppl.  
6), S37-S46

CODEN: JOHYD3; ISSN: 0263-6352

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Angiotensin-II receptor blockers (ARBs) have been shown to  
provide stroke, cardiac and renal protection in high-risk hypertensive  
patients. Telmisartan is a powerful and selective ARB that  
provides sustained blood pressure reduction for a full 24 h after a single  
dose and continues to protect against circadian blood pressure surges in  
the critical early morning hours. The objective of the Program of Research  
to show Telmisartan End-organ protection (PROTECTION) is to  
measure the end-organ protective effects of telmisartan in  
patients at high risk of renal, cardiac and vascular damage. An extensive  
series of clin. trials is being conducted to compare telmisartan  
with valsartan, losartan, amlodipine and ramipril in patients at increased  
risk of end-organ damage. Nine clin. studies will examine the effects of  
telmisartan in about 5000 hypertensive patients with isolated  
systolic hypertension, type 2 diabetes, obesity, left  
ventricular hypertrophy or renal disease. All of the studies will be  
conducted using state-of-the-art technol., including such techniques as  
ambulatory blood pressure monitoring and magnetic resonance imaging. This  
program will also investigate the effects of an ARB on key surrogate

markers of organ tissue damage. This series of trials will characterize the end-organ protective effects of telmisartan in hypertensive patient populations at high risk of clin. events.


IT 144701-48-4, Telmisartan

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(telmisartan treatment for end-organ protection in hypertensive patients and the telmisartan program PROTECTION)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:306863 CAPLUS

DOCUMENT NUMBER: 135:251642

TITLE: Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats

AUTHOR(S): Wienen, Wolfgang; Richard, Serge; Champeroux, Pascal; Audeval-Gerard, Chantal

CORPORATE SOURCE: Department of Pharma Research, Boehringer Ingelheim Pharma KG, Biberach, Germany

SOURCE: JRAAS (2001), 2(1), 31-36  
CODEN: JRAAAG; ISSN: 1470-3203

PUBLISHER: JRAAS Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This study compared the cardiovascular and renal effects of long-term telmisartan (3 and 10 mg/kg/day) and lisinopril (10 mg/kg/day) in an animal model combining hypertension and diabetes mellitus. It was a parallel-group study of diabetic, spontaneously hypertensive rats (SHR), treated with control or active treatment for eight months. A non-diabetic SHR control group was run in parallel. Diabetes was induced by streptozotocin (45 mg/kg i.v.) in SHRs aged 9-10 wk. Animals were treated with telmisartan (3 or 10 mg/kg/day), lisinopril (10 mg/kg/day) or vehicle. Plasma glucose levels, blood pressure (BP), and urinary protein and albumin excretion were measured monthly. Telmisartan treatment significantly reduced BP of diabetic SHRs in a dose-dependent manner ( $p < 0.05$ , low-dose,  $n = 18$ ;  $p < 0.01$ , high-dose,  $n = 15$ ). The BP reduction in the lisinopril group was similar to that in the telmisartan 10 mg/kg/day group. Compared with

non-diabetic SHR, untreated diabetic SHR developed severe proteinuria and albuminuria over the exptl. period ( $p < 0.01$ ). In diabetic SHR, proteinuria and albuminuria were dose-dependently and significantly attenuated by treatment with telmisartan ( $p < 0.01$  with the higher dose) and lisinopril ( $p < 0.01$ ). Compared with the untreated diabetic SHR, cardiac hypertrophy was significantly reduced after treatment with both doses of telmisartan and with lisinopril. Telmisartan, 10 mg/kg/day, but not lisinopril, significantly attenuated the diabetes-induced increase in glomerular volume. In conclusion, telmisartan, 10 mg/kg/day, is at least as beneficial as lisinopril, 10 mg/kg/day, in lowering BP, reducing cardiac hypertrophy and attenuating renal excretion of protein and albumin in this model.


IT 144701-48-4, Telmisartan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(comparative antihypertensive, renoprotective, and cardioprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:656399 CAPLUS

DOCUMENT NUMBER: 139:191449

TITLE: Renin-angiotensin II system inhibitor in diabetes mellitus diagnosis and therapy

INVENTOR(S): Pedersen-Bjergaard, Ulrik; Agerholm-Larsen, Birgit; Thorsteinsson, Birger; Pramming, Stig

PATENT ASSIGNEE(S): Den.

SOURCE: U.S. Pat. Appl. Publ., 17 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 2003158090	A1	20030821	US 2002-195330	20021004 <--

PRIORITY APPLN. INFO.:

US 2001-306859P

P 20010723


AB The present invention provides novel methods of treatment of diabetes mellitus as well as methods of diagnosing the susceptibility of hypoglycemia in an individual. The method of treatment includes administering to an individual a sufficient amount of at least one inhibitor of the renin-angiotensin II system and at least one antidiabetic, for example insulin. Another objective of the present invention is to provide methods of preventing hypoglycemia in an individual in need thereof comprising administering to said individual a pharmaceutical effective amount of an inhibitor of the renin-angiotensin II system. In particular, such an individual may be an individual suffering from diabetes mellitus. A further objective of the present invention is to provide methods to diagnose the susceptibility to hypoglycemia of an individual comprising detecting within a predetd. tissue sample the genotype of the angiotensin-converting enzyme (ACE) gene; or detecting within a predetd. tissue sample the activity of ACE; and correlating said genotype or activity to the susceptibility of hypoglycemia.

IT 144701-48-4, Telmisartan

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(renin-angiotensin II system inhibitor in diabetes mellitus diagnosis and therapy)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 6 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:376495 CAPLUS

DOCUMENT NUMBER: 135:236137

TITLE: The role of angiotensin II receptor antagonists in the management of diabetes

AUTHOR(S): Barnett, Anthony H.

CORPORATE SOURCE: Birmingham Heartlands Hospital, Birmingham, UK

SOURCE: Blood Pressure, Supplement (2001), (1), 21-26

CODEN: BPSUEY; ISSN: 0803-8023

PUBLISHER: Taylor & Francis

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Diabetic nephropathy, which develops in about 30% of patients with diabetes, is a progressive condition. It is characterized by increased blood pressure, declining glomerular filtration rate and

albuminuria. Lowering of blood pressure in diabetic patients is associated with reduced cardiovascular risk and renal protection. Inhibitors of angiotensin-converting enzyme (ACE) are the current gold standard treatment for hypertension in patients with type I diabetes because, in addition to their blood pressure lowering ability, they are thought to oppose the increased intraglomerular pressure that is mediated in part by angiotensin II. The angiotensin II receptor antagonists, a more recently developed class of antihypertensive agents, appear to be as effective as ACE inhibitors in delaying the progression of renal injury in animal models of diabetes. They act by selectively blocking the binding of angiotensin II to the AT1 receptor and may, therefore, offer a more complete blockade of the renin-angiotensin system than ACE inhibitors. The renal and antihypertensive effects of this class of drug in patients with diabetes are now being investigated in long-term clin. trials. The multicenter Diabetics Exposed to Telmisartan And Enalapril (DETAIL) study is a randomized, double-blind, parallel-group comparison of the renal and antihypertensive effects of the angiotensin II receptor antagonist telmisartan and the ACE inhibitor enalapril in 272 patients with type II diabetes. The primary outcome is change in glomerular filtration rate over the 5 yr of the study.


IT 144701-48-4, Telmisartan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(role of angiotensin II receptor antagonists in management of diabetes)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT:

41

THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:167787 CAPLUS

DOCUMENT NUMBER: 134:202715

TITLE: Pharmaceutical formulations of ACE and ATII inhibitors for prevention of stroke, diabetes and/or congestive heart failure

INVENTOR(S): Schoelkens, Bernward; Bender, Norbert; Rangoonwala, Badrudin; Dagenais, Gilles; Gerstein, Hertzal; Ljunggren, Anders; Yusuf, Salim

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany



SOURCE: PCT Int. Appl., 17 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015673	A2	20010308	WO 2000-EP8341	20000825 <--
WO 2001015673	A3	20020307		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2382387	C	20010308	CA 2000-2382387	20000825 <--
CA 2382387	A1	20010308		
CA 2500709	A1	20010308	CA 2000-2500709	20000825 <--
BR 2000013540	A	20020430	BR 2000-13540	20000825 <--
EP 1212081	A2	20020612	EP 2000-965898	20000825 <--
EP 1212081	B1	20051026		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200200518	T2	20020621	TR 2002-518	20000825 <--
TR 200202466	T2	20021223	TR 2002-2466	20000825 <--
TR 200202467	T2	20021223	TR 2002-2467	20000825 <--
HU 200202461	A2	20021228	HU 2002-2461	20000825 <--
JP 2003508426	T	20030304	JP 2001-519887	20000825 <--
EE 200200085	A	20030415	EE 2002-85	20000825 <--
EP 1437131	A1	20040714	EP 2004-6330	20000825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 307604	T	20051115	AT 2000-965898	20000825
RU 2272651	C2	20060327	RU 2002-107673	20000825
ES 2250192	T3	20060416	ES 2000-965898	20000825
BG 106319	A	20021229	BG 2002-106319	20020118 <--
NO 2002000850	A	20020221	NO 2002-850	20020221 <--
ZA 2002001471	A	20030303	ZA 2002-1471	20020221 <--
AU 2005203694	A1	20050908	AU 2005-203694	20050817
US 2006194868	A1	20060831	US 2006-415137	20060502

PRIORITY APPLN. INFO.:

SE 1999-3028	A	19990827
AU 2000-76484	A3	20000825
CA 2000-2382387	A3	20000825
EP 2000-965898	A3	20000825
US 2000-645556	B1	20000825
WO 2000-EP8341	W	20000825

AB The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS), i.e., inhibitors of angiotensin-converting enzyme (ACE) and angiotensin II type 1 receptor (ATII) antagonists or a pharmaceutically acceptable derivative thereof, particularly ramipril or ramiprilat, in the manufacture of a medicament for the prevention and/or treatment of stroke, diabetes and/or congestive heart failure (CHF). A large-scale clin. trial was designed to examine the effect of the ACE inhibitor ramipril vs. placebo in reducing cardiovascular events. There was a clear 32% reduction in the ramipril group in the number of patients who developed a stroke, and this is surprising since patients were normotensive when recruited to the study. The number of patients who developed CHF was significantly reduced by 21% in the ramipril group, which is unexpected since patients had no signs or symptoms of CHF at

study start. Equally surprising is the marked 36% reduction in the number of patients who developed diabetes in the ramipril group.


IT 144701-48-4, Telmisartan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. of inhibitors of renin-angiotensin system for prevention and/or treatment of stroke, diabetes and/or congestive heart failure)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 8 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:78061 USPATFULL

TITLE: Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications

INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
Kosoglou, Teddy, Jamison, PA, UNITED STATES

PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003053981	A1	20030320	<--
APPLICATION INFO.:	US 2002-57534	A1	20020125	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-264600P	20010126 (60)
	US 2001-323842P	20010921 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	
NUMBER OF CLAIMS:	81	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4194	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted  $\beta$ -lactam sterol

absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2002:323139 USPATFULL  
TITLE: Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications  
INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
Kosoglou, Teddy, Jamison, PA, UNITED STATES  
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002183305	A1	20021205	<--
APPLICATION INFO.:	US 2002-57646	A1	20020125	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-264275P	20010126 (60)
	US 2001-323842P	20010921 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	
NUMBER OF CLAIMS:	81	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4256	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one of nicotinic acid or derivatives thereof; and (b) at least one substituted azetidinone or substituted  $\beta$ -lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2002:336849 USPATFULL  
TITLE: Sterol absorption inhibitor compositions  
INVENTOR(S): Cho, Wing-Kee Philip, Princeton, NJ, UNITED STATES  
Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
Kosoglou, Teddy, Jamison, PA, UNITED STATES  
Picard, Gilles J., Braine L'Alleud, BELGIUM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002192203	A1	20021219	<--
	US 7030106	B2	20060418	
APPLICATION INFO.:	US 2002-136968	A1	20020501	(10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-57323, filed on 25 Jan 2002, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-264396P	20010126 (60)
	US 2001-323839P	20010921 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1,  
1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ,  
07033-0530

NUMBER OF CLAIMS: 101

EXEMPLARY CLAIM: 1

LINE COUNT: 4987

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations  
and methods including: (a) at least one peroxisome proliferator-  
activated receptor activator; and (b) at least one substituted  
azetidinone or substituted  $\beta$ -lactam sterol absorption inhibitor  
which can be useful for treating vascular conditions, diabetes  
, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2002:273408 USPATFULL

TITLE: Combinations of peroxisome proliferator-activated  
receptor (PPAR) activator(s) and sterol absorption  
inhibitor(s) and treatments for vascular indications

INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES

Kosoglou, Teddy, Jamison, PA, UNITED STATES

Picard, Gilles J., Brussels, BELGIUM

PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002151536	A1	20021017	<--
APPLICATION INFO.:	US 2002-57323	A1	20020125	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-264396P	20010126 (60)
	US 2001-323839P	20010921 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1,  
1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ,  
07033-0530

NUMBER OF CLAIMS: 101

EXEMPLARY CLAIM: 1

LINE COUNT: 5004

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations  
and methods including: (a) at least one peroxisome proliferator-  
activated receptor activator; and (b) at least one substituted  
azetidinone or substituted  $\beta$ -lactam sterol absorption inhibitor  
which can be useful for treating vascular conditions, diabetes  
, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:283080 USPATFULL

TITLE: Method of treatment and/or prophylaxis

INVENTOR(S): Smith, Maree Therese, Bardon, AUSTRALIA

Brown, Lindsay Charles, Sinnamon Park, AUSTRALIA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003199424	A1	20031023	<--
APPLICATION INFO.:	US 2003-393056	A1	20030320	(10).


	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-365858P	20020320 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111	
NUMBER OF CLAIMS:	64	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	2302	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to the use of angiotensin II receptor I (AT.sub.1 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of a neuropathic condition, especially a peripheral neuropathic condition such as painful diabetic neuropathy, in vertebrate animals and particularly in human subjects. The present invention also discloses the use of AT.sub.1 receptor antagonists for preventing, attenuating or reversing the development of reduced opioid sensitivity, and more particularly reduced opioid analgesic sensitivity, in individuals and especially in individuals having, or at risk of developing, a neuropathic condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(method of treatment and prophylaxis of neuropathic condition)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 13 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:245001 USPATFULL  
TITLE: Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors  
INVENTOR(S): Boehm, Peter, Gau-Algesheim, GERMANY, FEDERAL REPUBLIC OF  
Meinicke, Wolf Thomas, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF  
PATENT ASSIGNEE(S): Riedel, Axel, Maselheim, GERMANY, FEDERAL REPUBLIC OF  
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003171415	A1	20030911
APPLICATION INFO.:	US 2003-354713	A1	20030130 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2001-EP9428, filed on 16 Aug 2001, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-20691	20000822
	DE 2001-DE108215	20010220
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	574	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A method of treatment of indications which can be positively influenced by inhibition of AT.sub.1 mediated effects with maintenance of AT.sub.2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death, or of indications associated with the increase of AT.sub.1 receptors in the subepithelial area or increase of AT.sub.2 receptors in the epithelia, comprising coadministration of effective amounts of an angiotensin II antagonist and an ACE inhibitor, pharmaceutical compositions containing an angiotensin II antagonist together with an ACE inhibitor and the use of an angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)





TITLE: Amino acid complexes of C-aryl glucosides for treatment of diabetes and method  
INVENTOR(S): Gougoutas, Jack Z., Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003064935	A1	20030403	<--
	US 6774112	B2	20040810	
APPLICATION INFO.:	US 2002-117914	A1	20020408	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-283097P	20010411 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1995	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Crystalline complexes are obtained from a 1:1 or 2:1 mixtures of either the (D) or (L) enantiomer of natural amino acids and compounds of formula ##STR1##

wherein

R.sup.1, R.sup.2 and R.sup.2a are independently hydrogen, OH, OR.sup.5, alkyl, --OCHF.sub.2, --OCF.sub.3, --SR.sup.5a or halogen;

R.sup.3 and R.sup.4 are independently hydrogen, OH, OR.sup.5b, alkyl, cycloalkyl, CF.sub.3, --OCHF.sub.2, --OCF.sub.3, halogen, --CONR.sup.6R.sup.6a, --CO.sub.2R.sup.5c, --CO.sub.2H, --COR.sup.6b, --CH(OH)R.sup.6c, --CH(OR.sup.5d)R.sup.6d, --CN, --NHCOR.sup.5e, --NHSO.sub.2R.sup.5f, --NHSO.sub.2Aryl, --SR.sup.5g, --SOR.sup.5h, --SO.sub.2R.sup.5i, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2, or R.sup.3 and R.sup.4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2;

R.sup.5, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.5d, R.sup.5e, R.sup.5f, R.sup.5g, R.sup.5h and R.sup.5i are independently alkyl;

R.sup.6, R.sup.6a, R.sup.6b, R.sup.6c and R.sup.6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R.sup.6 and R.sup.6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2.

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above complex alone or in combination with another antidiabetic agent or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:759925 CAPLUS

DOCUMENT NUMBER: 139:316443

TITLE: Renal involvement in hypertensive cardiovascular disease

AUTHOR(S): Sharma, A. M.

CORPORATE SOURCE: McMaster University, Hamilton, ON, Can.  
SOURCE: European Heart Journal Supplements (2003),  
5(Suppl. F), F12-F18  
CODEN: EHJSFT; ISSN: 1520-765X  
PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Cardiovascular morbidity and mortality are elevated in renally impaired patients, especially if they are hypertensive. Diabetes is also associated with a high prevalence of cardiovascular morbidity and end-stage renal disease. Albuminuria, elevated serum creatinine, decreased creatinine clearance and proteinuria independently predict cardiovascular risk. Even patients with mild renal impairment should be treated to slow kidney disease progression and reduce vascular damage. Blood pressure control is effective in reducing vascular complications of diabetes, but not all classes of antihypertensive agents provide renoprotection. Angiotensin-converting enzyme inhibitors are superior to beta-blockers in preventing or delaying the loss of kidney function associated with hypertension. The renoprotection appears to be in part independent of the antihypertensive effect. Angiotensin II receptor blockers (ARBs) also reduce the risk of renal complications in diabetics. Telmisartan seems well suited to provide renoprotection because, unlike other ARBs, it is almost exclusively excreted by the liver and no initial dose adjustment is required for patients with mild-to-moderate renal impairment. Other advantages of telmisartan include its very high volume of distribution and long terminal elimination half-life. Clin. trials to evaluate telmisartan will address the problems of diabetes, renal impairment and end-organ disease.


IT 144701-48-4, Telmisartan

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(relationship between hypertensive cardiovascular disease and renal disease)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:166532 USPATFULL

TITLE: C-aryl glucoside SGLT2 inhibitors and method

INVENTOR(S): Washburn, William N., Titusville, NJ, UNITED STATES

Ellsworth, Bruce, Princeton, NJ, UNITED STATES  
Meng, Wei, Pennington, NJ, UNITED STATES  
Wu, Gang, Princeton, NJ, UNITED STATES  
Sher, Philip M., Plainsboro, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003114390	A1	20030619	<--
	US 6936590	B2	20050830	
APPLICATION INFO.:	US 2002-264410	A1	20021004	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-805341, filed on 13 Mar 2001, ABANDONED			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000			
NUMBER OF CLAIMS:	24			
EXEMPLARY CLAIM:	1			
LINE COUNT:	2410			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula ##STR1##

alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:96100 USPATFULL  
TITLE: Retinoid-related receptor function regulating agent  
INVENTOR(S): Sugiyama, Yasuo, Kawanishi, JAPAN  
Momose, Yu, Takarazuka, JAPAN  
Kimura, Hiroyuki, Sakai, JAPAN  
Sakamoto, Junichi, Toyonaka, JAPAN  
Odaka, Hiroyuki, Kobe, JAPAN  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, JAPAN  
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6545009	B1	20030408	<--
	WO 2000001679		20000113	<--
APPLICATION INFO.:	US 2000-720644	.	20001228	(9)
	WO 1999-JP3520		19990630	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-186698	19980701
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Tsang, Cecilia	
ASSISTANT EXAMINER:	Sackey, Ebenezer	
LEGAL REPRESENTATIVE:	Cha, Mark, Ramesh, Elaine	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2740	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 1,3-Azole derivatives, pharmaceutical compositions thereof and methods for regulating the function of retinoid-related receptors with 1,3-azole derivatives are disclosed. Such regulation may be useful for preventing or treating diabetes, preventing or treating hyperlipidemia,

preventing or treating impaired glucose tolerance (IGT) or for preventing transition from impaired glucose tolerance to diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:251945 USPATFULL  
TITLE: C-aryl glucoside SGLT2 inhibitors and method  
INVENTOR(S): Ellsworth, Bruce, Princeton, NJ, UNITED STATES  
Washburn, William N., Titusville, NJ, UNITED STATES  
Sher, Philip M., Plainsboro, NJ, UNITED STATES  
Wu, Gang, Princeton, NJ, UNITED STATES  
Meng, Wei, Pennington, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002137903	A1	20020926	<--
	US 6515117	B2	20030204	
APPLICATION INFO.:	US 2002-151436	A1	20020520	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-679027, filed on 4 Oct 2000, GRANTED, Pat. No. US 6414126			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-194615P	20000405 (60)
	US 1999-158773P	19991012 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1148	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An SGLT2 inhibiting compound is provided having the formula ##STR1##

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:160855 USPATFULL  
TITLE: C-aryl glucoside SGLT2 inhibitors and method  
INVENTOR(S): Ellsworth, Bruce, Princeton, NJ, United States  
Washburn, William N., Titusville, NJ, United States  
Sher, Philip M., Plainsboro, NJ, United States  
Wu, Gang, Princeton, NJ, United States  
Meng, Wei, Pennington, NJ, United States  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6414126	B1	20020702	<--
APPLICATION INFO.:	US 2000-679027		20001004	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-194615P	20000405 (60)
	US 1999-158773P	19991012 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Gitomer, Ralph  
 ASSISTANT EXAMINER: Khare, Devesh  
 LEGAL REPRESENTATIVE: Provoost, Jonathan N.  
 NUMBER OF CLAIMS: 30  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
 LINE COUNT: 2425  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB SGLT2 inhibiting compounds are provided having the formula ##STR1##

where

R.sup.1, R.sup.2, and R.sup.2a are independently hydrogen, OH, OR.sup.5, lower alkyl, CF.sub.3, OCHF.sub.2, OCF.sub.3, SR.sup.5i or halogen, or two of R.sup.1, R.sup.2 and R.sup.2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle;

R.sup.3 and R.sup.4 are independently hydrogen, OH, OR.sup.5a, OAryl, OCH.sub.2Aryl, lower alkyl, cycloalkyl, CF.sub.3, --OCHF.sub.2, --OCF.sub.3, halogen, --CN, --CO.sub.2R.sup.5b, --CO.sub.2H, --COR.sup.6b, --CH(OH)R.sup.6c, --CH(OR.sup.5h)R.sup.6d, --CONR.sup.6R.sup.6a, --NHCOR.sup.5c, --NHSO.sub.2R.sup.5d, --NHSO.sub.2Aryl, Aryl, --SR.sup.5e, --SOR.sup.5f, --SO.sub.2R.sup.5g, --SO.sub.2Aryl, or a five, six or seven membered heterocycle, or R.sup.3 and R.sup.4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle;

R.sup.5, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.5d, R.sup.5e, R.sup.5f, R.sup.5g, R.sup.5h and R.sup.5i are independently lower alkyl;

R.sup.6, R.sup.6a, R.sup.6b, R.sup.6c and R.sup.6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R.sup.6 and R.sup.6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle;

A is O, S, NH, or (CH.sub.2).sub.n where n is 0-3.

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:265968 USPATFULL  
 TITLE: Oxyiminoalkanoic acid derivatives  
 INVENTOR(S): Momose, Yu, Hyogo, JAPAN  
 Odaka, Hiroyuki, Hyogo, JAPAN  
 Imoto, Hiroshi, Shiga, JAPAN  
 Kimura, Hiroyuki, Osaka, JAPAN  
 Sakamoto, Junichi, Osaka, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003186985	A1	20031002
	US 6924300	B2	20050802
APPLICATION INFO.:	US 2002-331056	A1	20021227 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-714699, filed on 16 Nov 2000, GRANTED, Pat. No. US 6495581 Division of Ser. No. US 1999-423854, filed on 15 Nov 1999, GRANTED, Pat. No.		



	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-127921	19980511
	JP 1998-127922	19980511
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6054	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB To provide a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

A compound represented by the formula: ##STR1##

wherein R.sup.1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, --CO--, --CH(OH)-- or a group represented by --NR.sup.6-- wherein R.sup.6 is a hydrogen atom or an optionally substituted alkyl group; n is an integer of 1 to 3; Y is an oxygen atom, a sulfur atom, --SO--, --SO.sub.2-- or a group represented by --NR.sup.7-- wherein R.sup.7 is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R.sup.2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R.sup.3 is a hydroxy group, OR.sup.8 (R.sup.8 is an optionally substituted hydrocarbon group.) or NR.sup.9R.sup.10 (R.sup.9 and R.sup.10 are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group or R.sup.9 and R.sup.10 combine together to form a ring); R.sup.4 and R.sup.5 are the same or different groups which are selected from a hydrogen atom or an optionally substituted hydrocarbon group wherein R.sup.4 may form a ring with R.sup.2; provided that when R.sup.1 is a ethoxymethyl, a C.sub.1-3 alkyl, phenyl or p-methoxyphenyl and q=m=0, R.sup.3 is NR.sup.9R.sup.10; and provided that O-[2-chloro-4-(2-quinolylmethoxy)phenylmethyl]oxime and a methylpyruvate of [2-chloro-4-(2-quinolylmethoxy)phenylmethyl]-2-iminoxypropionic acid are excluded; or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:106793 USPATFULL  
TITLE: Method of treatment  
INVENTOR(S): Shahinfar, Shahnaz, Newton Square, PA, UNITED STATES  
Zhang, Zhongxin, Blue Bell, PA, UNITED STATES  
Brenner, Barry M., Weston, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003073705	A1	20030417	<--
APPLICATION INFO.:	US 2002-143415	A1	20020510	(10)

NUMBER	DATE
--------	------



-----  
PRIORITY INFORMATION: US 2001-290839P 20010514 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907  
NUMBER OF CLAIMS: 32  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 6 Drawing Page(s)  
LINE COUNT: 1200

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This disclosure relates to a method of preventing end stage renal disease using an angiotensin II antagonist in patients with impaired renal function. Angiotensin II antagonists such as candesartan, cilexetil, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, 2-butyl-4-chloro-1-[(2'-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazolecarboxylic acid and 3-(2'-(tetrazol-5-yl)-1,1'-biphen-4-yl)methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine, or pharmaceutically acceptable salts thereof are useful.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 22 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2001:97948 USPATFULL

TITLE: Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

INVENTOR(S): Momose, Yu, Takarazuka, Japan  
Odaka, Hiroyuki, Kobe, Japan  
Imoto, Hiroshi, Kusatsu, Japan  
Kimura, Hiroyuki, Sakai, Japan  
Sakamoto, Junichi, Toyonaka, Japan

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan  
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251926	B1	20010626

<--

APPLICATION INFO.: WO 9958510 19991118 <--  
 US 1999-423854 19991115 (9)  
 WO 1999-JP2407 19990510  
 19991115 PCT 371 date  
 19991115 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-127921	19980511
	JP 1998-127922	19980511
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Powers, Fiona T.	
ASSISTANT EXAMINER:	Wright, Sonya	
LEGAL REPRESENTATIVE:	Riesen, Philippe Y.	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5841	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:332756 USPATFULL  
 TITLE: Oxyiminoalkanoic acid derivatives  
 INVENTOR(S): Momose, Yu, Takarazuka, JAPAN  
 Odaka, Hiroyuki, Kobe, JAPAN  
 Imoto, Hiroshi, Kusatsu, JAPAN  
 Kimura, Hiroyuki, Sakai, JAPAN  
 Sakamoto, Junichi, Toyonaka, JAPAN  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, JAPAN  
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495581	B1	20021217 <--
APPLICATION INFO.:	US 2000-714699		20001116 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 423854, now patented, Pat. No. US 6251926		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-127921	19980511
	JP 1998-127922	19980511
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	McKane, Joseph K.	
ASSISTANT EXAMINER:	Wright, Sonya	
LEGAL REPRESENTATIVE:	Chao, Mark, Ramesh, Elaine M.	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	5850	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound represented by the formula: ##STR1##

wherein R.sup.1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, --CO--, --CH(OH)-- or a group represented by --NR.sup.6-- wherein R.sup.6 is a hydrogen atom or an optionally substituted alkyl group; n is an integer

of 1 to 3; Y is an oxygen atom, a sulfur atom, --SO--, --SO.sub.2-- or a group represented by --NR.sup.7-- wherein R.sup.7 is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R.sup.2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R.sup.3 is a hydroxy group, OR.sup.8 (R.sup.8 is an optionally substituted hydrocarbon group.) or NR.sup.9R.sup.10 (R.sup.9 and R.sup.10 are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group or R.sup.9 and R.sup.10 combine together to form a ring); R.sup.4 and R.sup.5 are the same or different groups which are selected from a hydrogen atom or an optionally substituted hydrocarbon group wherein R.sup.4 may form a ring with R.sup.2; provided that when R.sup.1 is a ethoxymethyl, a C.sub.1-3 alkyl, phenyl or p-methoxyphenyl and q=m=0, R.sup.3 is NR.sup.9R.sup.10; and provided that O-[2-chloro-4-(2-quinolylmethoxy)phenylmethyl]oxime and a methyl pyruvate of [2-chloro-4-(2-quinolylmethoxy)phenylmethyl]-2-iminoxypropionic acid are excluded; or a salt thereof which has excellent hypoglycemic and hypolipidemic actions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:283219 USPATFULL  
 TITLE: Heterocyclic containing biphenyl aP2 inhibitors and method  
 INVENTOR(S): Robl, Jeffrey A., Newtown, PA, UNITED STATES  
 Magnin, David R., Hamilton, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003199563	A1	20031023	<--
	US 6927227	B2	20050809	
APPLICATION INFO.:	US 2002-321137	A1	20021217	(10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-519079, filed on 6 Mar 2000, GRANTED, Pat. No. US 6548529			

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-127745P	19990405 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3547	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB aP2 inhibiting compounds are provided having the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X-Z and ##STR2##

are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:226410 USPATFULL  
 TITLE: Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors  
 INVENTOR(S): Anderson, Craig, Devonport/Auckland, NEW ZEALAND  
 Yusuf, Salim, Carlisle, CANADA  
 Sleight, Peter, Wheatley, Oxfordshire, UNITED KINGDOM  
 Hilbrich, Lutz, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158223	A1	20030821
APPLICATION INFO.:	US 2002-79703	A1	20020220 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	366		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treatment of dementia and/or regression of cognitive function, comprising co-administration of effective amounts of an Angiotensin II antagonist and an Angiotensin I Converting Enzyme inhibitor, pharmaceutical compositions containing an Angiotensin II antagonist together with an ACE inhibitor and the use of an Angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
 (pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors)  
 RN 144701-48-4 USPATFULL  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 26 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:172321 USPATFULL  
 TITLE: Tetrahydropyrimidone inhibitors of fatty acid binding protein and method  
 INVENTOR(S): Sulsky, Richard, West Trenton, NJ, UNITED STATES

Robl, Jeffrey A., Newtown, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002091078	A1	20020711	<--
	US 6649622	B2	20031118	
APPLICATION INFO.:	US 2001-771310	A1	20010126	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-178598P	20000128 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3597	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB aP2 inhibiting compounds are provided having the formula ##STR1##

wherein A, B, X, and Y are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2002:149184 USPATFULL

TITLE: Pyridone inhibitors of fatty acid binding protein and method

INVENTOR(S): Sulsky, Richard, West Trenton, NJ, UNITED STATES  
Robl, Jeffrey A., Newtown, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002077340	A1	20020620	<--
	US 6670380	B2	20031230	
APPLICATION INFO.:	US 2001-989212	A1	20011120	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-252014P	20001120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1335	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are provided having the formula ##STR1##

wherein A, Q, and X are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such compounds alone or in combination with other antidiabetic agents such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:888552 CAPLUS

DOCUMENT NUMBER: 137:380012

TITLE: Method of treatment for prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function

INVENTOR(S): Shahinfar, Shahnaz; Brenner, Barry M.; Zhang, Zhongxin

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092081	A1	20021121	WO 2002-US14919	20020510 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003073705	A1	20030417	US 2002-143415	20020510 <--
CA 2445913	A1	20031029	CA 2002-2445913	20020510 <--
EP 1389105	A1	20040218	EP 2002-731759	20020510
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005501815	T	20050120	JP 2002-588998	20020510
PRIORITY APPLN. INFO.:			US 2001-290839P	P 20010514
			WO 2002-US14919	W 20020510

AB This disclosure relates to a method of preventing end stage renal disease using an angiotensin II antagonist in patients with impaired renal function. Angiotensin II antagonists such as candesartan cilexetil, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, 2-butyl-4-chloro-1-(((2'-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazolecarboxylic acid and 3-(2'-(tetrazol-5-yl)-1,1'-biphen-4-yl)methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4, -b]pyridine, or pharmaceutically acceptable salts thereof are useful.

IT 144701-48-4, Telmisartan


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)





REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:226419 USPATFULL  
 TITLE: Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method  
 INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
 Zhang, Hao, Belle Mead, NJ, UNITED STATES  
 Hariharan, Narayanan, Richboro, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158232	A1	20030821
	US 6967212	B2	20051122
APPLICATION INFO.:	US 2002-294525	A1	20021114 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-153454, filed on 22 May 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-294380P	20010530 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	3975	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N; R<sup>sup.2a</sup>, R<sup>sup.2b</sup>, R<sup>sup.2c</sup>, X<sub>sub.1</sub> to X<sub>sub.7</sub>, R<sup>sup.1</sup>, R<sup>sup.2</sup>, R<sup>sup.3</sup>, R<sup>sup.3a</sup>, R<sup>sup.4</sup>, A, Y, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents. The present invention further provides a method for treating obesity and dyslipidemia in mammals including humans through simultaneous inhibition of peroxisome proliferator activated receptor-γ (PPARγ) and stimulation of peroxisome proliferator activated receptor-α (PPARα).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 30 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:134647 USPATFULL  
 TITLE: Substituted azole acid derivatives useful as  
 antidiabetic and antiobesity agents and method  
 INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
 Zhang, Hao, Belle Mead, NJ, UNITED STATES  
 Hariharan, Narayanan, Richboro, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003092736	A1	20030515	<--
APPLICATION INFO.:	US 2002-153454	A1	20020522	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-294380P	20010530 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	3412	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N; R.sup.2a, R.sup.2b, R.sup.2c, X.sub.1 to X.sub.7,  
 R.sup.1, R.sup.2, R.sup.3, R.sup.3a, R.sup.4, A, Y, m, and n are as  
 defined herein, which compounds are useful as antidiabetic,  
 hypolipidemic, and antiobesity agents. The present invention further  
 provides a method for treating obesity and dyslipidemia in mammals  
 including humans through simultaneous inhibition of peroxisome  
 proliferator activated receptor- $\gamma$  (PPAR $\gamma$ ) and stimulation of  
 peroxisome proliferator activated receptor- $\alpha$  (PPAR $\alpha$ ).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:102390 USPATFULL  
 TITLE: Heterocyclic containing biphenyl aP2 inhibitors and  
 method  
 INVENTOR(S): Robl, Jeffrey A., Newtown, PA, United States  
 Sulsky, Richard B., West Trenton, NJ, United States  
 Magnin, David R., Hamilton, NJ, United States  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United  
 States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6548529	B1	20030415	<--
APPLICATION INFO.:	US 2000-519079		20000306	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-127745P	19990405 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	McKane, Joseph K.	
ASSISTANT EXAMINER:	Shameem, Golam M M	
LEGAL REPRESENTATIVE:	Hermenau, Ronald S., Kilcoyne, John, Rodney, Burton	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	3405	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB aP2 inhibiting compounds are provided having the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X-Z and ##STR2##

are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:428761 CAPLUS

DOCUMENT NUMBER: 137:11000

TITLE: Pharmaceutical compositions containing angiotensin receptor blockers for treating sexual dysfunction

INVENTOR(S): Sahota, Pritam Singh

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen

Verwaltungsgesellschaft m.b.H.; Novartis Pharma. GmbH

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043807	A2	20020606	WO 2001-EP13976	20011129 <--
WO 2002043807	A3	20030814		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW			
RW:	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR			
CA 2430924	A1	20020606	CA 2001-2430924	20011129 <--
AU 2002026365	A5	20020611	AU 2002-26365	20011129 <--
EP 1353727	A2	20031022	EP 2001-995680	20011129 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004514703	T	20040520	JP 2002-545776	20011129
US 2002107236	A1	20020808	US 2001-8445	20011203 <--
US 2004087484	A1	20040506	US 2003-433189	20030624
PRIORITY APPLN. INFO.:			US 2000-250540P	P 20001201
			WO 2001-EP13976	W 20011129

AB The present invention relates to methods of treating sexual dysfunction associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an HMG-CoA reductase inhibitor. A film-coated tablet contained valsartan 8.00, microcryst. cellulose 54.00, crospovidone 20.00, colloidal silica 1.50, magnesium stearate 4.5, and Diolack pale red 00F34899 7.00 mg.

IT 144701-48-4, Telmisartan


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(pharmaceutical compns. containing angiotensin receptor blockers for treating sexual dysfunction)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 33 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:790344 CAPLUS  
 DOCUMENT NUMBER: 133:340269  
 TITLE: Preventives/remedies/progression inhibitors for  
 simplex retinopathy or preproliferating retinopathy  
 INVENTOR(S): Nakagawa, Shizue; Nagisa, Yasutaka; Ikeda, Hitoshi  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066161	A1	20001109	WO 2000-JP2766	20000427 <--
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2371554	A1	20001109	CA 2000-2371554	20000427 <--
BR 2000010084	A	20020115	BR 2000-10084	20000427 <--
EP 1197223	A1	20020417	EP 2000-921056	20000427 <--
EP 1197223	B1	20050216		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 514855	A	20040130	NZ 2000-514855	20000427
AU 774799	B2	20040708	AU 2000-41434	20000427
RU 2239454	C2	20041110	RU 2001-132073	20000427
AT 289204	T	20050315	AT 2000-921056	20000427
PT 1197223	T	20050429	PT 2000-921056	20000427
ES 2233362	T3	20050616	ES 2000-921056	20000427
JP 2001010975	A	20010116	JP 2000-134243	20000428 <--
US 7064141	B1	20060620	US 2001-958740	20011016
ZA 2001008527	A	20021017	ZA 2001-8527	20011017 <--
NO 2001005257	A	20011026	NO 2001-5257	20011026 <--

US 2006189669 A1 20060824 US 2006-406345 20060419  
 PRIORITY APPLN. INFO.: JP 1999-121498 A 19990428  
 WO 2000-JP2766 W 20000427  
 US 2001-958740 A3 20011016

OTHER SOURCE(S): MARPAT 133:340269

AB Disclosed are drugs which contain a compound having an angiotensin II antagonism or its salt and are useful in, for example, preventing or treating simplex retinopathy or preproliferating retinopathy by inhibiting the progression thereof. Administration of candesartan cilexetil to diabetes model rats inhibited the production of VEGF and improved retinal elec. potentials. Formulations for capsules, tablets, and ophthalmic suspensions containing the invention compds. are also provided.


IT 144701-48-4, Telmisartan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(angiotensin II antagonists for treatment of retinopathy)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 34 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:113449 USPATFULL  
 TITLE: Methods for tissue protection using highly effective inhibition of the renin-angiotensin system  
 INVENTOR(S): Weinberg, Marc S., Seekonk, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003078190	A1	20030424	<--
APPLICATION INFO.:	US 2002-155824	A1	20020524	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293835P	20010525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211	
NUMBER OF CLAIMS:	133	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	3074	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and pharmaceutical compositions are provided for protecting tissue of a subject from the effects of angiotensin II. The methods involve administering to subjects angiotensin receptor blockers (ARB), either by themselves at doses beyond those recommended or effective for the management of hypertension, or in combination with angiotensin-converting enzyme inhibitors (ACEI). The pharmaceutical compositions include both an ARB and an ACEI and are formulated in certain preferred embodiments for once-daily oral administration. The methods and pharmaceutical compositions are useful for the treatment of proteinuria, chronic or congestive heart failure, aneurysms, and vascular tissue hypertrophy.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan 144701-48-4D, Telmisartan, prodrug derivs.

(renin-angiotensin system inhibition for protecting tissue from effects of angiotensin II)


RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)





L6 ANSWER 35 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2001:36849 USPATFULL  
 TITLE: Method for reducing mortality with an angiotensin II antagonist  
 INVENTOR(S): Beere, Polly A., Lahaska, PA, United States  
 Chang, Paul I., Doylestown, PA, United States  
 Pitt, Bertram, Ann Arbor, MI, United States  
 Rucinska, Eva J., Blue Bell, PA, United States  
 Segal, Robert, Gwynedd Valley, PA, United States  
 Sharma, Divakar, Hatfield, PA, United States  
 Snavelly, Duane B., Chalfont, PA, United States  
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6201002	B1	20010313	<--
APPLICATION INFO.:	US 1998-3159		19980106	(9)


	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-34927P	19970110 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Krass, Frederick	
LEGAL REPRESENTATIVE:	Camara, Valerie J., Daniel, Mark R.	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	2373	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Angiotensin II receptor antagonists are useful in reducing and preventing mortality and sudden cardiac death in symptomatic heart failure patients. Losartan potassium has been shown to reduce mortality and sudden cardiac death in this patient population. Additionally, losartan potassium has been shown to reduce the need for hospitalization of symptomatic heart failure patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
 (angiotensin II antagonists to treat symptomatic heart failure)  
 RN 144701-48-4 USPATFULL  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 36 OF 113 MEDLINE on STN  
 ACCESSION NUMBER: 2002652897 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 12411451  
 TITLE: Angiotensin blockade prevents type 2 diabetes by  
 formation of fat cells.  
 AUTHOR: Sharma Arya M; Janke Jurgen; Gorzelniak Kerstin; Engeli  
 Stefan; Luft Friedrich C  
 CORPORATE SOURCE: HELIOS Klinikum Berlin, Franz Volhard Clinic-Charite,  
 Humboldt University of Berlin, and Max Delbrück Center for  
 Molecular Medicine, Berlin, Germany..  
 sharma@ccc.mcmaster.ca  
 SOURCE: Hypertension, (2002 Nov) Vol. 40, No. 5, pp.  
 609-11.  
 Journal code: 7906255. E-ISSN: 1524-4563.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200211  
 ENTRY DATE: Entered STN: 5 Nov 2002  
 Last Updated on STN: 11 Dec 2002  
 Entered Medline: 8 Nov 2002

AB Obesity is the prime risk factor for the development of type 2  
 diabetes. Recent clinical trials have shown that blockade of the  
 renin-angiotensin system, either by inhibiting the angiotensin-converting  
 enzyme or blocking the angiotensin type 1 receptor, may substantially  
 lower the risk for type 2 diabetes. The mechanism underlying  
 this effect is unknown. Based on our recent observation that angiotensin  
 II markedly inhibits adipogenic differentiation of human adipocytes via  
 the angiotensin type I receptor and that expression of angiotensin  
 II-forming enzymes in adipose tissue is inversely correlated with insulin  
 sensitivity, we propose the hypothesis that blockade of the  
 renin-angiotensin system prevents diabetes by promoting the  
 recruitment and differentiation of adipocytes. Increased formation of  
 adipocytes would counteract the ectopic deposition of lipids in other  
 tissues (muscle, liver, pancreas), thereby improving insulin sensitivity  
 and preventing the development of type 2 diabetes.

L6 ANSWER 37 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:122803 CAPLUS  
 DOCUMENT NUMBER: 142:219083  
 TITLE: Preparation of phosphorus-containing rapamycin  
 derivatives for use in pharmaceutical compositions as  
 immunosuppressive and anticancer agents  
 INVENTOR(S): Metcalf, Chester A., III; Rozamus, Leonard W.; Wang,  
 Yihan; Bernstein, David L.  
 PATENT ASSIGNEE(S): Ariad Gene Therapeutics, Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S.  
 Ser. No. 635,054.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2005032825	A1	20050210	US 2004-862149	20040604
US 7091213	B2	20060815		
US 2003220297	A1	20031127	US 2003-357152	20030203 <--
US 2004073024	A1	20040415	US 2003-635054	20030806
US 2006264405	A1	20061123	US 2006-429582	20060505


US 2006264456  
PRIORITY APPLN. INFO.:

A1 20061123

US 2006-494418	20060727
US 2002-353252P	P 20020201
US 2002-426928P	P 20021115
US 2002-428383P	P 20021122
US 2002-433930P	P 20021217
US 2003-357152	A2 20030203
US 2003-635054	A2 20030806
US 2003-486367P	P 20030711
US 2004-862149	A2 20040604
US 2004-889163	B2 20040712
US 2005-711859P	P 20050826

OTHER SOURCE(S):  
GI

CASREACT 142:219083; MARPAT 142:219083




AB Rapamycin derivs. containing phosphorus moiety, such as I [A = O, S, NR<sub>2</sub>, absent; Q = V, OV, SV, NR<sub>2</sub>, absent; V = aliphatic, heteroaliph., aryl, heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR<sub>2</sub>VA; J = P(:K)(YR<sub>5</sub>)<sub>2</sub>, P(YR<sub>5</sub>)<sub>2</sub>, P(:K)(YR<sub>5</sub>)GR<sub>6</sub>; K = O, S; Y = O, S, NR<sub>2</sub>, bond; R<sub>2</sub>, R<sub>5</sub> = aliphatic, heteroaliph., aryl, heteroaryl, H; R<sub>6</sub> = PK(YR<sub>5</sub>)YR<sub>5</sub>, SO<sub>2</sub>YR<sub>5</sub>, C(O)YR<sub>5</sub>; G = O, S, NR<sub>2</sub>, (M)X; M = (un)substituted methylene, alkyl, alkylene; X = 1-6], and pharmaceutically acceptable derivs. thereof, were prepared for therapeutic use as immunosuppressive and anticancer agents. These rapamycin derivs. are useful for treatment of graft vs. host disease, lupus, rheumatoid arthritis, diabetes mellitus, myasthenia gravis, multiple sclerosis, psoriasis, dermatitis, eczema, seborrhea, inflammatory bowel disease, pulmonary inflammation, ocular uveitis; adult T-cell leukemia, lymphoma, fungal infections, hyperproliferative restenosis, graft vascular atherosclerosis, coronary artery disease, cerebrovascular disease, arteriosclerosis, atherosclerosis, nonatheromatous arteriosclerosis, or vascular wall damage from cellular events leading toward immune mediated vascular damage, stroke or multi-infarct dementia. Thus, I [A-QJ = OP(O)(OBu)Me] was prepared by reacting rapamycin with methylphosphonic dichloride and n-butanol using 3,5-lutidine in CH<sub>2</sub>Cl<sub>2</sub> under a nitrogen atmospheric Binding affinity of the rapamycin phosphorus derivs. for human FKBP-12 protein was assayed, dosages for restenosis prevention were discussed.

IT 144701-48-4, Telmisartan

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of phosphorus-containing rapamycin derivs. for use in pharmaceutical compns. as immunosuppressive and anticancer agents)

RN 144701-48-4 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 38 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:157602 CAPLUS  
 DOCUMENT NUMBER: 136:205430  
 TITLE: Pharmaceutical compositions containing AT-receptor antagonist or insulin secretion enhancers  
 INVENTOR(S): Allison, Malcolm; Gatlin, Marjorie Regan  
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma. GmbH  
 SOURCE: PCT Int. Appl., 24 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002015933	A2	20020228	WO 2001-EP9587	20010820 <--
WO 2002015933	A3	20030814		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001087698	A5	20020304	AU 2001-87698	20010820 <--
EP 1351683	A2	20031015	EP 2001-967289	20010820 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004514654	T	20040520	JP 2002-520854	20010820
US 2004034065	A1	20040219	US 2003-362340	20030616
US 2006089389	A1	20060427	US 2005-295928	20051207
US 2006281790	A1	20061214	US 2006-508353	20060823

PRIORITY APPLN. INFO.:


US 2000-643641 A 20000822  
 US 2000-327553P P 20000822  
 WO 2001-EP9587 W 20010820  
 US 2003-362340 B1 20030616  
 US 2005-295928 B1 20051207

AB A pharmaceutical composition comprises as active ingredients an AT1-receptor antagonist or a salt, an insulin secretion enhancer or a its salt or an insulin sensitizier or its salt. Thus, tablets contained Starlix DS 60, lactose monohydrate 141.5, microcryst. cellulose 71, Povidone-K30 12, and Croscarmellose sodium 18.4, colloidal SiO2 6.4, Mg stearate 5.7, and Opadry 9 mg.

IT 144701-48-4, Telmisartan  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical compns. containing AT-receptor antagonist or insulin secretion enhancers)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 39 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:762798 CAPLUS

DOCUMENT NUMBER: 135:308910

TITLE: Pharmaceutical compositions containing an aldosterone synthase inhibitor and an AT1-receptor antagonist

INVENTOR(S): Steele, Ronald Edward

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001076574	A2	20011018	WO 2001-EP4116	20010410 <--
WO 2001076574	A3	20020425		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,

VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2405895	A1	20011018	CA 2001-2405895	20010410 <--
BR 2001010079	A	20021231	BR 2001-10079	20010410 <--
EP 1282410	A2	20030212	EP 2001-940317	20010410 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003530343	T	20031014	JP 2001-574092	20010410 <--
NZ 521855	A	20041029	NZ 2001-521855	20010410
NZ 534086	A	20060831	NZ 2001-534086	20010410
US 2003083342	A1	20030501	US 2002-149107	20020827 <--
IN 2002CN01650	A	20050128	IN 2002-CN1650	20021008
NO 2002004920	A	20021127	NO 2002-4920	20021011 <--
ZA 2002008204	A	20031014	ZA 2002-8204	20021011 <--
US 2004204444	A1	20041014	US 2004-826106	20040415
US 2005059697	A1	20050317	US 2004-940544	20040914
US 2006122217	A1	20060608	US 2005-291008	20051130

PRIORITY APPLN. INFO.:

US 2000-196742P	P	20000412
NZ 2001-521855	A1	20010410
WO 2001-EP4116	W	20010410
US 2002-149107	A3	20020827
US 2004-940544	B1	20040914

AB The invention relates to a pharmaceutical composition, of (i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof either alone or in combination with (ii) an AT1-receptor antagonist combined with a diuretic, or in each case, a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier. A pharmaceutical composition comprising an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof is used for the prevention of, delay of progression of, and treatment of a disease or condition selected from the group consisting of hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery, atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, hypothyroidism, myocardial infarction, etc. For example, a hard gelatin capsules were prepared containing valsartan 80.0 mg, microcryst. cellulose 110.0 mg, Polyvidone K30 45.2 mg, sodium lauryl sulfate 1.2 mg, crospovidone 26.0 mg, and magnesium stearate 2.6 mg by a granulation method.

IT 144701-48-4, Telmisartan


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral compns. containing aldosterone synthase inhibitor and AT1-receptor antagonist for therapeutic uses)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)





L6 ANSWER 40 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:188513 USPATFULL  
 TITLE: Substituted acid derivatives useful as antidiabetic and  
 antiobesity agents and method  
 INVENTOR(S): Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
 Jeon, Yoon T., Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003130306	A1	20030710	<--
	US 6673815	B2	20040106	
APPLICATION INFO.:	US 2002-289053	A1	20021106	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333022P	20011106 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1699	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB Compounds are provided which have the structure ##STR1##		

wherein Q is C or N, X.sub.1 is CH or N and, A, E, M, G, X.sub.2,  
 X.sub.3, X.sub.4, R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c,  
 R.sup.3, Y, x, m, and n are as defined herein, which compounds are  
 useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:134608 USPATFULL  
 TITLE: Conformationally constrained analogs useful as  
 antidiabetic and antiobesity agents and method  
 INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
 Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
 Wang, Wei, Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003092697	A1	20030515	<--

APPLICATION INFO.: US 7105556 B2 20060912  
US 2002-153342 A1 20020522 (10)

NUMBER DATE  
-----  
PRIORITY INFORMATION: US 2001-294505P 20010530 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Stephen B. Davis, Bristol-Myers Squibb Company, Patent  
Department, P.O. Box 4000, Princeton, NJ, 08543-4000  
NUMBER OF CLAIMS: 34  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2127  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, X.sub.1 is C or N, and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, A, m, n, X.sub.2, X.sub.3 and X.sub.4 are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 42 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:757520 CAPLUS  
DOCUMENT NUMBER: 139:255390  
TITLE: Method of treatment and prophylaxis of neuropathic condition  
INVENTOR(S): Smith, Maree Therese; Brown, Lindsay  
PATENT ASSIGNEE(S): The University of Queensland, Australia  
SOURCE: PCT Int. Appl., 87 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003077912	A1	20030925	WO 2003-AU336	20030320 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003209851	A1	20030929	AU 2003-209851	20030320 <--
US 2003199424	A1	20031023	US 2003-393056	20030320 <--
PRIORITY APPLN. INFO.:			US 2002-365858P P	20020320
			WO 2003-AU336 W	20030320

AB The invention is involves the use of angiotensin II receptor 1 (AT1 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of a neuropathic condition, especially a peripheral neuropathic condition such as painful diabetic neuropathy, in vertebrate animals and particularly in human subjects. The invention also discloses the use of AT1 receptor antagonists for preventing, attenuating or reversing the development of reduced opioid sensitivity, and more particularly reduced opioid analgesic sensitivity, in individuals and especially in individuals having, or at risk of developing, a neuropathic condition.

IT 144701-48-4, Telmisartan  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (method of treatment and prophylaxis of neuropathic condition)  
 RN 144701-48-4 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-  
 benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 43 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:390959 CAPLUS  
 DOCUMENT NUMBER: 133:12837  
 TITLE: Clinical pharmacokinetics of angiotensin II (AT1)  
 receptor blockers in hypertension  
 AUTHOR(S): Israili, Z. H.  
 CORPORATE SOURCE: Emory University School of Medicine, Atlanta, GA,  
 30303, USA  
 SOURCE: Journal of Human Hypertension (2000),  
 14(Suppl. 1), S73-S86  
 CODEN: JHHYEN; ISSN: 0950-9240  
 PUBLISHER: Nature Publishing Group  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English

AB A review with 174 refs. Angiotensin II receptor blockers (ARBs) represent a new class of effective and well tolerated orally active antihypertensive agents. Recent clin. trials have shown the added benefits of ARBs in hypertensive patients (reduction in left ventricular hypertrophy, improvement in diastolic function, decrease in ventricular arrhythmias, reduction in microalbuminuria, and improvement in renal function), and cardioprotective effect in patients with heart failure. Several large long-term studies are in progress to assess the beneficial effects of ARBs on cardiac hypertrophy, renal function, and cardiovascular and cerebrovascular morbidity and mortality in hypertensive patients with or without diabetes mellitus, and the value of these drugs in patients with heart disease and diabetic nephropathy. The ARBs specifically block the interaction of angiotensin II at the AT<sub>1</sub> receptor, thereby relaxing smooth muscle, increasing salt and water excretion, reducing plasma volume, and decreasing cellular hypertrophy. These agents exert their blood pressure-lowering effect mainly by reducing peripheral vascular resistance usually without a rise in heart rate. Most of the com. available ARBs control blood pressure for 24 h after once daily dosing. Sustained efficacy of blood pressure control, without any evidence of tachyphylaxis,

has been demonstrated after long-term administration (3 yr) of some of the ARBs. The efficacy of ARBs is similar to that of thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors or calcium channel blockers in patients with similar degree of hypertension. Higher daily doses, dietary salt restriction, and concomitant diuretic or ACE inhibitor administration amplify the antihypertensive effect of ARBs. The ARBs have a low incidence of adverse effects (headache, upper respiratory infection, back pain, muscle cramps, fatigue and dizziness), even in the elderly patients. After the approval of losartan, five other ARBs (candesartan cilexetil, eprosartan, irbesartan, telmisartan, and valsartan) and three combinations with hydrochlorothiazide (irbesartan, losartan and valsartan) have been approved as antihypertensive agents, and some 28 compds. are in various stages of development. The ARBs are non-peptide compds. with varied structures; some (candesartan, losartan, irbesartan, and valsartan) have a common tetrazolo-biphenyl structure. Except for irbesartan, all active ARBs have a carboxylic acid group. Candesartan cilexetil is a prodrug, while losartan has a metabolite (EXP3174) which is more active than the parent drug. No other metabolites of ARBs contribute significantly to the antihypertensive effect. The variation in the mol. structure of the ARBs results in differences in the binding affinity to the receptor and pharmacokinetic profiles. The differences observed in lipid solubility, absorption/distribution, plasma protein binding, bioavailability, biotransformation, plasma half-life, and systemic elimination influence the time of onset, duration of action, and efficacy of the ARBs. On the basis of the daily mg dose, the anti-hypertensive potency of the ARBs follows the sequence: candesartan cilexetil > telmisartan losartan > irbesartan valsartan > eprosartan. After oral administration, the ARBs are rapidly absorbed (time for peak plasma levels = 0.5-4 h) but they have a wide range of bioavailability (from a low of 13% for eprosartan to a high of 60-80% for irbesartan); food does not influence the bioavailability, except for valsartan (a reduction of 40-50%) and eprosartan (increase). A limited dose-peak plasma levels/areas under the plasma level-time curve proportionality is observed for some of the ARBs. Most of these drugs have high plasma protein binding (95-100%); irbesartan has the lowest binding among the group (90%). The steady-state vols. of distribution vary from a low of 9 L (candesartan) to a high of 500 L (telmisartan). Plasma elimination half-life is short for candesartan cilexetil and losartan (1-4 h), intermediate for eprosartan and valsartan (5-10 h), and longer for candesartan, irbesartan and telmisartan (11-38 h); the active metabolite of losartan has a longer half-life than for the parent drug. The drugs and their active metabolites do not accumulate to a significant extent after repeated dosing, except for telmisartan (100%). Most of the orally administered dose of ARBs is excreted via bile into the feces; from 2% (telmisartan) to 33% (candesartan) of the oral dose is excreted in the urine. In most cases, changes in pharmacokinetic parameters due to aging, mild to moderate renal disease and heart failure do not require dosage modification; dosage has to be individualized for eprosartan, losartan, telmisartan and valsartan in patients with hepatic disease. In general, pharmacokinetic drug-drug interactions are rare, with the exception of combination of digoxin and telmisartan. The ARBs are an important treatment option for hypertension, being relatively safe and efficacious. The beneficial effects of the ARB therapy go beyond blood pressure control. They may prove to have beneficial hemodynamic and neurohormonal effects in heart failure and provide renoprotection in diabetic nephropathy.

REFERENCE COUNT: 189 THERE ARE 189 CITED REFERENCES AVAILABLE FOR  
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT

L6 ANSWER 44 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:141004 USPATFULL  
TITLE: Substituted acid derivatives useful as antidiabetic and  
antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
Chen, Sean, Princeton, NJ, UNITED STATES  
Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003096846	A1	20030522	<--
	US 6653314	B2	20031125	
APPLICATION INFO.:	US 2002-80981	A1	20020222	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-812960, filed on 20 Mar 2001, GRANTED, Pat. No. US 6414002			
	Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5718	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds are provided which have the structure ##STR1##	

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 45 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:100110 USPATFULL  
TITLE: Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions  
INVENTOR(S): Kosoglou, Teddy, Jamison, PA, UNITED STATES  
Ress, Rudyard J., Flemington, NJ, UNITED STATES  
Strony, John T., Lebanon, NJ, UNITED STATES  
Veltri, Enrico P., Princeton, NJ, UNITED STATES  
Hauer, William, Warren, NJ, UNITED STATES  
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003069221	A1	20030410	<--
APPLICATION INFO.:	US 2002-57339	A1	20020125	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-323842P	20010921 (60)
	US 2001-264396P	20010126 (60)
	US 2001-264600P	20010126 (60)
	US 2001-264275P	20010126 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	



NUMBER OF CLAIMS: 49  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3423

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 46 OF 113 MEDLINE on STN  
ACCESSION NUMBER: 2003255815 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 12781906  
TITLE: The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.  
AUTHOR: Unger Thomas  
CORPORATE SOURCE: Institute of Pharmacology and Toxicology, Charite Hospital, Humboldt University at Berlin, Berlin, Germany..  
Thomas.unger@charite.de  
SOURCE: The American journal of cardiology, (2003 May 22)  
Vol. 91, No. 10A, pp. 28G-34G. Ref: 52  
Journal code: 0207277. ISSN: 0002-9149.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 200307  
ENTRY DATE: Entered STN: 4 Jun 2003  
Last Updated on STN: 10 Jul 2003  
Entered Medline: 9 Jul 2003

AB The renin-angiotensin system evolved to maintain volume homeostasis and blood pressure and to prevent ischemia during acute volume loss. But in the present age, these mechanisms are redundant, and the clinical significance of angiotensin II results from its pathologic effects, which are mediated by the angiotensin II type 1 (AT(1)) receptor. Activation of AT(1) receptors has been linked to pathologic processes that contribute to atherosclerosis and ischemic events, including oxidative stress, inflammatory processes, low-density lipoprotein cholesterol trafficking, and prothrombotic states. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) program will compare the efficacy of the angiotensin II receptor blocker (ARB) telmisartan, the angiotensin-converting enzyme (ACE) inhibitor ramipril, and combination therapy with telmisartan plus ramipril for reducing cardiovascular risk. The ARB telmisartan is distinguished by its long duration of action, which compares favorably with some other ARBs and conventional antihypertensives. Ramipril was shown in the Heart Outcomes Prevention Evaluation (HOPE) study to reduce the risk for myocardial infarction (MI) and other cardiovascular events in patients at high risk for cardiovascular events but without heart failure or a low ejection fraction. The ONTARGET program consists of 2 randomized, double-blind, multicenter international trials: a principal trial, ONTARGET, and a parallel trial, Telmisartan Randomized Assessment Study in ACE-I Intolerant Patients with Cardiovascular Disease (TRANSCEND). The treatment arms for the principal ONTARGET study are telmisartan 80 mg, ramipril 10 mg, and combination therapy with telmisartan 80 mg plus ramipril 10 mg; for the parallel study TRANSCEND, the treatment arms are telmisartan 80 mg and placebo. Both trials will assess cardiovascular outcomes in patients at high risk using the same criteria as that of the HOPE study, with a single exception: the TRANSCEND trial will enroll patients who do not tolerate



ACE inhibitor treatment. The primary end points in both ONTARGET and TRANSCEND are death caused by cardiovascular disease, acute MI, stroke, and hospitalization because of congestive heart failure. The secondary end points include newly diagnosed heart failure, revascularization, new-onset type 2 diabetes mellitus, nephropathy, cognitive decrease and dementia, and newly diagnosed atrial fibrillation; these will be used for hypothesis generation.

L6 ANSWER 47 OF 113 MEDLINE on STN  
ACCESSION NUMBER: 2002274881 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 12015188  
TITLE: Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.  
AUTHOR: Rippin J; Bain S C; Barnett A H  
CORPORATE SOURCE: Department of Medicine, University of Birmingham, Birmingham B9 5SS, UK. (DETAIL study).  
SOURCE: Journal of diabetes and its complications, (2002 May-Jun) Vol. 16, No. 3, pp. 195-200.  
Journal code: 9204583. ISSN: 1056-8727.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(MULTICENTER STUDY)  
(RANDOMIZED CONTROLLED TRIAL)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200210  
ENTRY DATE: Entered STN: 17 May 2002  
Last Updated on STN: 8 Oct 2002  
Entered Medline: 4 Oct 2002

AB The DETAIL (diabetics exposed to telmisartan and enalapril) study will compare the long-term renal outcome of treatment with the angiotensin II receptor antagonist (ARA) telmisartan versus the angiotensin-converting enzyme (ACE) inhibitor enalapril in patients with mild-to-moderate hypertension and diabetic nephropathy. In short-term clinical studies, ACE inhibitors reduce microalbuminuria and, in the longer term, they are superior to conventional therapies in maintaining normal renal function. ARAs also appear to be renoprotective in diabetic animals. In this double-blind, parallel-group study, 252 patients with Type 2 diabetes and concurrent hypertension (mean seated systolic blood pressure  $\leq$  180 mm Hg, on treatment seated diastolic blood pressure  $\leq$  95 mm Hg) have been randomised to once-daily telmisartan 40 mg or enalapril 10 mg; doses are mandatorily titrated to 80 and 20 mg once daily, respectively, after 4 weeks. The primary endpoint will be the change from baseline in glomerular filtration rate (GFR) after 5 years of therapy, using the iohexol method and central laboratory analysis. The secondary endpoints to be evaluated will be: changes in GFR in relation to baseline after 1-4 years of therapy; percentage changes in albumin excretion rate after 1-5 years; and incidences of end-stage renal disease, cardiovascular events, all-cause mortality, and adverse events. The planned date for the completion of the study is 2005.

L6 ANSWER 48 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:203196 CAPLUS  
DOCUMENT NUMBER: 138:215317  
TITLE: Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin  
INVENTOR(S): Liang, Matthew H.; Manson, Joann E.  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 14 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent

LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003049314	A1	20030313	US 2001-942084	20010828 <--
US 6576256	B2	20030610		


PRIORITY APPLN. INFO.: US 2001-942084 20010828

AB Methods and compns. are provided for reducing the risk of cardiovascular events in individuals who are at elevated cardiovascular risk, including individuals who have systemic lupus erythematosus. The methods comprise administering a combination of: a cholesterol-lowering agent, such as an HMG CoA reductase inhibitor; an inhibitor of the renin-angiotensin system, such as an ACE inhibitor; aspirin; and optionally one or more of vitamin B6, vitamin B12, and folic acid. Pharmaceutical formulations combining all the active agents in unit-dose form for once-daily dosing are provided. Tablets containing pravastatin 40 mg, ramipril 10 mg, aspirin (in enteric coated granules) 81 mg, Vitamin B6 50 mg, Vitamin B12 1 mg, folic acid 3 mg, calcium carbonate 50 mg, magnesium oxide 25 mg, magnesium carbonate 25 mg, microcryst. cellulose 25 mg, lactose 25 mg, and magnesium stearate 1 mg are used to treat subjects at elevated cardiac risk.

IT 144701-48-4, Telmisartan  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(as renin-angiotensin system inhibitor; treatment of patients at elevated cardiovascular risk with combination of cholesterol-lowering agent, inhibitor of renin-angiotensin system, and aspirin)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 49 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:574955 CAPLUS

DOCUMENT NUMBER: 137:129903

TITLE: Combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions

INVENTOR(S): Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.; Hauer, William

PATENT ASSIGNEE(S): Schering Corporation, USA


SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 12  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058731	A2	20020801	WO 2002-US1196	20020125 <--
WO 2002058731	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2434436	A1	20020801	CA 2002-2434436	20020125 <--
CA 2562982	A1	20020801	CA 2002-2562982	20020125 <--
CA 2563051	A1	20020801	CA 2002-2563051	20020125 <--
US 2003069221	A1	20030410	US 2002-57339	20020125 <--
EP 1385548	A2	20040204	EP 2002-707500	20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002006644	A	20040225	BR 2002-6644	20020125
HU 200303923	A2	20040301	HU 2003-3923	20020125
EP 1413331	A2	20040428	EP 2004-161	20020125
EP 1413331	A3	20040630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517919	T	20040617	JP 2002-559065	20020125
CN 1582168	A	20050216	CN 2002-804219	20020125
EP 1541175	A2	20050615	EP 2005-3029	20020125
EP 1541175	A3	20060412		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1671650	A1	20060621	EP 2006-5831	20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1915429	A	20070221	CN 2006-10126233	20020125
ZA 2003005692	A	20041025	ZA 2003-5692	20030723
ZA 2003005694	A	20041025	ZA 2003-5694	20030723
ZA 2003005693	A	20050209	ZA 2003-5693	20030723
IN 2003CN01150	A	20050422	IN 2003-CN1150	20030724
NO 2003003358	A	20030912	NO 2003-3358	20030725 <--
US 2004097482	A1	20040520	US 2003-639900	20030813
US 2005153952	A1	20050714	US 2004-998400	20041129
US 2006199793	A1	20060907	US 2005-158429	20050622
PRIORITY APPLN. INFO.:				
			US 2001-264275P	P 20010126
			US 2001-264396P	P 20010126
			US 2001-264600P	P 20010126
			US 2001-323842P	P 20010921
			US 2001-323839P	P 20010921
			CA 2002-2434682	A3 20020125
			CN 2002-807208	A3 20020125
			EP 2002-705933	A3 20020125
			EP 2002-707500	A3 20020125
			EP 2002-714773	A3 20020125
			US 2002-57323	A3 20020125
			US 2002-57646	A1 20020125
			WO 2002-US1196	W 20020125
			US 2002-136968	A3 20020501
OTHER SOURCE(S): MARPAT 137:129903				

GI



I


AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols. Tablets were prepared containing cardiovascular agents which can be coadministered with formulations containing, e.g., I. The preparation of I was given.

IT 144701-48-4, Telmisartan

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 50 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:127720 USPATFULL

TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
Chen, Sean, Princeton, NJ, UNITED STATES  
Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087935	A1	20030508
	US 6727271	B2	20040427
APPLICATION INFO.:	US 2002-81075	A1	20020222 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5712	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds are provided which have the structure ##STR1##	

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 51 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:100164 USPATFULL  
 TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method  
 INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
 Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
 Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
 Chen, Sean, Princeton, NJ, UNITED STATES  
 Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069275	A1	20030410
	US 6919358	B2	20050719
APPLICATION INFO.:	US 2002-80965	A1	20020222 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5710	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds are provided which have the structure ##STR1##	

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic,

hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 52 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:708455 CAPLUS

DOCUMENT NUMBER: 138:378867

TITLE: Angiotensin II Receptor Antagonists and  
Angiotensin-Converting Enzyme Inhibitors Lower In  
Vitro the Formation of Advanced Glycation End  
Products: Biochemical Mechanisms

AUTHOR(S): Miyata, Toshio; van Ypersele de Strihou, Charles;  
Ueda, Yasuhiko; Ichimori, Kohji; Inagi, Reiko; Onogi,  
Hiroshi; Ishikawa, Naoyoshi; Nangaku, Masaomi;  
Kurokawa, Kiyoshi

CORPORATE SOURCE: Institute of Medical Sciences and Department of  
Medicine, Tokai University School of Medicine,  
Kanagawa, Japan

SOURCE: Journal of the American Society of Nephrology (  
2002), 13(10), 2478-2487

CODEN: JASNEU; ISSN: 1046-6673

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The implication of advanced glycation end products (AGE) in the  
pathogenesis of atherosclerosis and of diabetic and uremic complications  
has stimulated a search for AGE inhibitors. This study evaluates the AGE  
inhibitory potential of several well-tolerated hypotensive drugs.  
Olmesartan, an angiotensin II type 1 receptor (AIIR) antagonist, as well  
as temocaprilat, an angiotensin-converting enzyme (ACE) inhibitor, unlike  
nifedipine, a calcium blocker, inhibit in vitro the formation of two AGE,  
pentosidine and N $\epsilon$ -carboxymethyllysine (CML), during incubation of  
nonuremic diabetic, nondiabetic uremic, or diabetic uremic plasma or of  
BSA fortified with arabinose. This effect is shared by all tested AIIR  
antagonists and ACE inhibitors. On an equimolar basis, they are more  
efficient than aminoguanidine or pyridoxamine. Unlike the latter two  
compds., they do not trap reactive carbonyl precursors for AGE, but impact  
on the production of reactive carbonyl precursors for AGE by chelating  
transition metals and inhibiting various oxidative steps, including  
carbon-centered and hydroxyl radicals, at both the pre- and post-Amadori  
steps. Their effect is paralleled by a lowered production of reactive  
carbonyl precursors. Finally, they do not bind pyridoxal, unlike  
aminoguanidine. Altogether, this study demonstrates for the first time  
that widely used hypotensive agents, AIIR antagonists and ACE inhibitors,  
significantly attenuate AGE production. This study provides a new framework  
for the assessment of families of AGE-lowering compds. according to their  
mechanisms of action.

IT 144701-48-4, Telmisartan


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL  
(Biological study)

(angiotensin II receptor antagonists and angiotensin-converting enzyme  
inhibitors lower formation of advanced glycation end products and  
mechanisms therein)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-  
benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)





REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 53 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:160755 USPATFULL  
 TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method  
 INVENTOR(S): Cheng, Peter T., Princeton, NJ, United States  
 Devasthale, Pratik, Plainsboro, NJ, United States  
 Jeon, Yoon, Belle Mead, NJ, United States  
 Chen, Sean, Princeton, NJ, United States  
 Zhang, Hao, Belle Mead, NJ, United States  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6414002	B1	20020702
APPLICATION INFO.:	US 2001-812960		20010320 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Higel, Floyd D.	
ASSISTANT EXAMINER:	Sackey, Ebenezer	
LEGAL REPRESENTATIVE:	Burton Rodney	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	5133	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 54 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2003:759924 CAPLUS  
 DOCUMENT NUMBER: 139:316442  
 TITLE: New definitions in cardiovascular risk management: is it time for angiotensin II receptor blockers to become first-line medication?  
 AUTHOR(S): Jennings, G.  
 CORPORATE SOURCE: Baker Heart Research Institute, Melbourne, Australia  
 SOURCE: European Heart Journal Supplements (2003), 5(Suppl. F), F3-F11  
 CODEN: EHJSFT; ISSN: 1520-765X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English

AB A review. The risk for coronary heart disease (CHD) increases with the number of risk factors. Thus, the clin. focus in prevention of CHD should be on patients with multiple risk factors. Both hypertension and a history of myocardial infarction are acknowledged risk factors for heart failure - the most severe form of CHD - but hypertension is more common. Anal. of data from the Framingham Heart Study shows that hypertension is associated with a greater population-attributable risk for heart failure. Angiotensin II, acting via the angiotensin II type 1 receptor, has been implicated in pathol. associated with ischemic heart disease and heart failure. Data on the efficacy of angiotensin-converting enzyme inhibitors in reducing cardiovascular events are comprehensive, with benefits demonstrated for patients with multiple risk factors, target organ damage, acute myocardial infarction and heart failure. Several recent trials have shown that angiotensin II receptor blockers reduce the progression of nephropathy in patients with type 2 diabetes mellitus. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Trial Program will provide a large body of data on the efficacy of the angiotensin II receptor Mocker telmisartan in lowering cardiovascular morbidity and mortality in patients with multiple risk factors.

IT 144701-48-4, Telmisartan  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (role of angiotensin II receptor blockers in cardiovascular risk management)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT:

58

THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 55 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:166611 USPATFULL  
TITLE: Combinations  
INVENTOR(S): Cohen, David Saul, New Providence, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003114469	A1	20030619	<--
APPLICATION INFO.:	US 2002-231427	A1	20020828	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-325485P	20010927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2636	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a pharmaceutical composition,  
comprising

(a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable  
salt thereof and

(b) at least one of the active ingredients selected from the group  
consisting of

(i) an anti-diabetic agent;

(ii) HMG-Co-A reductase inhibitors;

(iii) an anti-hypertensive agent; and

(iv) a serotonin reuptake inhibitor (SSRI)

or, in each case, or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier. The pharmaceutical composition  
may be employed for the treatment of sexual dysfunction, hyperglycemia,  
hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia,  
diabetes, insulin resistance, impaired glucose metabolism,  
conditions of impaired glucose tolerance (IGT), conditions of impaired  
fasting plasma glucose, obesity, diabetic retinopathy, diabetic  
nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X,  
erectile dysfunction, coronary heart disease, hypertension, especially  
ISH, angina pectoris, myocardial infarction, stroke, vascular  
restenosis, endothelial dysfunction, impaired vascular compliance,  
congestive heart failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 56 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:266021 USPATFULL  
TITLE: Fibrinogen-lowering agents  
INVENTOR(S): Imura, Yoshimi, Toyono-gun, JAPAN  
Hirakata, Masao, Kobe-shi, JAPAN

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2003187038 A1 20031002 <--  
 APPLICATION INFO.: US 2003-344719 A1 20030214 (10)  
 WO 2001-JP7239 20010824


	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-260881	20000825
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1512	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We offer a fibrinogen-lowering agent comprising a compound having an angiotensin II antagonistic activity, a prodrug thereof, or a salt thereof. Because of having an excellent effect of lowering fibrinogen, the above fibrinogen-lowering agent is useful as a prophylactic or therapeutic agent for various diseases caused by hyperfibrionogenemia, etc.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
 (fibrinogen lowering agents containing angiotensin II antagonists)  
 RN 144701-48-4 USPATFULL  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 57 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:201442 USPATFULL  
 TITLE: Combinations  
 INVENTOR(S): Cohen, David Saul, New Providence, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003139429	A1	20030724 <--
	US 7019010	B2	20060328
APPLICATION INFO.:	US 2002-236651	A1	20020906 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-325485P	20010927 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK  
DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ,  
07936-1080  
NUMBER OF CLAIMS: 10  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1304

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a pharmaceutical composition,  
comprising

(a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable  
salt thereof and

(b) at least one of the active ingredients selected from the group  
consisting of

(i) an anti-diabetic agent;

(ii) HMG-Co-A reductase inhibitors;

(iii) an anti-hypertensive agent; and

(iv) a serotonin reuptake inhibitor (SSRI)

or, in each case, or a pharmaceutically acceptable salt thereof and a  
pharmaceutically acceptable carrier. The pharmaceutical composition may  
be employed for the treatment of sexual dysfunction, hyperglycemia,  
hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia,  
diabetes, insulin resistance, impaired glucose metabolism,  
conditions of impaired glucose tolerance (IGT), conditions of impaired  
fasting plasma glucose, obesity, diabetic retinopathy, diabetic  
nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X,  
erectile dysfunction, coronary heart disease, hypertension, especially  
ISH, angina pectoris, myocardial infarction, stroke, vascular  
restenosis, endothelial dysfunction, impaired vascular compliance,  
congestive heart failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 58 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:120858 USPATFULL  
TITLE: Combination of organic compounds  
INVENTOR(S): Steele, Ronald Edward, Long Valley, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003083342	A1	20030501	<--
APPLICATION INFO.:	US 2002-149107	A1	20020827	(10)
	WO 2001-EP4116		20010410	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK			
	DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ,			
	07936-1080			
NUMBER OF CLAIMS:	10			
EXEMPLARY CLAIM:	1			
LINE COUNT:	726			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a pharmaceutical composition, of (i) an  
aldosterone synthase inhibitor or a pharmaceutically acceptable salt  
thereof either alone or in combination with (ii) an AT.sub.1-receptor  
antagonist combined with a diuretic, or in each case, a pharmaceutically

acceptable salt thereof and (iii) a pharmaceutically acceptable carrier.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(oral compns. containing aldosterone synthase inhibitor and AT1-receptor antagonist for therapeutic uses)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 59 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2001:173610 USPATFULL  
TITLE: Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist  
INVENTOR(S): Segal, Robert, Gwynedd Valley, PA, United States  
Robinson, Paul J., Hertfordshire, United Kingdom  
Deckelbaum, Lawrence I., Gladwyne, PA, United States  
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6300356	B1	20011009	<--
	WO 9943210		19990902	<--
APPLICATION INFO.:	US 2000-601938		20000810	(9)
	WO 1999-US3828		19990222	
			20000810	PCT 371 date
			20000810	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-8937	19980427
	US 1998-75915P	19980225 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Krass, Frederick	
LEGAL REPRESENTATIVE:	Camara, Valerie J., Daniel, Mark R.	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	1520	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



AB Angiotensin II receptor antagonists are useful for decreasing QT dispersion or inhibiting the progression of QT prolongation in patients. Also disclosed is a method for monitoring the reduction in the risk of experiencing an adverse cardiac event, such as sudden cardiac death, myocardial infarction or arrhythmias, using QT dispersion in patients treated with a therapeutically effective amount of an angiotensin II antagonist.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(angiotensin II receptor antagonists for decreasing QT dispersion or inhibiting progression of QT prolongation in humans)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 60 OF 113 MEDLINE on STN

ACCESSION NUMBER: 2002104848 MEDLINE

DOCUMENT NUMBER: PubMed ID: 11835907

TITLE: From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.

AUTHOR: Yusuf Salim

CORPORATE SOURCE: Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.. yusufs@mcmaster.ca

SOURCE: The American journal of cardiology, (2002 Jan 24) Vol. 89, No. 2A, pp. 18A-25A; discussion 25A-26A.

Journal code: 0207277. ISSN: 0002-9149.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (META-ANALYSIS)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 200202

ENTRY DATE: Entered STN: 12 Feb 2002

Last Updated on STN: 23 Feb 2002

Entered Medline: 22 Feb 2002

AB The Heart Outcomes Prevention Evaluation (HOPE) study conclusively demonstrated that ramipril, an angiotensin-converting enzyme (ACE) inhibitor, reduces the risk of cardiovascular death, myocardial infarction (MI), and death in patients at risk for cardiovascular events but without heart failure. The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE) substudy demonstrated that ramipril also reduced atherosclerosis. These results

suggest that the renin-angiotensin system (RAS) has a more important role in the development and progression of atherosclerosis than previously believed, and they indicate the need for further clinical studies to define the range of benefits available from modifying the RAS. Achieving maximum benefit may require treatment with both an ACE inhibitor and an angiotensin II type-1 receptor blocker (ARB). The Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) study indicated that combining an ACE inhibitor with an ARB decreased blood pressure and improved the ejection fraction more than treatment with either drug alone in patients with congestive heart failure. The Valsartan in Heart Failure Trial (Val-HeFT) showed that the combination of an ACE inhibitor and an ARB reduced hospitalization for heart failure in patients with congestive heart failure by 27.5%, although no decrease in all-cause mortality was observed. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) is a large, long-term study (23,400 patients, 5.5 years). It will compare the benefits of ACE inhibitor treatment, ARB treatment, and treatment with an ACE inhibitor and ARB together, in a study population with established coronary artery disease, stroke, peripheral vascular disease, or diabetes with end-organ damage. Patients with congestive heart failure will be excluded. In a parallel study, patients unable to tolerate an ACE inhibitor will be randomized to receive telmisartan or placebo (the Telmisartan Randomized Assessment Study in ACE-I Intolerant Patients with Cardiovascular Disease [TRANSCEND]). The primary endpoint for both trials is a composite of cardiovascular death, MI, stroke, and hospitalization for heart failure. Secondary endpoints will investigate reductions in the development of diabetes mellitus, nephropathy, dementia, and atrial fibrillation. These 2 trials are expected to provide new insights into the optimal treatment of patients at high risk of complications from atherosclerosis.

L6 ANSWER 61 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:709669 CAPLUS

DOCUMENT NUMBER: 140:1129

TITLE: Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation

AUTHOR(S): Yamagishi, S.; Amano, S.; Inagaki, Y.; Okamoto, T.; Inoue, H.; Takeuchi, M.; Choei, H.; Sasaki, N.; Kikuchi, S.

CORPORATE SOURCE: Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume, 830-0011, Japan

SOURCE: Drugs under Experimental and Clinical Research (2003), 29(2), 75-80

CODEN: DECRDP; ISSN: 0378-6501

PUBLISHER: Bioscience Ediprint Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The renin-angiotensin system has been implicated in the development and progression of atherosclerosis, thereby contributing to adverse cardiovascular events. However, its role in diabetic retinopathy remains to be elucidated. Since pericyte loss and dysfunction have been considered as one of the characteristic changes of the early phase of diabetic retinopathy, we investigated the effects of angiotensin II (Ang II) on the growth and function of bovine cultured retinal pericytes. Ang II stimulated intracellular reactive oxygen species (ROS) generation in pericytes in a dose-dependent manner. Telmisartan, a newly developed Ang II type 1 receptor antagonist, completely inhibited ROS generation in pericytes induced by Ang II. Ang II decreased DNA synthesis in pericytes, which was significantly prevented by an antioxidant N-acetylcysteine. Furthermore, telmisartan or N-acetylcysteine were found to completely inhibit the Ang II-induced upregulation of

vascular endothelial growth factor mRNA levels in pericytes. The present results suggest that Ang II-type 1 receptor interaction could induce pericyte loss and dysfunction through intracellular ROS generation, thus being involved in the development and progression of diabetic retinopathy.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 62 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2005:33212 USPATFULL

TITLE: Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof

INVENTOR(S): Ojima, Mami, Amagasaki, JAPAN  
Kitayoshi, Takahito, Suita, JAPAN  
Miyamoto, Masaomi, Takarazuka, JAPAN

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6852743	B1	20050208	
	WO 2001005428		20010125	<--
APPLICATION INFO.:	US 2002-31398		20020118	(10)
	WO 2000-JP4830		20000719	
			20020118	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-205877	19990721
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Powers, Fiona T.	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack, L.L.P.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1291	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB There is provided an agent for preventing the recurrence of cerebrovascular disorder and an agent for ameliorating troubles following cerebrovascular disorder and inhibiting the progress thereof which contain a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(preventives for recurrence of cerebrovascular failure containing benzimidazoles as angiotensin II antagonists)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 63 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:289188 USPATFULL  
 TITLE: Activator of PPAR delta  
 INVENTOR(S): Chao, Esther Yu-Hsuan, Durham, NC, UNITED STATES  
 Haffner, Curt Dale, Durham, NC, UNITED STATES  
 Lambert, Millard Hurst, III, Durham, NC, UNITED STATES  
 Maloney, Patrick Reed, Durham, NC, UNITED STATES  
 Sierra, Michael Lawrence, Les Ulis, FRANCE  
 Sternbach, Daniel David, Durham, NC, UNITED STATES  
 Sznajdman, Marcos Luis, Durham, NC, UNITED STATES  
 Willson, Timothy Mark, Durham, NC, UNITED STATES  
 Xu, Huaqiang Eric, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003203947	A1	20031030
	US 6723740	B2	20040420
APPLICATION INFO.:	US 2003-383011	A1	20030306 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-18935, filed on 19 Dec 2001, PENDING A 371 of International Ser. No. WO 2000-EP5720, filed on 22 Jun 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-14977	19990625
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1942	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds of Formula (I) are disclosed. These compounds include selective activators of human PPAR delta.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 64 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:127094 USPATFULL  
 TITLE: Methods for identifying novel multimeric agents that modulate receptors  
 INVENTOR(S): Christensen, Burton G., Alamo, CA, UNITED STATES

Griffin, John H., Atherton, CA, UNITED STATES  
Jenkins, Thomas E., La Honda, CA, UNITED STATES  
Judice, J. Kevin, El Granada, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003087306	A1	20030508	<--
APPLICATION INFO.:	US 2001-15534	A1	20011213	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-493462, filed on 28 Jan 2000, ABANDONED Continuation of Ser. No. US 1999-327904, filed on 8 Jun 1999, ABANDONED			

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92938P	19980715 (60)
	US 1998-88466P	19980608 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THERAVANCE, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	52 Drawing Page(s)	
LINE COUNT:	8387	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological processes/functions thereof. Each of the ligands is covalently attached to a linker or linkers which may be the same or different to provide for the multi-binding compound. The linker is selected such that the multi-binding compound so constructed demonstrates increased modulation or disruption of the biological processes/functions of the cell. Also disclosed is a method for identifying such novel multi-binding compounds which bind cellular receptors and a method for generating a mixture of such novel multi-binding compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 65 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2004:72635 USPATFULL  
TITLE: Activators of PPAR delta  
INVENTOR(S): Chao, Esther Yu-Hsuan, Durham, NC, United States  
Haffner, Curt Dale, Durham, NC, United States  
Lambert, III, Millard Hurst, Durham, NC, United States  
Maloney, Patrick Reed, Durham, NC, United States  
Sierra, Michael Lawrence, Les Ulis, FRANCE  
Sternbach, Daniel David, Durham, NC, United States  
Sznajdman, Marcos Luis, Durham, NC, United States  
Willson, Timothy Mark, Durham, NC, United States  
Xu, Huaqiang Eric, Durham, NC, United States  
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6710063	B1	20040323	
	WO 2001000603		20010104	<--
APPLICATION INFO.:	US 2001-18935		20011219	(10)
	WO 2000-EP5720		20000622	

NUMBER	DATE
-----	

PRIORITY INFORMATION: GB 1999-14977 19990625  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Rotman, Alan L.  
ASSISTANT EXAMINER: Shameem, Golam M. M.  
LEGAL REPRESENTATIVE: Brink, Robert H.  
NUMBER OF CLAIMS: 20  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
LINE COUNT: 2021  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds of Formula (1) are disclosed. These compounds include  
selective activators of human PPAR delta. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 66 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:306948 USPATFULL  
TITLE: Composition and method for treating hypertension  
INVENTOR(S): Stokes, Gordon, St Leonards, AUSTRALIA  
PATENT ASSIGNEE(S): Northern Sydney Area Health Service (non-U.S.  
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003216384	A1	20031120	<--
APPLICATION INFO.:	US 2002-255447	A1	20020925	(10)


	NUMBER	DATE
PRIORITY INFORMATION:	AU 2002-2369	20020516
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	902	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention relates to a composition for the treatment and/or  
prevention of hypertension, said composition comprising an synergistic  
anti-hypertensive combination of a therapeutically effective amount of  
at least one angiotensin II inhibitor, and a therapeutically effective  
amount of at least one nitric oxide donor; said composition optionally  
further comprising a pharmaceutically acceptable carrier, diluent and/or  
adjuvant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(angiotensin II inhibitor-nitric oxide donor synergistic combination  
for treating hypertension)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-  
benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)





L6 ANSWER 67 OF 113 USPTF on STN  
 ACCESSION NUMBER: 2003:312692 USPTF  
 TITLE: Phosphorus-containing compounds and uses thereof  
 INVENTOR(S): Bernstein, David L., Waban, MA, UNITED STATES  
 Metcalf, Chester A., III, Needham, MA, UNITED STATES  
 Rozamus, Leonard W., Bedford, MA, UNITED STATES  
 Wang, Yihan, Newton, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003220297	A1	20031127	<--
APPLICATION INFO.:	US 2003-357152	A1	20030203	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353252P	20020201 (60)
	US 2002-426928P	20021115 (60)
	US 2002-428383P	20021122 (60)
	US 2002-433930P	20021217 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: David L. Bernstein, ARIAD Gene Therapeutics, Inc., 26  
 Landsdowne Street, Cambridge, MA, 02139-4234  
 NUMBER OF CLAIMS: 39  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 3696

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns a new family of phosphorus-containing compounds containing a moiety JQA--in which:

A is absent or is --O--, --S-- or --NR.sup.2--;

Q is absent or (if A is --O--, --S-- or --NR.sup.2--) Q may be --V--, --OV--, --SV--, or --NR.sup.2V--, where V is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR.sup.2VA; ##STR1##

K is O or S;

each occurrence of Y is independently --O--, --S--, --NR.sup.2--, or a chemical bond linking a R.sup.5 moiety to P;

and the other variables are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 68 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:199127 USPATFULL  
TITLE: Methods of treating sexual dysfunction associated with hypertension  
INVENTOR(S): Sahota, Pritam Singh, New Providence, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002107236	A1	20020808	<--
APPLICATION INFO.:	US 2001-8445	A1	20011203	(10)


	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-250540P	20001201 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	665	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods of treating SD associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an HMG-CoA reductase inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(pharmaceutical compns. containing angiotensin receptor blockers for treating sexual dysfunction)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 69 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:759933 CAPLUS  
DOCUMENT NUMBER: 139:301175  
TITLE: PROGRESS beyond HOPE and LIFE: the ONTARGET trial

programme  
AUTHOR(S): Sleight, P.  
CORPORATE SOURCE: John Radcliffe Hospital, Oxford, UK  
SOURCE: European Heart Journal Supplements (2003),  
5(Suppl. F), F40-F47  
CODEN: EHJSFT; ISSN: 1520-765X  
PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Large-scale cardiovascular trials traditionally have targeted clin. hypertension, diabetes or survivors of myocardial infarction, but the recent trend in such trials has been to consider the treatment of high-risk individuals rather than specific diseases. This allows the use of a much broader screening process to enroll patients. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) act directly on the renin-angiotensin system to effect blood pressure control. The Heart Outcomes Prevention Evaluation (HOPE) and the Perindopril pROtection against REcurrent Stroke Study (PROGRESS) showed that angiotensin-converting enzyme inhibitors (ramipril and perindopril plus the diuretic indapamide), significantly decreased the risk for stroke and other adverse cardiovascular outcomes. Both studies showed benefits in patients with conventionally normal blood pressure. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial showed that losartan, an ARB, could also significantly decrease the risk of stroke to an extent greater than that predicted by the decrease in blood pressure. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Trial Program is currently underway to study the effect of ramipril and the ARB telmisartan, and a combination of the two agents in patients at high risk of cardiovascular disease.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 70 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:99270 USPATFULL

TITLE: Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same

INVENTOR(S): Kamei, Shigeru, Takarazuka-shi, JAPAN  
Ojima, Mami, Amagasaki-shi, JAPAN  
Kitayoshi, Takahito, Suita-shi, JAPAN  
Igari, Yasutaka, Kobe-shi, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003068374	A1	20030410	<--
APPLICATION INFO.:	US 2002-204185	A1	20020819	(10)
	WO 2001-JP1191		20010220	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-48980	20000221
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2121	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sustained-release preparation containing a physiologically active compound slightly soluble in water, a component obtained by treating with water a polyvalent metal compound slightly soluble in water, and a biodegradable polymer which are improved in the release-control and

stabilization of the physiologically active compound slightly soluble in water and can be produced by a process suitable for mass production.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(sustained-release compns. containing physiol. active compds. hardly-soluble in water, polyvalent metal compds., and biodegradable polymers)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 71 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2002:266305 USPATFULL

TITLE: Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions

INVENTOR(S): Kosoglou, Teddy, Jamison, PA, UNITED STATES  
Ress, Rudyard J., Flemington, NJ, UNITED STATES  
Strony, John T., Lebanon, NJ, UNITED STATES  
Veltri, Enrico P., Princeton, NJ, UNITED STATES

PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002147184	A1	20021010	<--
APPLICATION INFO.:	US 2002-56680	A1	20020125	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-324123P	20010921 (60)
	US 2001-264396P	20010126 (60)
	US 2001-264600P	20010126 (60)
	US 2001-264275P	20010126 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530

NUMBER OF CLAIMS: 48

EXEMPLARY CLAIM: 1

LINE COUNT: 3296

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor; and

(b) at least one blood modifier, which can be useful for treating vascular conditions and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 72 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2006:154381 USPATFULL  
TITLE: Method for preventing, treating or inhibiting development of simple retinopathy and preproliferative retinopathy  
INVENTOR(S): Nakagawa, Shizue, Osaka, JAPAN  
Nagisa, Yasutaka, Higashiosaka, JAPAN  
Ikeda, Hitoshi, Higashiosaka, JAPAN  
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Osaka, JAPAN  
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 7064141	B1	20060620	
	WO 2000066161		20001109	<--
APPLICATION INFO.:	US 2000-958740		20000427	(9)
	WO 2000-JP2766		20000427	
			20011016	PCT 371 date


	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-121498	19990428
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Fay, Zohreh	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack, L.L.P.	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1057	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB To provide a pharmaceutical composition for preventing, treating or development-inhibiting simple retinopathy or preproliferative retinopathy, comprising a compound having angiotensin II antagonistic activity, or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(angiotensin II antagonists for treatment of retinopathy)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 73 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:173948 USPATFULL  
 TITLE: Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women  
 INVENTOR(S): Strony, John T., Lebanon, NJ, UNITED STATES  
 PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119796	A1	20030626
	US 7056906	B2	20060606
APPLICATION INFO.:	US 2002-247085	A1	20020919 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-166942, filed on 11 Jun 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-324118P	20010921 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2932	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one hormone replacement therapy composition; and (b) at least one sterol absorption inhibitor which can be useful for treating vascular conditions in post-menopausal women and lowering plasma levels of sterols or 5 $\alpha$ -stanols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 74 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:99262 USPATFULL  
 TITLE: Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin  
 INVENTOR(S): Chungi, Shubha, Sharon, MA, UNITED STATES  
 Iorio, Theodore L., Millis, MA, UNITED STATES



	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003068366	A1	20030410
	US 6669955	B2	20031230
APPLICATION INFO.:	US 2001-941948	A1	20010828 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	59		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1701		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An orally administrable pharmaceutical formulation is provided that combines, as active agents, a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, aspirin, and optionally at least one of vitamin B.sub.6, B.sub.12, and folate; the active agents are each present in a unit dose appropriate for once-daily dosing, and at least one of the active agents is contained in a dosage unit within the dosage form that physically separates it from the other active agents. The formulation is provided as a simple and convenient therapy to reduce the risk of cardiovascular events in individuals who are at elevated cardiovascular risk, including individuals who have systemic lupus erythematosus. The formulation is also therapeutic for individuals during or immediately following an occurrence of acute myocardial infarction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 75 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:330256 USPATFULL  
 TITLE: Use of inhibitors of the renin-angiotensin system  
 INVENTOR(S): Montgomery, Hugh Edward, London, UNITED KINGDOM  
 Martin, John Francis, London, UNITED KINGDOM  
 Erusalimsky, Jorge Daniel, London, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002187939	A1	20021212
	US 7071183	B2	20060704
APPLICATION INFO.:	US 2002-206659	A1	20020726 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-529628, filed on 15 Jun 2000, PENDING A 371 of International Ser. No. WO 1998-GB3122, filed on 19 Oct 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-22026	19971017
	GB 1998-10855	19980520
	US 1997-67819P	19971205 (60)
	US 1998-94902P	19980731 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1304	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that inhibitors of the renin-angiotensin system are useful for the treatment or prevention of conditions associated with

hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(renin-angiotensin system inhibitors for treatment or prevention of a condition associated with hypoxia or impaired metabolic function or efficiency or for enhancing metabolic function)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 76 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:120855 USPATFULL

TITLE: Compositions and methods for treating colorectal polyps and cancer

INVENTOR(S): Tamura, Masaaki, Nashville, TN, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003083339	A1	20030501	<--
APPLICATION INFO.:	US 2002-133056	A1	20020426	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-286621P	20010426 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	4380	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of decreasing a biological function of an AT.sub.2 receptor in a subject in need thereof is disclosed. The method includes administering an effective amount of a therapeutic agent to the subject to decrease a biological function of an AT.sub.2 receptor. Cancer

therapy, particularly colorectal cancer therapy, by the method is also disclosed.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(compns. and methods for treating colorectal polyps and cancer)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 77 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:113776 USPATFULL  
TITLE: In vivo delivery methods and compositions  
INVENTOR(S): Kensey, Kenneth, Malvern, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078517	A1	20030424
APPLICATION INFO.:	US 2001-839785	A1	20010420 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-819924, filed on 28 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, GRANTED, Pat. No. US 6322525 Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, GRANTED, Pat. No. US 6322524 Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, GRANTED, Pat. No. US 6019735		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	19 Drawing Page(s)		
LINE COUNT:	2736		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood

viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(in vivo delivery methods and compns.)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 78 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:79112 USPATFULL

TITLE: Tnf-alpha inhibitors

INVENTOR(S): Ikeya, Kazuaki, Ikoma-gun, JAPAN  
Kitayoshi, Takahito, Suita-shi, JAPAN


	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055039	A1	20030320
	US 6833381	B2	20041221
APPLICATION INFO.:	US 2002-203805	A1	20020814 (10)
	WO 2001-JP1069		20010215
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1230		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB TNF- $\alpha$  inhibitors containing a heterocyclic compound having angiotensin II antagonistic activity which are useful as preventives/remedies for inflammatory diseases, etc.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(TNF- $\alpha$  inhibitors containing heterocyclic compds. having angiotensin  
II antagonisms)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-  
benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 79 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:119847 USPATFULL  
TITLE: In vivo delivery methods and compositions  
INVENTOR(S): Kensey, Kenneth R., Malvern, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061835	A1	20020523	<--
APPLICATION INFO.:	US 2001-828761	A1	20010409	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, PATENTED Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, PATENTED Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, PATENTED			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212			
NUMBER OF CLAIMS:	36			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	19 Drawing Page(s)			
LINE COUNT:	2173			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in

combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(methods for in vivo drug delivery based on monitoring blood flow parameters)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 80 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2002:54986 USPATFULL

TITLE: In vivo delivery methods and compositions

INVENTOR(S): Kensey, Kenneth, Malvern, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002032149	A1	20020314	<--
APPLICATION INFO.:	US 2001-841389	A1	20010424	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-819924, filed on 28 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, GRANTED, Pat. No. US 6322525 Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, GRANTED, Pat. No. US 6322524 Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, GRANTED, Pat. No. US 6019735			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212			
NUMBER OF CLAIMS:	36			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	19 Drawing Page(s)			
LINE COUNT:	2747			
CAS INDEXING IS AVAILABLE FOR THIS PATENT.				



AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(apparatus and methods for monitoring blood viscosity and other parameters in drug delivery for diagnostics and treatment)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 81 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2001:212586 USPATFULL  
TITLE: In vivo delivery methods and compositions  
INVENTOR(S): Kensey, Kenneth R., Malvern, PA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001044584	A1	20011122	<--
APPLICATION INFO.:	US 2001-819924	A1	20010328	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, GRANTED, Pat. No. US 6019735			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET,			

PHILADELPHIA, PA, 19103-2212


NUMBER OF CLAIMS: 36  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 19 Drawing Page(s)  
LINE COUNT: 2120

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(apparatus and methods for monitoring blood viscosity and other parameters in drug delivery for diagnostics and treatment)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 82 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2002:328709 CAPLUS  
DOCUMENT NUMBER: 137:345373  
TITLE: Angiotensin II receptor antagonists role in arterial hypertension  
AUTHOR(S): Hernandez-Hernandez, R.; Sosa-Canache, B.; Velasco, M.; Armas-Hernandez, M. J.; Armas-Padilla, M. C.; Cammarata, R.  
CORPORATE SOURCE: Clinical Pharmacology Unit, Center of Biomedical Research, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venez.  
SOURCE: Journal of Human Hypertension (2002), 16(Suppl. 1), S93-S99  
CODEN: JHHYEN; ISSN: 0950-9240

PUBLISHER: Nature Publishing Group  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Angiotensin II receptor blockers represent a class of effective and well tolerated orally active antihypertensive drugs. Activation of AT1 receptors leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone and promote growth of vascular and cardiac muscle. AT1 receptor blockers antagonize all those effects. Losartan was the first drug of this class marketed, shortly followed by valsartan, irbesartan, telmisartan, candesartan, eprosartan and others on current investigation. All these drugs have the common properties of blockading the AT1 receptor thereby relaxing vascular smooth muscle, increase salt excretion, decrease cellular hypertrophy and induce antihypertensive effect without modifying heart rate or cardiac output. Most of the AT1 receptor blockers in use controlled blood pressure during the 24 h with a once-daily dose, without evidence of producing tolerance to the antihypertensive effect and being with low incidence of side effects even at long term use. Monotherapy in mild-to-moderate hypertension controls blood pressure in 40 to 50% of these patients; when a low dose of thiazide diuretic is added, 60-70% of patients are controlled. The efficacy is similar to angiotensin-converting enzyme (ACE) inhibitors, diuretics, calcium antagonists and beta-blocking agents. AT1 receptor blockers are specially indicated in patients with hypertension who are being treated with ACE inhibitors and developed side effects such as, cough or angioedema. The final position in the antihypertensive therapy in this special population and other clin. situations, such as left ventricular hypertrophy, heart failure, diabetes mellitus and renal disease, has to be determined in large prospective clin. trials, some of which are now being conducted and seem promising.

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 83 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:390956 CAPLUS

DOCUMENT NUMBER: 133:187

TITLE: Angiotensin II receptor antagonists in arterial hypertension

AUTHOR(S): Hernandez-Hernandez, R.; Velasco, M.; Armas-Hernandez, M. J.; Armas-Padilla, M. C.

CORPORATE SOURCE: Clinical Pharmacology Unit, Center of Biomedical Research, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venez.

SOURCE: Journal of Human Hypertension (2000), 14(Suppl. 1), S69-S72  
CODEN: JHHYEN; ISSN: 0950-9240

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 34 refs. Angiotensin II receptor antagonists (AT-1) represent a new group of orally active antihypertensive agents. Activation on AT-1 receptor leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone with production of thirst, and promote growth of vascular and cardiac muscle; these effects are blocked by AT-1 antagonist agents. The first chemical useful, orally active AT-1 receptor antagonist was losartan, followed by other agents currently in clin. use, such as: valsartan, eprosartan, irbesartan, telmisartan, candesartan, and many others under investigation. AT-1 receptor antagonists are effective in reducing high blood pressure in hypertensive patients. Monotherapy in mild to moderate hypertension controls blood pressure in 40 to 50% of these patients; when a low dose of a thiazide diuretic is added, 60 to 70% of patients are controlled. The efficacy is similar to angiotensin-converting enzyme inhibitors,

diuretics, calcium antagonists and beta-blocking agents. Tolerability has been reported to be very good. AT-1 receptor antagonists would be a drug of choice in otherwise well-controlled hypertensive patients treated with angiotensin-converting enzyme inhibitors who developed cough or angioedema. The final position in the antihypertensive therapy in this special population and other clin. situations, such as left ventricular hypertrophy, heart failure, diabetes mellitus and renal disease, has to be determined in large prospective clin. trials, some of which are now being conducted.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 84 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:232558 USPATFULL  
TITLE: Aldosterone blocker therapy to prevent or treat inflammation-related disorders  
INVENTOR(S): Rocha, Ricardo, Gurnee, IL, UNITED STATES  
Zack, Marc, Evanston, IL, UNITED STATES  
McMahon, Ellen, Sunset Hills, MO, UNITED STATES  
Blasi, Eileen R., St. Louis, MO, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003162759	A1	20030828	<--
APPLICATION INFO.:	US 2001-916136	A1	20010726	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-221358P	20000727 (60)
	US 2001-261352P	20010112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006	
NUMBER OF CLAIMS:	71	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	55 Drawing Page(s)	
LINE COUNT:	5061	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Aldosterone blockers used for the treatment and prevention of inflammation are disclosed	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 85 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:173961 USPATFULL  
TITLE: Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors  
INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003119809	A1	20030626	<--
	US 7132415	B2	20061107	
APPLICATION INFO.:	US 2002-247095	A1	20020919	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-323942P	20010921 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ,	

07033-0530  
NUMBER OF CLAIMS: 23  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2722

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides therapeutic combinations and methods including at least one sterol or 5 $\alpha$ -stanol absorption inhibitor that can be useful for treating xanthomas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 86 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:322441 USPATFULL  
TITLE: Haplotypes of the AGTR1 gene  
INVENTOR(S): Anastasio, Alison E., New Haven, CT, UNITED STATES  
Finkel, Kevin, Cheshire, CT, UNITED STATES  
Koshy, Beena, North Haven, CT, UNITED STATES  
Lee, Helen, Shelton, CT, UNITED STATES  
PATENT ASSIGNEE(S): Genaissance Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002182605	A1	20021205	<--
	US 6521747	B2	20030218	
APPLICATION INFO.:	US 2001-867915	A1	20010530	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-228542P	20000828 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENAISSANCE PHARMACEUTICALS, 5 SCIENCE PARK, NEW HAVEN, CT, 06511	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	2631	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel genetic variants of the Angiotensin Receptor 1 (AGTR1) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the AGTR1 gene. Compositions and methods for haplotyping and/or genotyping the AGTR1 gene in an individual are also disclosed. Polynucleotides defined by the sequence of the haplotypes disclosed herein are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 87 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:119917 USPATFULL  
TITLE: Ethers of 7-desmethyldapamycin  
INVENTOR(S): Zhu, Tianmin, Monroe, NY, UNITED STATES  
Enever, Robin, New City, NY, UNITED STATES  
PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061905	A1	20020523	<--
	US 6440991	B2	20020827	
APPLICATION INFO.:	US 2001-956322	A1	20010919	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-237469P	20001002 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation,  
Patent Law Department - 2B, Five Giralda Farms,  
Madison, NJ, 07940

NUMBER OF CLAIMS: 12  
EXEMPLARY CLAIM: 1  
LINE COUNT: 552

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides ethers of 7-desmethyrapamycin which are useful  
in inducing immunosuppression and in the treatment of transplantation  
rejection, autoimmune diseases, solid tumors, fungal infections, and  
vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 88 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:119916 USPATFULL  
TITLE: Hydroxyesters of 7-desmethyrapamycin  
INVENTOR(S): Zhu, Tianmin, Monroe, NY, UNITED STATES  
Enever, Robin, New City, NY, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061904	A1	20020523	<--
	US 6399626	B2	20020604	
APPLICATION INFO.:	US 2001-955685	A1	20010919	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-237470P	20001002 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	640	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides hydroxyesters of 7-desmethyrapamycin which are  
useful in inducing immunosuppression and in the treatment of  
transplantation rejection, autoimmune diseases, solid tumors, fungal  
infections, and vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 89 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:119915 USPATFULL  
TITLE: 1-oxorapamycins  
INVENTOR(S): Zhu, Tianmin, Monroe, NY, UNITED STATES  
PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ (U.S.  
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061903	A1	20020523	<--
	US 6399625	B2	20020604	
APPLICATION INFO.:	US 2001-954880	A1	20010918	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-235750P	20000927 (60)
DOCUMENT TYPE:	Utility	



FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation,  
Patent Law Department - 2B, Five Giralda Farms,  
Madison, NJ, 07940  
NUMBER OF CLAIMS: 22  
EXEMPLARY CLAIM: 1  
LINE COUNT: 854  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides 1-oxorapamycins, which are useful in inducing immunosuppression, as a neurotrophic agent, and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 90 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:78778 USPATFULL  
TITLE: Use of angiotensin II receptor antagonists for treating acute myocardial infarction  
INVENTOR(S): Mann, Jessica M., Basel, SWITZERLAND  
Oddou, Pascale, Basel, SWITZERLAND  
Neuhart, Eric Michel, Mulhouse, FRANCE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002042436	A1	20020411	<--
	US 6544968	B2	20030408	
APPLICATION INFO.:	US 2001-915048	A1	20010725	(9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-EP525, filed on 24 Jan 2000, UNKNOWN			


	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-810061	19990126
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	627	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute MI and for the secondary prevention of acute MI.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(angiotensin II receptor antagonists for treating acute myocardial infarction)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 91 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:17328 USPATFULL  
 TITLE: Dha-pharmaceutical agent conjugates of taxanes  
 INVENTOR(S): Shashoua, Victor, Brookline, MA, UNITED STATES  
 Swindell, Charles, Merion, PA, UNITED STATES  
 Webb, Nigel, Bryn Mawr, PA, UNITED STATES  
 Bradley, Matthews, Layton, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002010208	A1	20020124 <--
	US 6602902	B2	20030805
APPLICATION INFO.:	US 2001-846838	A1	20010501 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-135291, filed on 17 Aug 1998, ABANDONED Continuation of Ser. No. US 1996-651312, filed on 22 May 1996, GRANTED, Pat. No. US 5795909		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Edward R. Gates, Esq., Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Page(s)		
LINE COUNT:	2437		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 92 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2001:123317 USPATFULL  
 TITLE: Rapidly disintegrable solid preparation  
 INVENTOR(S): Shimizu, Toshihiro, Hyogo, Japan  
 Sugaya, Masae, Osaka, Japan  
 Nakano, Yoshinori, Hyogo, Japan

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001010825	A1	20010802 <--
	US 7070805	B2	20060704

APPLICATION INFO.: US 2001-800839 A1 20010307 (9)  
RELATED APPLN. INFO.: Division of Ser. No. US 1999-403429, filed on 20 Oct  
1999, PENDING A 371 of International Ser. No. WO  
1999-JP4015, filed on 27 Jul 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-213049	19980728
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TAKEDA PHARMACEUTICALS AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1509	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A rapidly disintegrable solid preparation which comprises (i) a  
pharmacologically active ingredient, (ii) a sugar and (iii) a  
low-substituted hydroxypropylcellulose having 5% by weight or more to  
less than 7% by weight of hydroxypropoxyl group. The rapidly  
disintegrable solid preparation has fast disintegrability, suitable  
strength and no roughness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 93 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2001:90260 USPATFULL  
TITLE: Fatty acid-pharmaceutical agent conjugates  
INVENTOR(S): Webb, Nigel L., Bryn Mawr, PA, United States  
Bradley, Matthews O., Laytonsville, MD, United States  
Swindell, Charles S., Merion, PA, United States  
Shashoua, Victor E., Brookline, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001002404	A1	20010531
	US 6576636	B2	20030610
APPLICATION INFO.:	US 2000-730450	A1	20001205 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Page(s)		
LINE COUNT:	2511		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty acids and pharmaceutical  
agents useful in treating noncentral nervous system conditions. Methods  
for selectively targeting pharmaceutical agents to desired tissues are  
provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 94 OF 113 MEDLINE on STN  
ACCESSION NUMBER: 2004085581 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14974331  
TITLE: [Vascular patient with high infarction risk. Does the AT-1  
blocker protect as well as an ACE inhibitor?].  
Gefasspatient mit hohem Infarkttrisiko. Schutzt der  
AT1-Blocker so gut wie ein ACE-Hemmer?.

AUTHOR: Anonymous  
 SOURCE: MMW Fortschritte der Medizin, (2003 Dec 18) Vol. 145, No. 51-52, pp. 39.  
 Journal code: 100893959. ISSN: 1438-3276.  
 PUB. COUNTRY: Germany: Germany, Federal Republic of  
 DOCUMENT TYPE: (COMPARATIVE STUDY)  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: German  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200404  
 ENTRY DATE: Entered STN: 21 Feb 2004  
 Last Updated on STN: 28 Apr 2004  
 Entered Medline: 27 Apr 2004

L6 ANSWER 95 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:334719 USPATFULL  
 TITLE: Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent  
 INVENTOR(S): Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES  
 Patel, Mahesh V., Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235595	A1	20031225 <--
APPLICATION INFO.:	US 2003-397969	A1	20030325 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 Continuation-in-part of Ser. No. US 2000-751968, filed on 29 Dec 2000, GRANTED, Pat. No. US 6458383 Continuation-in-part of Ser. No. US 1999-375636, filed on 17 Aug 1999, GRANTED, Pat. No. US 6309663		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	110		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3903		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to oral pharmaceutical compositions and methods for improved delivery of therapeutic agents, e.g., lipid-regulating agents. Compositions of the present invention include a carrier, where the carrier contains a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the composition forms a clear, aqueous dispersion. The invention also pertains to methods for treating lipid disorders such as hypercholesterolemia, hypertriglyceridemia, and mixed dyslipidemia by oral administration of the compositions provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 96 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:307001 USPATFULL  
 TITLE: Thrombin receptor antagonists  
 INVENTOR(S): Chackalamannil, Samuel, Califon, NJ, UNITED STATES  
 Clasby, Martin C., Plainsboro, NJ, UNITED STATES  
 Greenlee, William J., Teaneck, NJ, UNITED STATES  
 Wang, Yuguang, North Brunswick, NJ, UNITED STATES  
 Xia, Yan, Edison, NJ, UNITED STATES  
 Veltri, Enrico P., Princeton, NJ, UNITED STATES  
 Chelliah, Mariappan V., Edison, NJ, UNITED STATES

PATENT ASSIGNEE(S): SCHERING CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003216437	A1	20031120	<--
APPLICATION INFO.:	US 2003-412982	A1	20030414	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-373072P	20020416 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1651	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Heterocyclic-substituted tricyclics of the formula ##STR1##	

or a pharmaceutically acceptable salt thereof, wherein:

the dotted line represents an optional single bond;

represents an optional double bond;

n is 0-2;

Q is cycloalkyl, optionally substituted by R.sup.13 and R.sup.14;

R.sup.13 and R.sup.14 are independently selected from (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl, --OH, (C.sub.1-C.sub.6)alkoxy, R.sup.27-aryl(C.sub.1-C.sub.6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or

R.sup.13 and R.sup.14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms;

Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and

B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 97 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:277178 USPATFULL  
TITLE: PDE9 inhibitors for treating cardiovascular disorders  
INVENTOR(S): DeNinno, Michael Paul, Gales Ferry, CT, UNITED STATES  
Hughes, Bernadette, Sandwich, UNITED KINGDOM  
Kemp, Mark Ian, Sandwich, UNITED KINGDOM  
Palmer, Michael John, Sandwich, UNITED KINGDOM  
Wood, Anthony, Sandwich, UNITED KINGDOM  
PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2003195205 A1 20031016 <--  
APPLICATION INFO.: US 2002-283514 A1 20021030 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-26395	20011102
	GB 2001-30695	20011221
	GB 2002-16761	20020718
	US 2002-350777P	20020122 (60)
	US 2002-399905P	20020730 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1888	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to PDE9 inhibitors for treating cardiovascular disorders. Preferred PDE9 inhibitors are compounds of formula I wherein R.sup.1 is H or C.sub.1-6 alkyl, wherein R.sup.1 is attached to either N.sup.1 or N.sup.2; R.sup.2 is C.sub.1-6 alkyl optionally substituted by hydroxy or alkoxy; C.sub.3-7 cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-membered heterocycle optionally substituted by alkyl, hydroxy or alkoxy; het1 or Ar.sup.1; R.sup.3 is C.sub.1-6 alkyl optionally substituted by 1 or 2 groups independently selected from: Ar.sup.2; C.sub.3-7cycloalkyl optionally substituted by C.sub.1-6alkyl; OAr.sup.2; SAR.sup.2; NHC(O)C.sub.1-6 alkyl; het.sup.2; xanthene; and naphthalene. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 98 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:238541 USPATFULL  
TITLE: Use of angiotensin II receptor antagonists for treating acute myocardial infarction  
INVENTOR(S): Mann, Jessica M., Basel, SWITZERLAND  
Oddou, Pascale, Basel, SWITZERLAND  
Neuhart, Eric Michel, Mulhouse, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166699	A1	20030904 <--
	US 6767905	B2	20040727
APPLICATION INFO.:	US 2003-376049	A1	20030227 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-915048, filed on 25 Jul 2001, GRANTED, Pat. No. US 6544968 Continuation of Ser. No. WO 2000-EP525, filed on 24 Jan 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-810061	19990126
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	626	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute MI and for the



secondary prevention of acute MI.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(angiotensin II receptor antagonists for treating acute myocardial infarction)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 99 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:214427 USPATFULL

TITLE: Method of treating cardiovascular disease

INVENTOR(S): Azrolan, Neal I., Lawrenceville, NJ, UNITED STATES

Sehgal, Surendra N., Snohomish, WA, UNITED STATES

Adelman, Steven J., Doylestown, PA, UNITED STATES

PATENT ASSIGNEE(S): Wyeth, Madison, NJ (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003149070	A1	20030807	<--
	US 6670355	B2	20031230	
APPLICATION INFO.:	US 2002-313217	A1	20021206	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-880295, filed on 13 Jun 2001, ABANDONED			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-212117P	20000616 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
LINE COUNT:	574	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a method of treating or inhibiting cardiovascular, cerebral vascular, or peripheral vascular disease in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 100 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:173960 USPATFULL  
TITLE: Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects  
INVENTOR(S): LeBeaut, Alexandre P., Morristown, NJ, UNITED STATES  
Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003119808	A1	20030626	<--
APPLICATION INFO.:	US 2002-246996	A1	20020919	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-324121P	20010921 (60)
	US 2002-351957P	20020125 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3092	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects associated with certain HMG-CoA reductase inhibitors by coadministration of at least one sterol or 5 $\alpha$ -stanol absorption inhibitor, pharmaceutically acceptable salts or solvates thereof, and at least one HMG-CoA reductase inhibitor, the latter being used sparingly in amounts insufficient to cause muscle degeneration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 101 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:173582 USPATFULL  
TITLE: Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors  
INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
Ress, Rudyard J., Flemington, NJ, UNITED STATES  
Strony, John T., Lebanon, NJ, UNITED STATES  
Veltri, Enrico P., Princeton, NJ, UNITED STATES  
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003119428	A1	20030626	<--
	US 7053080	B2	20060530	
APPLICATION INFO.:	US 2002-247397	A1	20020919	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-166942, filed on 11 Jun 2002, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-323840P	20010921 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	

NUMBER OF CLAIMS: 35  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3027

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for the treatment of obesity using sterol or 5 $\alpha$ -stanol absorption inhibitors and compositions and therapeutic combinations including sterol or 5 $\alpha$ -stanol absorption inhibitors and at least one obesity control medication.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 102 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:110457 USPATFULL

TITLE: Method and apparatus for dispensing inhalator medicament

INVENTOR(S): Johnson, Keith A., Durham, NC, UNITED STATES  
Casper, Robert A., Sanford, NC, UNITED STATES  
Gardner, David L., Chapel Hill, NC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003075172	A1	20030424	<--
APPLICATION INFO.:	US 2002-267013	A1	20021008	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-344544P	20011019 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORRISS, BATEMAN, O'BRYANT & COMPAGNI, 136 SOUTH MAIN STREET, SUITE 700, SALT LAKE CITY, UT, 84101	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	846	

AB An apparatus and method for delivering a plurality of medication includes providing first and second medicament on a medicament pack in separate containers for preventing either medicament from interfering with the stability of the other. In accordance with the method, the medicaments are preferably delivered in a single inhalation.

L6 ANSWER 103 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2002:37867 USPATFULL

TITLE: Methods for effecting neuroprotection

INVENTOR(S): Ferguson, Alastair V., Kingston, CANADA  
Bains, Jaideep S., Calgary, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002022587	A1	20020221	<--
APPLICATION INFO.:	US 2001-817229	A1	20010327	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-192585P	20000328 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1199	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for preventing damage to excitable cells following ischemic by administering to a patient who is undergoing or who has undergone an ischemic event an effective amount of a compound which increases a transient potassium (K<sub>sup.</sub>+) conductance in the excitable cells of the patient. The present invention also provides a method for screening for compounds which increase a transient K<sub>sup.</sub>+ current in the excitable cells of a patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 104 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2001:173168 USPATFULL  
TITLE: Solid pharmaceutical preparation  
INVENTOR(S): Shimizu, Toshihiro, Itami, Japan  
Sugaya, Masae, Ikeda, Japan  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan  
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6299904	B1	20011009	<--
	WO 9853798		19981203	<--
APPLICATION INFO.:	US 1999-424434		19991123	(9)
	WO 1998-JP2298		19980526	
			19991123	PCT 371 date
			19991123	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-136724	19970527
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Fubara, Blessing	
LEGAL REPRESENTATIVE:	Chao, Mark, Ramesh, Elaine M.	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	679	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solid preparation which comprises (i) a pharmaceutically active ingredient, (ii) one or more water-soluble sugar alcohols selected from the group consisting of sorbitol, maltitol, reduced starch saccharide, xylitol, reduced palatinose and erythritol, and (iii) low-substituted hydroxypropylcellulose having hydroxypropoxyl group contents of 7.0 to 9.9 percent by weight; which exhibits excellent buccal disintegration and dissolution and also appropriate strength.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 105 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2001:119057 USPATFULL  
TITLE: Solid preparation  
INVENTOR(S): Toshihiro, Shimizu, Osaka, Japan  
Masae, Sugaya, Osaka, Japan

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001009678	A1	20010726	<--
	US 6586004	B2	20030701	
APPLICATION INFO.:	US 2001-800748	A1	20010307	(9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-424434, filed on 23 Nov 1999, PENDING A 371 of International Ser. No. WO 1998-JP2298, filed on 26 May 1998, UNKNOWN			

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	JP 1997-136724	19970527
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TAKEDA PHARMACEUTICALS AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	705	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solid preparation which comprises (i) a pharmaceutically active ingredient, (ii) one or more water-soluble sugar alcohol selected from the group consisting of sorbitol, maltitol, reduced starch saccharide, xylitol, reduced palatinose and erythritol, and (iii) low-substituted hydroxypropylcellulose having hydroxypropoxyl group contents of 7.0 to 9.9 percent by weight; which exhibits excellent buccal disintegration and dissolution and also appropriate strength.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 106 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 1998:98932 USPATFULL  
 TITLE: DHA-pharmaceutical agent conjugates of taxanes  
 INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States  
 Swindell, Charles S., Merion, PA, United States  
 Webb, Nigel L., Bryn Mawr, PA, United States  
 Bradley, Matthews O., Laytonsville, MD, United States  
 PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE	
	-----	-----	-----	
PATENT INFORMATION:	US 5795909		19980818	<--
APPLICATION INFO.:	US 1996-651312		19960522	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Jarvis, William R. A.			
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.			
NUMBER OF CLAIMS:	12			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)			
LINE COUNT:	2451			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 107 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:214415 USPATFULL  
 TITLE: Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders  
 INVENTOR(S): Eisert, Wolfgang, Hannover, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
	-----	-----	-----	
PATENT INFORMATION:	US 2003149058	A1	20030807	<--
APPLICATION INFO.:	US 2003-376072	A1	20030227	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-694610, filed on 23  
Oct 2000, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1999-991211210	19991022
	US 1999-167797P	19991129 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	456	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treatment of the human or non-human animal body for treating  
fibrin-dependent microcirculation disorders is disclosed, for example,  
microcirculation disorders caused by metabolic diseases, inflammatory  
reactions or autoimmune diseases; peripheral microcirculation disorders  
or microcirculation disorders associated with increased cell  
fragmentation comprising administering to a human or non-human animal  
body in need of such treatment an effective amount of a pharmaceutical  
composition containing a pyrimido-pyrimidine selected from dipyridamole,  
mopidamol and the pharmaceutically acceptable salts thereof, and the use  
of said pyrimido-pyrimidine for the manufacture of a corresponding  
pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 108 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:85867 USPATFULL  
TITLE: Oral delivery formulation  
INVENTOR(S): Compton, Bruce Jon, Lexington, MA, UNITED STATES  
Solari, Nancy E., West Newton, MA, UNITED STATES  
Flangan, Margaret A., Stow, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003059471	A1	20030327 <--
APPLICATION INFO.:	US 2001-997277	A1	20011129 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-55560, filed on 6 Apr 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69501P	19971215 (60)
	US 1998-73867P	19980204 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Stephen J Gaudet, 68H Stiles Road, Salem, NH, 03079	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2950	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Flakes containing drugs and methods for forming and using such flakes  
are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 109 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:323094 USPATFULL  
TITLE: Dipeptide derivatives  
INVENTOR(S): Fink, Cynthia Anne, Lebanon, NJ, UNITED STATES



	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002183260	A1	20021205	<--
	US 6777443	B2	20040817	
APPLICATION INFO.:	US 2002-142693	A1	20020509	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-291088P	20010515 (60)
	US 2001-339575P	20011211 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1570	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds of the formula ##STR1##	

wherein R, R.sub.1, COOR.sub.2, R.sub.3-R.sub.7, alk, and X have meaning as defined, such being useful as dual inhibitors of angiotensin converting enzyme and neutral endopeptidase, as well as inhibitors of endothelin converting enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 110 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:32538 USPATFULL  
 TITLE: Treatment for cardiovascular disease  
 INVENTOR(S): Kivlighn, Saluh, Doylestown, PA, UNITED STATES  
 Johnson, Richard, Bellaire, TX, UNITED STATES  
 Mazzali, Marilda, Houston, TX, UNITED STATES  
 PATENT ASSIGNEE(S): Merck & Co., Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002019360	A1	20020214	<--
APPLICATION INFO.:	US 2001-892505	A1	20010628	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-214825P	20000628 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	McDERMOTT, WILL & EMERY, 600 13th Street, N.W., Washington, DC, 20005-3096	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	1402	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB This invention relates to a method for treating and preventing hypertension by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment. Additionally, the scope of the invention includes a method of treating coronary heart disease by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 111 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:22499 USPATFULL  
 TITLE: Method of treating cardiovascular disease  
 INVENTOR(S): Azrolan, Neal I., Lawrenceville, NJ, UNITED STATES  
 Sehgal, Surendra N., Snohomish, WA, UNITED STATES  
 Adelman, Steven J., Doylestown, PA, UNITED STATES  
 PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ,  
 07054-0874 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002013335	A1	20020131	<--
APPLICATION INFO.:	US 2001-880295	A1	20010613	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-212117P	20000616 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	464	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a method of treating or inhibiting cardiovascular, cerebral vascular, or peripheral vascular disease in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 112 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2001:48090 USPATFULL  
 TITLE: Method for reducing pericardial fibrosis and adhesion formation  
 INVENTOR(S): Spinale, Francis G., Charleston, SC, United States  
 de Gasparo, Marc, Rossemaison, Switzerland  
 PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6211217	B1	20010403	<--
APPLICATION INFO.:	US 1999-270412		19990316	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Spivack, Phyllis G.			
LEGAL REPRESENTATIVE:	Ferraro, Gregory D.			
NUMBER OF CLAIMS:	10			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 3 Drawing Page(s)			
LINE COUNT:	1012			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods of reducing fibrosis and adhesion formation in a surgical patient wherein the AT.sub.1 receptor antagonist, the compound (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine (valsartan) of formula ##STR1##

or a salt thereof, in particular a pharmaceutically acceptable salt thereof, is administered to the patient. In particular, disclosed are methods of reducing pericardial fibrosis and pericardial adhesion formation which results from cardiac surgery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 113 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2001:21788 USPATFULL  
TITLE: Stabilized pharmaceutical preparation  
INVENTOR(S): Fukuta, Makoto, Nara, Japan  
Itoh, Hiroki, Suita, Japan  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan  
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6187340	B1	20010213	<--
APPLICATION INFO.:	US 1998-149122		19980909	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-245778	19970910
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Williamson, Michael A.	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack, L.L.P.	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1140	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A stabilized pharmaceutical preparation which is coated with a coating agent comprising an agent for the protection from light, said agent being capable of producing free radicals when exposed to ultraviolet rays, and a free radical scavenger; which is stable to light, especially ultraviolet rays, or heat, and which has excellent storage-stability.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

## Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells

Arya M. Sharma, Jürgen Janke, Kerstin Gorzelniak, Stefan Engeli, Friedrich C. Luft

**Abstract**—Obesity is the prime risk factor for the development of type 2 diabetes. Recent clinical trials have shown that blockade of the renin-angiotensin system, either by inhibiting the angiotensin-converting enzyme or blocking the angiotensin type 1 receptor, may substantially lower the risk for type 2 diabetes. The mechanism underlying this effect is unknown. Based on our recent observation that angiotensin II markedly inhibits adipogenic differentiation of human adipocytes via the angiotensin type I receptor and that expression of angiotensin II-forming enzymes in adipose tissue is inversely correlated with insulin sensitivity, we propose the hypothesis that blockade of the renin-angiotensin system prevents diabetes by promoting the recruitment and differentiation of adipocytes. Increased formation of adipocytes would counteract the ectopic deposition of lipids in other tissues (muscle, liver, pancreas), thereby improving insulin sensitivity and preventing the development of type 2 diabetes. (*Hypertension*. 2002;40:609-611.)

**Key Words:** angiotensin ■ diabetes ■ adipose tissue ■ insulin resistance ■ obesity

Recent clinical trials suggest that blockade of the renin-angiotensin system (RAS), either by inhibiting the angiotensin-converting enzyme (ACE)<sup>1,2</sup> or by blocking the angiotensin type 1 (AT<sub>1</sub>)<sup>3</sup> receptor, may substantially lower the risk for type 2 diabetes. Thus, in the Captopril Primary Prevention Project (CAPPP) trial, incidence of diabetes was 14% lower in the captopril group than in the conventional group,<sup>1</sup> whereas, in the Heart Outcomes Prevention Evaluation (HOPE) trial, there was 34% reduction in relative risk for the development of type 2 diabetes.<sup>2</sup> Similarly, in the Intervention For Endpoint Reduction in Hypertension study (LIFE), the incidence of type 2 diabetes was reduced by 25% in the losartan group, albeit versus patients treated with atenolol.<sup>3</sup> The mechanism underlying this effect is unknown. Based on our recent observation that angiotensin II (Ang II) inhibits adipogenic differentiation of human adipocytes via the AT<sub>1</sub> receptor<sup>4</sup> and that expression of Ang II-forming enzymes in adipose tissue is inversely correlated with insulin sensitivity,<sup>5</sup> we propose the hypothesis that RAS blockade prevents diabetes by promoting the differentiation of adipocytes.

Obesity is by far the strongest risk factor for the development of type 2 diabetes. Paradoxically, however, failure to expand adipose tissue to accommodate excess calories has been recently implicated in the development of type 2 diabetes.<sup>6</sup> According to this idea, failure of adipocyte differentiation promotes the storage of excess calories in the liver, muscles, pancreas, and other tissues, thereby contributing to the development of insulin resistance and  $\beta$ -cell failure ("lipotoxicity" hypothesis).<sup>7</sup> This

hypothesis is supported by several observations: surgical implantation of adipose tissue reverses diabetes in lipodystrophic mice,<sup>8</sup> large adipocyte size (suggesting difficulty in differentiating) is the best correlate for diabetes onset in obese Pima Indians,<sup>9</sup> insulin sensitivity during overfeeding correlates with the recruitment of new adipocytes, and the in vitro yield of newly differentiated adipocytes is greater in lean than in obese subjects.<sup>10</sup> Furthermore, hepatic steatosis and excess lipid in muscle and pancreas is characteristic of obese diabetics.<sup>7</sup> It has also recently been suggested that the prime mechanism by which thiazolidinediones reverse insulin resistance is by stimulating the adipogenic differentiation of fat cell precursors.<sup>11</sup>

Our hypothesis is summarized in the Figure. We suggest that increased formation of angiotensin II by large insulin-resistant adipocytes inhibits recruitment of preadipocytes, resulting in increased storage of lipids in muscle and other tissues, thereby increasing insulin sensitivity. In contrast, RAS blockade promotes recruitment of preadipocytes, thereby increasing the number of small insulin-sensitive adipocytes. Redistribution of lipids from muscle and other tissues to adipose tissue would result in improved insulin sensitivity.

### Testing the Hypothesis

Testing the hypothesis that RAS blockade prevents diabetes by promoting the differentiation of new fat cells is not straightforward. As a first step, it would be helpful to further

Received July 15, 2002; first decision August 8, 2002; revision accepted August 21, 2002.

From HELIOS Klinikum Berlin, Franz Volhard Clinic-Charité, Humboldt University of Berlin, and Max Delbrück Center for Molecular Medicine, Berlin, Germany.

Correspondence to Arya M. Sharma, MD, Canada Research Chair for Cardiovascular Obesity Research and Management, McMaster University, Hamilton, Ontario L8L 2X2, Canada. E-mail sharma@ccc.mcmaster.ca

A.M.S. and F.C.L. have served as consultants and have received research support from several companies producing ACE inhibitors or angiotensin receptor blockers. Work leading to the proposition of this hypothesis was supported by a grant-in-aid to A.M.S. from Sanofi-Synthelabo, a manufacturer of an angiotensin receptor blocker.


© 2002 American Heart Association, Inc.

*Hypertension* is available at <http://www.hypertensionaha.org>

DOI: 10.1161/01.HYP.0000036448.44066.53

- PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. *Lancet*. 1999;353:611-616.
2. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolfenbutter BH, Zinman B. Ramipril and the development of diabetes. *JAMA*. 2001;286:1882-1885.
  3. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002;359:995-1003.
  4. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin-type 1 receptors. *Diabetes*. 2002;51:1699-1707.
  5. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. *J Hypertension*. 2002;20:965-973.
  6. Danforth E Jr. Failure of adipocyte differentiation causes type II diabetes mellitus? *Nat Genet*. 2000;26:13.
  7. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. *Diabetologia*. 1999;42:128-138.
  8. Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M, Reitman ML. Surgical implantation of adipose tissue reverses diabetes in lipotrophic mice. *J Clin Invest*. 2000;105:271-278.
  9. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. *Diabetologia*. 1995;38:1213-1217.
  10. Kashiwagi A, Mott D, Bogardus C, Lillioja S, Reaven GM, Foley JE. The effects of short-term overfeeding on adipocyte metabolism in Pima Indians. *Metabolism*. 1985;34:364-370.
  11. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. *J Clin Invest*. 1998;101:1354-1361.
  12. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK, O'Rahilly S. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. *J Clin Invest*. 1997;100:3149-3153.
  13. Kissebah AH, Krakower GR. Regional adiposity and morbidity. *Physiol Rev*. 1994;74:761-811.
  14. Saint-Marc P, Kozak LP, Ailhaud G, Darimont C, Negrel R. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. *Endocrinology*. 2001;142:487-492.
  15. Weyer C, Wolford JK, Hanson RL, Foley JE, Tataranni PA, Bogardus C, Pratley RE. Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21-q23 and is associated with a common polymorphism in LMNA in Pima Indians. *Mol Genet Metab*. 2001;72:231-238.





This figure summarizes our hypothesis. A, Increased formation of angiotensin II by large insulin-resistant adipocytes inhibits recruitment of preadipocytes, resulting in increased storage of lipids in muscle and other tissues, thereby decreasing insulin sensitivity. B, Blockade of the renin-angiotensin system promotes recruitment of preadipocytes, thereby increasing the number of small insulin-sensitive adipocytes. Redistribution of lipids from muscle and other tissues to adipose tissue results in improved insulin sensitivity.

explore the regulation and function of the adipose-tissue RAS, particularly regarding the issue whether large insulin-resistant fat cells do indeed produce more Ang II than smaller adipocytes. These studies will need to go beyond gene-expression analyses and should include functional assays on Ang II formation, always taking into consideration that in vitro conditions such as hypoxia may sometimes lead to results that cannot be extrapolated to the intact organism. It would also be of interest to explore whether there are regional differences in the influence of RAS blockade on adipocyte differentiation. Thus, for example, the prodifferentiating effects of thiazolidinediones have been demonstrated to be stronger on subcutaneous than on omental preadipocytes.<sup>12</sup> This issue is of importance because further expansion of visceral adipose tissue by RAS blockade would be undesired, given its involvement in the metabolic and vascular complications of obesity.<sup>13</sup>

Demonstrating that the profound stimulatory effect of AT<sub>1</sub>-receptor blockade on adipogenic differentiation observed in our in vitro study is indeed present in vivo is clearly not a trivial task. One approach could perhaps be to perform fat biopsies in human subjects before and at some time point (weeks or months) during AT<sub>1</sub>-receptor blockade. If our hypothesis is correct, AT<sub>1</sub>-receptor blockade should perhaps reduce the average adipocyte size as a sign of new adipocyte

formation in individuals without weight loss. Similar observations have been made with thiazolidinediones, where troglitazone did not change the total weight of white adipose tissues but increased the number of small adipocytes approximately 4-fold and decreased the number of large adipocytes by approximately 50%.<sup>11</sup> One would also need to demonstrate that any decrease in adipocyte size by RAS blockade should result both in an improvement in ex vivo insulin sensitivity of these adipocytes and improvement of insulin sensitivity of the patient. Furthermore, AT<sub>1</sub>-receptor blockade should result in the disappearance of lipids from muscle and liver as these are redistributed back to adipose tissue, a process that can be followed by nuclear magnetic resonance spectroscopy.

Ultimately, however, larger prospective studies would be necessary to demonstrate that induction of adipogenic differentiation by AT<sub>1</sub>-receptor blockade is indeed related to the prevention of type 2 diabetes in high-risk individuals. Such a study would not only require a large number of subjects but also would take several years to perform.

In rodent models, Ang II has been shown to promote adipogenic differentiation of preadipocytes,<sup>14</sup> the exact opposite of our finding in humans. Thus, rodent models would apparently not be suited for testing our hypothesis.

### Implications for Clinical Practice

Currently, several large studies are underway to further explore the relationship between RAS blockade and the development of type 2 diabetes. Thus, the Diabetes REduction Approaches with Medication (DREAM) study will follow 4000 individuals with impaired glucose tolerance at high risk of developing diabetes who are randomized to ramipril, rosiglitazone, or placebo. The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), a study in 29 000 cardiovascular high-risk patients, will also include the new development of type 2 diabetes as a secondary endpoint. If these studies confirm the preventive effect of RAS blockade on the development of type 2 diabetes, the demonstration that RAS blockade promotes the differentiation of adipocytes would provide a scientific rationale for the use of ACE inhibitors or AT<sub>1</sub>-receptor blockers for the prevention of diabetes in high-risk individuals. Furthermore, it would also allow us to target individuals who have larger adipocytes and/or higher activities of angiotensin-forming enzymes in their adipose tissue. Such patients would, therefore, be more likely to develop diabetes than individuals with smaller adipocytes. The same may apply to individuals who have hepatic steatosis or increased myocytic lipid stores, signs of impaired adipose-tissue expansion. Recent genetic studies have identified a locus on chromosome 1 related to adipocyte size.<sup>15</sup> It would clearly be of interest to explore the effect of RAS blockade on adipocyte growth and function and the development of diabetes in individuals with an apparently increased genetic predisposition for large adipocytes. [Author: The last 2 references<sup>14,15</sup> were not cited in this paper. Per journal style, please cite or delete references.]

### References

1. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlöf B, de Faire U, Morlin C, Karlberg BE, Wester



# From the HOPE to the ONTARGET and the TRANSCEND Studies: Challenges in Improving Prognosis

Salim Yusuf, DPhil

The Heart Outcomes Prevention Evaluation (HOPE) study conclusively demonstrated that ramipril, an angiotensin-converting enzyme (ACE) inhibitor, reduces the risk of cardiovascular death, myocardial infarction (MI), and death in patients at risk for cardiovascular events but without heart failure. The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE) substudy demonstrated that ramipril also reduced atherosclerosis. These results suggest that the renin-angiotensin system (RAS) has a more important role in the development and progression of atherosclerosis than previously believed, and they indicate the need for further clinical studies to define the range of benefits available from modifying the RAS. Achieving maximum benefit may require treatment with both an ACE inhibitor and an angiotensin II type-1 receptor blocker (ARB). The Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) study indicated that combining an ACE inhibitor with an ARB decreased blood pressure and improved the ejection fraction more than treatment with either drug alone in patients with congestive heart failure. The Valsartan in Heart Failure Trial (Val-HeFT) showed that the combination of an ACE inhibitor and an ARB reduced hospitalization for heart failure in patients with congestive

heart failure by 27.5%, although no decrease in all-cause mortality was observed. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) is a large, long-term study (23,400 patients, 5.5 years). It will compare the benefits of ACE inhibitor treatment, ARB treatment, and treatment with an ACE inhibitor and ARB together, in a study population with established coronary artery disease, stroke, peripheral vascular disease, or diabetes with end-organ damage. Patients with congestive heart failure will be excluded. In a parallel study, patients unable to tolerate an ACE inhibitor will be randomized to receive telmisartan or placebo (the Telmisartan Randomized Assessment Study in ACE-I Intolerant Patients with Cardiovascular Disease [TRANSCEND]). The primary endpoint for both trials is a composite of cardiovascular death, MI, stroke, and hospitalization for heart failure. Secondary endpoints will investigate reductions in the development of diabetes mellitus, nephropathy, dementia, and atrial fibrillation. These 2 trials are expected to provide new insights into the optimal treatment of patients at high risk of complications from atherosclerosis. ©2002 by Excerpta Medica, Inc.

Am J Cardiol 2002;89(suppl):18A-26A

**T**he Heart Outcomes Prevention Evaluation (HOPE) trial showed that the angiotensin-converting enzyme (ACE) inhibitor ramipril is effective in preventing major cardiovascular events in high-risk patients without hypertension or those whose hypertension is sufficiently controlled with other treatments.<sup>1</sup> These data suggest that ACE inhibitors may exert direct actions on blood vessels beyond their hemodynamic effects. The results stimulate research in 2 directions: (1) toward understanding how modulating the renin-angiotensin system (RAS) protects blood vessels and (2) toward clinical studies defining the complete spectrum of benefit that can result from inhibiting the RAS system using multiple approaches. This article reviews recent data and research directions culminating in the design of the Ongoing Telmisartan Alone and in

Combination with Ramipril Global Endpoint Trial (ONTARGET) study and the Telmisartan Randomized Assessment Study in Angiotensin-Converting Enzyme Inhibitor-Intolerant Patients with Cardiovascular Disease (TRANSCEND), which are intended to further both of the above goals.

## A POSSIBLE ROLE FOR ANGIOTENSIN II IN THE DEVELOPMENT AND PROGRESSION OF CARDIOVASCULAR DISEASE

Historically, the RAS has been viewed as a regulatory system limited to blood pressure and fluid electrolyte regulation. Disorders of this system contribute to the pathophysiology of hypertension, renal disease, and congestive heart failure. These conditions can be improved by ACE inhibition and/or blockade of angiotensin II type-1 receptors.<sup>2</sup> However, recent work suggests that angiotensin II also has a direct role in atherothrombosis.<sup>3</sup>

Victor Dzau<sup>3</sup> has proposed that angiotensin II, which is produced by the effects of ACE on angiotensin I, is critical to a number of steps in the development of atherosclerosis and thrombosis (Figure 1).

From the Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Reprints are not available.

Address for correspondence: Salim Yusuf, DPhil, Division of Cardiology, Department of Medicine, McMaster University, Hamilton General Hospital, Room 253, McMaster Clinic, 237 Barton Street East, Hamilton, Ontario L8L2X2, Canada. E-mail: yusufs@mcmaster.ca.




FIGURE 1. Proposed model integrating angiotensin II (A II) into the development and progression of vascular disease. ACE = angiotensin-converting enzyme; BP = blood pressure; ICAM = intracellular adhesion molecule; LDL = low-density lipoprotein cholesterol; NO = nitric oxide; PAI-1 = plasminogen activator inhibitor-1; VCAM = vascular cell adhesion molecule. (Reprinted with permission from *Hypertension*.<sup>3</sup>)

Angiotensin II is synthesized by the endothelium and could directly constrict the vessel wall. ACE, angiotensin II, and its receptor are increased within atherosclerotic lesions,<sup>4</sup> perhaps because of increased oxidative stress or endothelial dysfunction caused by known risk factors.<sup>3</sup> Increased tissue ACE and angiotensin II may contribute to vessel pathology through a combination of mechanisms (Figure 1). Angiotensin II stimulates receptors on different cell types within the lesion, resulting in production of secondary mediators, such as endothelin, plasminogen activator inhibitor-1, tissue factor, cytokines, growth factors, and proteolytic enzymes. In turn, these mediators cause vasoconstriction, thrombosis, inflammation, plaque rupture, and vascular lesion formation (Figure 1), which could lead to cardiovascular events.

A hypothesis derived from this model is that reduction of angiotensin II production via inhibition of ACE or prevention of angiotensin II type 1 signaling

by an angiotensin II type-1 receptor blocker (ARB) may disrupt the cascade of events causing development and progression of heart disease. From this perspective, patients with any form of existing atherosclerosis would be considered high-risk patients and would therefore be expected to benefit from inhibition of the RAS. Data from the HOPE study are consistent with this possibility.

### THE HEART OUTCOMES PREVENTION EVALUATION STUDY

The HOPE study<sup>1</sup> randomized 9,297 high-risk patients >55 years of age, who had clinical evidence of vascular disease (coronary artery disease, cerebrovascular disease, or peripheral arterial disease), or diabetes and 1 other cardiovascular risk factor (hypertension, elevated levels of total cholesterol, low levels of high-density lipoprotein cholesterol, cigarette smoking, or microalbuminuria). None had heart failure or




FIGURE 2. Kaplan-Meier estimates of the primary composite outcome of myocardial infarction, stroke, or death from cardiovascular causes from the Hypertension Outcomes Prevention Evaluation (HOPE) study. (Reprinted with permission from *N Engl J Med*.<sup>1</sup> Copyright © 2000 Massachusetts Medical Society. All rights reserved.)

were known to have a low ejection fraction. The population did not include patients with hypertension unless the blood pressure was already controlled (average blood pressure at entry was  $139 \pm 20/79 \pm 11$  mm Hg at baseline). After randomization, patients were treated with placebo or ramipril orally once daily at 2.5 mg for 1 week, 5 mg for the next 3 weeks, and then 10 mg for the rest of the trial (a mean of 4.5 years).<sup>1</sup>

The primary outcome was a composite of myocardial infarction (MI), stroke, or death from cardiovas-

cular causes (Figure 2, Table 1). A significant 21% decrease in the primary endpoint was observed with ramipril treatment (event rate of 17.8% [placebo] to 14% [ramipril]). There were clear and significant reductions in cardiovascular death, stroke, and MI. The shape of the Kaplan-Meier curve shows that the difference between the ramipril- and placebo-treated groups appeared fairly early and increased over time, suggesting even greater benefit with prolonged treatment (Figure 2).<sup>1</sup>

TABLE 1 Outcomes of the Heart Outcomes Prevention (HOPE) Evaluation Study

Outcome	Relative Risk (95% CI)	p-Value
Primary outcomes and incidence of death from any cause		
• Myocardial infarction, stroke, or death due to cardiovascular causes	0.78 (0.70–0.86)	<0.001
–Death due to cardiovascular causes	0.74 (0.64–0.87)	<0.001
–Myocardial infarction	0.80 (0.70–0.90)	<0.001
–Stroke	0.68 (0.56–0.84)	<0.001
• Death due to noncardiovascular causes	1.03 (0.85–1.26)	0.74
• Death due to any cause	0.84 (0.75–0.95)	0.005
Secondary outcomes		
• Revascularization	0.85 (0.77–0.94)	0.002
• Hospitalization for unstable angina	0.98 (0.87–1.10)	0.68
• Complications related to diabetes	0.84 (0.72–0.98)	0.03
• Hospitalization for heart failure	0.88 (0.70–1.10)	0.25
Other outcomes		
• Heart failure	0.77 (0.67–0.87)	<0.001
• Cardiac arrest	0.62 (0.41–0.94)	0.02
• Worsening angina	0.89 (0.82–0.96)	0.004
• New diagnosis of diabetes	0.66 (0.51–0.85)	0.001
• Unstable angina with electrocardiographic changes	0.97 (0.79–1.19)	0.76

Adapted from *N Engl J Med*.<sup>1</sup>




FIGURE 3. Beneficial effects of treatment with ramipril on the composite outcome (myocardial infarction, stroke, cardiovascular death) in various predefined subgroups with different sources of cardiovascular risk. (Reprinted with permission from *N Engl J Med*.<sup>1</sup> Copyright © 2000 Massachusetts Medical Society. All rights reserved.)

A significant decrease in death from cardiovascular causes (from 8.1% to 6.1%) and death from any cause (from 12.2% to 10.4%) was observed (Table 1).<sup>1</sup> No difference in death from noncardiovascular causes was found, reinforcing the observation that decreases in mortality are caused by reductions in cardiovascular disease. The incidence of MI was reduced by 19% (from 12.3% to 9.9%), and the incidence of stroke was reduced by 31% (from 4.9% to 3.1%), which is 3 times the decrease that would be predicted based on the modest reduction (3.5/1.5 mm Hg) of blood pressure alone. Significant reductions were also observed in the need for revascularization procedures, complications related to diabetes, the incidence of heart failure, cardiac arrest, worsening angina, and a new diagnosis of diabetes (Table 1).<sup>1</sup> The reductions in the range of endpoints affected support the hypothesis that ACE inhibition modifies the fundamental processes in the vascular wall in multiple territories.

Another important finding from the HOPE study was that the reduction in vascular events was observed

in patients with different types of underlying vascular disease. Consistent benefits were observed in patients, regardless of age; presence or absence of diabetes, hypertension, prior MI, cerebrovascular disease, peripheral vascular disease, or microalbuminuria; or gender (Figure 3).<sup>1</sup> All subgroups studied showed benefit.

### THE STUDY TO EVALUATE CAROTID ULTRASOUND CHANGES IN PATIENTS TREATED WITH RAMIPRIL AND VITAMIN E

A substudy of the HOPE trial—the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE)—was directed at measuring the impact of ramipril treatment on progression of atherosclerosis.<sup>5</sup> A total of 732 patients matching the previously described selection criteria underwent duplicate B-mode carotid ultrasound examinations at baseline, at about 2.5 years, and at the end of the study. The results are shown in



Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1616BSK

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	29	Feb 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	30	Feb 26	MEDLINE reloaded with enhancements
NEWS	31	Feb 26	EMBASE enhanced with Clinical Trial Number field
NEWS	32	Feb 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	33	Feb 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	34	Feb 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:15:39 ON 02 MAR 2007

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:15:53 ON 02 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 FEB 2007 HIGHEST RN 923894-67-1  
DICTIONARY FILE UPDATES: 28 FEB 2007 HIGHEST RN 923894-67-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>


=> s telmisartan  
L1 8 TELMISARTAN

=> d 8

L1 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 144701-48-4 REGISTRY  
ED Entered STN: 02 Dec 1992  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]- (9CI)  
OTHER NAMES:  
CN 4'-[[4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl]-2-biphenylcarboxylic acid  
CN BIBR 277



CN BIBR 277SE  
 CN Micardis  
 CN Pritor  
 CN Telmisartan  
 MF C33 H30 N4 O2  
 CI COM  
 SR CA  
 LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA,  
 CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM,  
 DDFU, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE,  
 MRCK\*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SCISEARCH,  
 SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: WHO



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

598 REFERENCES IN FILE CA (1907 TO DATE)  
 9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 600 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus uspatful medline

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.35	7.56

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:16:26 ON 02 MAR 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:16:26 ON 02 MAR 2007  
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:16:26 ON 02 MAR 2007

=> s l1 or telmisartan or pritor or micardis or bibr 277 or bibr 277se  
 L2 1943 L1 OR TELMISARTAN OR PRITOR OR MICARDIS OR BIBR 277 OR BIBR  
 277SE

=> s 12 and (diabetes or diabete or insuline resistance or hyperinsulinemia or  
glucose intolerance or insuline sensitivity )  
L3 761 L2 AND (DIABETES OR DIABETE OR INSULINE RESISTANCE OR HYPERINSUL  
INEMIA OR GLUCOSE INTOLERANCE OR INSULINE SENSITIVITY )

=> s 13 and pd<+2003  
<-----User Break----->

=> s 13 and pd<=2003  
L4 124 L3 AND PD<=2003

=> dup rem l4  
PROCESSING COMPLETED FOR L4  
L5 113 DUP REM L4 (11 DUPLICATES REMOVED)

=> focus  
PROCESSING COMPLETED FOR L5  
L6 113 FOCUS L5 1-

=> d ibib abs hitstr 1-113

L6 ANSWER 1 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:96709 CAPLUS  
DOCUMENT NUMBER: 138:163224  
TITLE: Effects of telmisartan on arterial stiffness  
in type 2 diabetes patients with essential  
hypertension  
AUTHOR(S): Asmar, Roland; Gosse, Phillipe; Topouchian, Jirar;  
N'tela, Gilbert; Dudley, Amanda; Shepherd, Gillian L.  
CORPORATE SOURCE: The Cardiovascular Institute, Paris, Fr.  
SOURCE: JRAAS (2002), 3(3), 176-180  
CODEN: JRAAAG; ISSN: 1470-3203  
PUBLISHER: JRAAS Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English


AB Arterial wall stiffness, an important independent risk factor for  
cardiovascular disease in patients with hypertension, is worsened by the  
coexistence of diabetes mellitus. This randomized, prospective,  
double-blind, crossover trial assessed the effects of telmisartan  
on arterial stiffness in patients with Type 2 diabetes with  
essential hypertension. After a two-week placebo wash out period, 28  
ambulatory patients received telmisartan (40 mg) or placebo for  
three weeks. Following a second two-week placebo wash out period,  
patients received the alternate treatment for a further three weeks.  
Augmentation index and central blood pressure (BP) were determined using the  
SphygmoCor device and pulse wave velocity (PWV) was measured using an  
automatic device, the Complior, at the beginning and the end of each  
period. Telmisartan significantly reduced the carotid-femoral  
PWV compared with placebo (mean adjusted treatment difference -0.95 m/s;  
95% CI: -1.67, -0.23 m/s; p = 0.013). Peripheral and central diastolic,  
systolic and pulse pressures were also significantly reduced with  
telmisartan compared with placebo. In conclusion,  
telmisartan reduces arterial stiffness and peripheral and central  
BPs as assessed by PWV and pulse contour anal. in hypertensive patients  
with Type 2 diabetes. These properties of telmisartan  
suggest that it may improve cardiovascular outcome in this patient  
population.

IT 144701-48-4, Telmisartan  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(telmisartan effect on arterial stiffness in type 2  
diabetes patients with essential hypertension)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-

benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:824351 CAPLUS

DOCUMENT NUMBER: 136:112467

TITLE: Effect of telmisartan on arterial distensibility and central blood pressure in patients with mild to moderate hypertension and type 2 diabetes mellitus

AUTHOR(S): Asmar, Roland

CORPORATE SOURCE: The Cardiovascular Institute, Paris, 75016, Fr.

SOURCE: JRAAS (2001), 2(Suppl. 2), S8-S11

CODEN: JRAAAG; ISSN: 1470-3203

PUBLISHER: JRAAS Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Arterial wall stiffness is an important independent risk factor for cardiovascular disease in hypertensive patients, which is further exacerbated by co-existent diabetes mellitus. Increased arterial stiffness is directly associated with an increase in pulse wave velocity (PWV) and indirectly with increased central and peripheral blood pressure. Following a two-week placebo run-in period, 27 patients with mild to moderate essential hypertension and Type 2 diabetes mellitus, were randomized to once daily treatment with either telmisartan 40 mg or placebo for three weeks, and after a two-week washout period, crossed-over to the alternative treatment for a further three weeks. Carotid/femoral and carotid/radial PWV were measured non-invasively using the automatic Complior device, and central parameters (central blood pressure, pulse contour anal., and augmentation index) were measured using the SphygmoCor system, at the start and end of each treatment period. Compared with placebo, treatment with telmisartan significantly reduced carotid/femoral PWV (mean adjusted treatment difference -0.95 m/s, 95% confidence intervals: -1.67, -0.23 m/s,  $p=0.013$ ), as well as peripheral and central diastolic, systolic and pulse pressure. In conclusion, the results of this study show that telmisartan is effective in reducing arterial stiffness in hypertensive patients with Type 2 diabetes mellitus, and may potentially have beneficial effects on cardiovascular outcomes, beyond blood-pressure lowering effects, in this patient group.


IT 144701-48-4, Telmisartan

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)  
(telmisartan effect on arterial distensibility and central  
blood pressure in patients with hypertension and type 2  
diabetes mellitus)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:795609 CAPLUS

DOCUMENT NUMBER: 139:270158

TITLE: The telmisartan programme of research to  
show telmisartan end-organ protection  
(PROTECTION) programme

AUTHOR(S): Weber, Michael

CORPORATE SOURCE: State University of New York Downstate College of  
Medicine, New York, USA

SOURCE: Journal of Hypertension (2003), 21(Suppl.  
6), S37-S46

CODEN: JOHYD3; ISSN: 0263-6352

PUBLISHER: Lippincott Williams & Wilkins


DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Angiotensin-II receptor blockers (ARBs) have been shown to provide stroke, cardiac and renal protection in high-risk hypertensive patients. Telmisartan is a powerful and selective ARB that provides sustained blood pressure reduction for a full 24 h after a single dose and continues to protect against circadian blood pressure surges in the critical early morning hours. The objective of the Program of Research to show Telmisartan End-organ protection (PROTECTION) is to measure the end-organ protective effects of telmisartan in patients at high risk of renal, cardiac and vascular damage. An extensive series of clin. trials is being conducted to compare telmisartan with valsartan, losartan, amlodipine and ramipril in patients at increased risk of end-organ damage. Nine clin. studies will examine the effects of telmisartan in about 5000 hypertensive patients with isolated systolic hypertension, type 2 diabetes, obesity, left ventricular hypertrophy or renal disease. All of the studies will be conducted using state-of-the-art technol., including such techniques as ambulatory blood pressure monitoring and magnetic resonance imaging. This program will also investigate the effects of an ARB on key surrogate

markers of organ tissue damage. This series of trials will characterize the end-organ protective effects of telmisartan in hypertensive patient populations at high risk of clin. events.

IT 144701-48-4, Telmisartan  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(telmisartan treatment for end-organ protection in hypertensive patients and the telmisartan program PROTECTION)  
RN 144701-48-4 CAPLUS  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2001:306863 CAPLUS  
DOCUMENT NUMBER: 135:251642  
TITLE: Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats  
AUTHOR(S): Wienen, Wolfgang; Richard, Serge; Champeroux, Pascal; Audeval-Gerard, Chantal  
CORPORATE SOURCE: Department of Pharma Research, Boehringer Ingelheim Pharma KG, Biberach, Germany  
SOURCE: JRAAS (2001), 2(1), 31-36  
CODEN: JRAAAG; ISSN: 1470-3203  
PUBLISHER: JRAAS Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB This study compared the cardiovascular and renal effects of long-term telmisartan (3 and 10 mg/kg/day) and lisinopril (10 mg/kg/day) in an animal model combining hypertension and diabetes mellitus. It was a parallel-group study of diabetic, spontaneously hypertensive rats (SHR), treated with control or active treatment for eight months. A non-diabetic SHR control group was run in parallel. Diabetes was induced by streptozotocin (45 mg/kg i.v.) in SHRs aged 9-10 wk. Animals were treated with telmisartan (3 or 10 mg/kg/day), lisinopril (10 mg/kg/day) or vehicle. Plasma glucose levels, blood pressure (BP), and urinary protein and albumin excretion were measured monthly. Telmisartan treatment significantly reduced BP of diabetic SHRs in a dose-dependent manner (p<0.05, low-dose, n=18; p<0.01, high-dose, n=15). The BP reduction in the lisinopril group was similar to that in the telmisartan 10 mg/kg/day group. Compared with

non-diabetic SHRs, untreated diabetic SHRs developed severe proteinuria and albuminuria over the exptl. period ( $p < 0.01$ ). In diabetic SHRs, proteinuria and albuminuria were dose-dependently and significantly attenuated by treatment with telmisartan ( $p < 0.01$  with the higher dose) and lisinopril ( $p < 0.01$ ). Compared with the untreated diabetic SHRs, cardiac hypertrophy was significantly reduced after treatment with both doses of telmisartan and with lisinopril. Telmisartan, 10 mg/kg/day, but not lisinopril, significantly attenuated the diabetes-induced increase in glomerular volume. In conclusion, telmisartan, 10 mg/kg/day, is at least as beneficial as lisinopril, 10 mg/kg/day, in lowering BP, reducing cardiac hypertrophy and attenuating renal excretion of protein and albumin in this model.


IT 144701-48-4, Telmisartan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(comparative antihypertensive, renoprotective, and cardioprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT:

28

THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:656399 CAPLUS

DOCUMENT NUMBER: 139:191449

TITLE: Renin-angiotensin II system inhibitor in diabetes mellitus diagnosis and therapy

INVENTOR(S): Pedersen-Bjergaard, Ulrik; Agerholm-Larsen, Birgit; Thorsteinsson, Birger; Pramming, Stig

PATENT ASSIGNEE(S): Den.

SOURCE: U.S. Pat. Appl. Publ., 17 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003158090	A1	20030821	US 2002-195330	20021004 <--



PRIORITY APPLN. INFO.:

US 2001-306859P

P 20010723

AB The present invention provides novel methods of treatment of diabetes mellitus as well as methods of diagnosing the susceptibility of hypoglycemia in an individual. The method of treatment includes administering to an individual a sufficient amount of at least one inhibitor of the renin-angiotensin II system and at least one antidiabetic, for example insulin. Another objective of the present invention is to provide methods of preventing hypoglycemia in an individual in need thereof comprising administering to said individual a pharmaceutical effective amount of an inhibitor of the renin-angiotensin II system. In particular, such an individual may be an individual suffering from diabetes mellitus. A further objective of the present invention is to provide methods to diagnose the susceptibility to hypoglycemia of an individual comprising detecting within a predetd. tissue sample the genotype of the angiotensin-converting enzyme (ACE) gene; or detecting within a predetd. tissue sample the activity of ACE; and correlating said genotype or activity to the susceptibility of hypoglycemia.


IT 144701-48-4, Telmisartan

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(renin-angiotensin II system inhibitor in diabetes mellitus diagnosis and therapy)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 6 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:376495 CAPLUS

DOCUMENT NUMBER: 135:236137

TITLE: The role of angiotensin II receptor antagonists in the management of diabetes

AUTHOR(S): Barnett, Anthony H.

CORPORATE SOURCE: Birmingham Heartlands Hospital, Birmingham, UK

SOURCE: Blood Pressure, Supplement (2001), (1), 21-26

CODEN: BPSUEY; ISSN: 0803-8023

PUBLISHER: Taylor & Francis

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Diabetic nephropathy, which develops in about 30% of patients with diabetes, is a progressive condition. It is characterized by increased blood pressure, declining glomerular filtration rate and

albuminuria. Lowering of blood pressure in diabetic patients is associated with reduced cardiovascular risk and renal protection. Inhibitors of angiotensin-converting enzyme (ACE) are the current gold standard treatment for hypertension in patients with type I diabetes because, in addition to their blood pressure lowering ability, they are thought to oppose the increased intraglomerular pressure that is mediated in part by angiotensin II. The angiotensin II receptor antagonists, a more recently developed class of antihypertensive agents, appear to be as effective as ACE inhibitors in delaying the progression of renal injury in animal models of diabetes. They act by selectively blocking the binding of angiotensin II to the AT1 receptor and may, therefore, offer a more complete blockade of the renin-angiotensin system than ACE inhibitors. The renal and antihypertensive effects of this class of drug in patients with diabetes are now being investigated in long-term clin. trials. The multicenter Diabetics Exposed to Telmisartan And Enalapril (DETAIL) study is a randomized, double-blind, parallel-group comparison of the renal and antihypertensive effects of the angiotensin II receptor antagonist telmisartan and the ACE inhibitor enalapril in 272 patients with type II diabetes. The primary outcome is change in glomerular filtration rate over the 5 yr of the study.


IT 144701-48-4, Telmisartan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(role of angiotensin II receptor antagonists in management of diabetes)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:167787 CAPLUS

DOCUMENT NUMBER: 134:202715

TITLE: Pharmaceutical formulations of ACE and ATII inhibitors for prevention of stroke, diabetes and/or congestive heart failure

INVENTOR(S): Schoelkens, Bernward; Bender, Norbert; Rangoonwala, Badrudin; Dagenais, Gilles; Gerstein, Hertzfel; Ljunggren, Anders; Yusuf, Salim

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 17 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015673	A2	20010308	WO 2000-EP8341	20000825 <--
WO 2001015673	A3	20020307		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2382387	C	20010308	CA 2000-2382387	20000825 <--
CA 2382387	A1	20010308		
CA 2500709	A1	20010308	CA 2000-2500709	20000825 <--
BR 2000013540	A	20020430	BR 2000-13540	20000825 <--
EP 1212081	A2	20020612	EP 2000-965898	20000825 <--
EP 1212081	B1	20051026		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
TR 200200518	T2	20020621	TR 2002-518	20000825 <--
TR 200202466	T2	20021223	TR 2002-2466	20000825 <--
TR 200202467	T2	20021223	TR 2002-2467	20000825 <--
HU 200202461	A2	20021228	HU 2002-2461	20000825 <--
JP 2003508426	T	20030304	JP 2001-519887	20000825 <--
EE 200200085	A	20030415	EE 2002-85	20000825 <--
EP 1437131	A1	20040714	EP 2004-6330	20000825
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
AT 307604	T	20051115	AT 2000-965898	20000825
RU 2272651	C2	20060327	RU 2002-107673	20000825
ES 2250192	T3	20060416	ES 2000-965898	20000825
BG 106319	A	20021229	BG 2002-106319	20020118 <--
NO 2002000850	A	20020221	NO 2002-850	20020221 <--
ZA 2002001471	A	20030303	ZA 2002-1471	20020221 <--
AU 2005203694	A1	20050908	AU 2005-203694	20050817
US 2006194868	A1	20060831	US 2006-415137	20060502

PRIORITY APPLN. INFO.:

SE 1999-3028	A	19990827
AU 2000-76484	A3	20000825
CA 2000-2382387	A3	20000825
EP 2000-965898	A3	20000825
US 2000-645556	B1	20000825
WO 2000-EP8341	W	20000825

AB The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS), i.e., inhibitors of angiotensin-converting enzyme (ACE) and angiotensin II type 1 receptor (ATII) antagonists or a pharmaceutically acceptable derivative thereof, particularly ramipril or ramiprilat, in the manufacture of a medicament for the prevention and/or treatment of stroke, diabetes and/or congestive heart failure (CHF). A large-scale clin. trial was designed to examine the effect of the ACE inhibitor ramipril vs. placebo in reducing cardiovascular events. There was a clear 32% reduction in the ramipril group in the number of patients who developed a stroke, and this is surprising since patients were normotensive when recruited to the study. The number of patients who developed CHF was significantly reduced by 21% in the ramipril group, which is unexpected since patients had no signs or symptoms of CHF at

study start. Equally surprising is the marked 36% reduction in the number of patients who developed diabetes in the ramipril group.


IT 144701-48-4, Telmisartan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. of inhibitors of renin-angiotensin system for prevention and/or treatment of stroke, diabetes and/or congestive heart failure)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 8 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:78061 USPATFULL

TITLE: Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications

INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
Kosoglou, Teddy, Jamison, PA, UNITED STATES

PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003053981	A1	20030320	<--
APPLICATION INFO.:	US 2002-57534	A1	20020125	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-264600P	20010126 (60)
	US 2001-323842P	20010921 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	

NUMBER OF CLAIMS: 81

EXEMPLARY CLAIM: 1

LINE COUNT: 4194

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted  $\beta$ -lactam sterol

absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2002:323139 USPATFULL  
TITLE: Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications  
INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
Kosoglou, Teddy, Jamison, PA, UNITED STATES  
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002183305	A1	20021205	<--
APPLICATION INFO.:	US 2002-57646	A1	20020125	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-264275P	20010126 (60)
	US 2001-323842P	20010921 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	
NUMBER OF CLAIMS:	81	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4256	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one of nicotinic acid or derivatives thereof; and (b) at least one substituted azetidinone or substituted  $\beta$ -lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2002:336849 USPATFULL  
TITLE: Sterol absorption inhibitor compositions  
INVENTOR(S): Cho, Wing-Kee Philip, Princeton, NJ, UNITED STATES  
Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
Kosoglou, Teddy, Jamison, PA, UNITED STATES  
Picard, Gilles J., Braine L'Alleud, BELGIUM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002192203	A1	20021219	<--
	US 7030106	B2	20060418	
APPLICATION INFO.:	US 2002-136968	A1	20020501	(10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-57323,		filed on 25 Jan 2002,	PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-264396P	20010126 (60)
	US 2001-323839P	20010921 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1,  
1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ,  
07033-0530

NUMBER OF CLAIMS: 101  
EXEMPLARY CLAIM: 1  
LINE COUNT: 4987

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations  
and methods including: (a) at least one peroxisome proliferator-  
activated receptor activator; and (b) at least one substituted  
azetidinone or substituted  $\beta$ -lactam sterol absorption inhibitor  
which can be useful for treating vascular conditions, diabetes  
, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2002:273408 USPATFULL

TITLE: Combinations of peroxisome proliferator-activated  
receptor (PPAR) activator(s) and sterol absorption  
inhibitor(s) and treatments for vascular indications

INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
Kosoglou, Teddy, Jamison, PA, UNITED STATES  
Picard, Gilles J., Brussels, BELGIUM

PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002151536	A1	20021017	<--
APPLICATION INFO.:	US 2002-57323	A1	20020125	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-264396P	20010126 (60)
	US 2001-323839P	20010921 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1,  
1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ,  
07033-0530

NUMBER OF CLAIMS: 101  
EXEMPLARY CLAIM: 1  
LINE COUNT: 5004

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations  
and methods including: (a) at least one peroxisome proliferator-  
activated receptor activator; and (b) at least one substituted  
azetidinone or substituted  $\beta$ -lactam sterol absorption inhibitor  
which can be useful for treating vascular conditions, diabetes  
, obesity and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:283080 USPATFULL

TITLE: Method of treatment and/or prophylaxis

INVENTOR(S): Smith, Maree Therese, Bardon, AUSTRALIA  
Brown, Lindsay Charles, Sinnamon Park, AUSTRALIA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003199424	A1	20031023	<--
APPLICATION INFO.:	US 2003-393056	A1	20030320	(10)



	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-365858P	20020320 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111	
NUMBER OF CLAIMS:	64	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	2302	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention is directed to the use of angiotensin II receptor I (AT.sub.1 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of a neuropathic condition, especially a peripheral neuropathic condition such as painful diabetic neuropathy, in vertebrate animals and particularly in human subjects. The present invention also discloses the use of AT.sub.1 receptor antagonists for preventing, attenuating or reversing the development of reduced opioid sensitivity, and more particularly reduced opioid analgesic sensitivity, in individuals and especially in individuals having, or at risk of developing, a neuropathic condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(method of treatment and prophylaxis of neuropathic condition)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 13 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:245001 USPATFULL

TITLE: Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors

INVENTOR(S): Boehm, Peter, Gau-Algesheim, GERMANY, FEDERAL REPUBLIC OF  
Meinicke, Wolf Thomas, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF  
Riedel, Axel, Maselheim, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003171415	A1	20030911	<--
APPLICATION INFO.:	US 2003-354713	A1	20030130	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2001-EP9428, filed on 16 Aug 2001, UNKNOWN			

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-20691	20000822
	DE 2001-DE108215	20010220
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	574	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB A method of treatment of indications which can be positively influenced by inhibition of AT.sub.1 mediated effects with maintenance of AT.sub.2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death, or of indications associated with the increase of AT.sub.1 receptors in the subepithelial area or increase of AT.sub.2 receptors in the epithelia, comprising coadministration of effective amounts of an angiotensin II antagonist and an ACE inhibitor, pharmaceutical compositions containing an angiotensin II antagonist together with an ACE inhibitor and the use of an angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 14 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:93574 USPATFULL

TITLE: Amino acid complexes of C-aryl glucosides for treatment  
of diabetes and method  
INVENTOR(S): Gougoutas, Jack Z., Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003064935	A1	20030403	<--
	US 6774112	B2	20040810	
APPLICATION INFO.:	US 2002-117914	A1	20020408	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-283097P	20010411 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1995	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Crystalline complexes are obtained from a 1:1 or 2:1 mixtures of either  
the (D) or (L) enantiomer of natural amino acids and compounds of  
formula ##STR1##

wherein

R.sup.1, R.sup.2 and R.sup.2a are independently hydrogen, OH, OR.sup.5,  
alkyl, --OCHF.sub.2, --OCF.sub.3, --SR.sup.5a or halogen;

R.sup.3 and R.sup.4 are independently hydrogen, OH, OR.sup.5b, alkyl,  
cycloalkyl, CF.sub.3, --OCHF.sub.2, --OCF.sub.3, halogen,  
--CONR.sup.6R.sup.6a, --CO.sub.2R.sup.5c, --CO.sub.2H, --COR.sup.6b,  
--CH(OH)R.sup.6c, --CH(OR.sup.5d)R.sup.6d, --CN, --NHCOR.sup.5e,  
--NHSO.sub.2R.sup.5f, --NHSO.sub.2Aryl, --SR.sup.5g, --SOR.sup.5h,  
--SO.sub.2R.sup.5i, or a five, six or seven membered heterocycle which  
may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or  
SO.sub.2, or R.sup.3 and R.sup.4 together with the carbons to which they  
are attached form an annelated five, six or seven membered carbocycle or  
heterocycle which may contain 1 to 4 heteroatoms in the ring which are  
N, O, S, SO, and/or SO.sub.2;

R.sup.5, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.5d, R.sup.5e, R.sup.5f,  
R.sup.5g, R.sup.5h and R.sup.5i are independently alkyl;

R.sup.6, R.sup.6a, R.sup.6b, R.sup.6c and R.sup.6d are independently  
hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R.sup.6 and R.sup.6a  
together with the nitrogen to which they are attached form an annelated  
five, six or seven membered heterocycle which may contain 1 to 4  
heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2.

A method is also provided for treating diabetes and related  
diseases employing an SGLT2 inhibiting amount of the above complex alone  
or in combination with another antidiabetic agent or other therapeutic  
agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:759925 CAPLUS  
DOCUMENT NUMBER: 139:316443  
TITLE: Renal involvement in hypertensive cardiovascular  
disease  
AUTHOR(S): Sharma, A. M.

CORPORATE SOURCE: McMaster University, Hamilton, ON, Can.  
SOURCE: European Heart Journal Supplements (2003),  
5(Suppl. F), F12-F18  
CODEN: EHJSFT; ISSN: 1520-765X  
PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Cardiovascular morbidity and mortality are elevated in renally impaired patients, especially if they are hypertensive. Diabetes is also associated with a high prevalence of cardiovascular morbidity and end-stage renal disease. Albuminuria, elevated serum creatinine, decreased creatinine clearance and proteinuria independently predict cardiovascular risk. Even patients with mild renal impairment should be treated to slow kidney disease progression and reduce vascular damage. Blood pressure control is effective in reducing vascular complications of diabetes, but not all classes of antihypertensive agents provide renoprotection. Angiotensin-converting enzyme inhibitors are superior to beta-blockers in preventing or delaying the loss of kidney function associated with hypertension. The renoprotection appears to be in part independent of the antihypertensive effect. Angiotensin II receptor blockers (ARBs) also reduce the risk of renal complications in diabetics. Telmisartan seems well suited to provide renoprotection because, unlike other ARBs, it is almost exclusively excreted by the liver and no initial dose adjustment is required for patients with mild-to-moderate renal impairment. Other advantages of telmisartan include its very high volume of distribution and long terminal elimination half-life. Clin. trials to evaluate telmisartan will address the problems of diabetes, renal impairment and end-organ disease.


IT 144701-48-4, Telmisartan

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(relationship between hypertensive cardiovascular disease and renal disease)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 113

ACCESSION NUMBER: 2003:166532 USPATFULL

TITLE: C-aryl glucoside SGLT2 inhibitors and method

INVENTOR(S): Washburn, William N., Titusville, NJ, UNITED STATES

Ellsworth, Bruce, Princeton, NJ, UNITED STATES  
Meng, Wei, Pennington, NJ, UNITED STATES  
Wu, Gang, Princeton, NJ, UNITED STATES  
Sher, Philip M., Plainsboro, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003114390	A1	20030619	<--
	US 6936590	B2	20050830	
APPLICATION INFO.:	US 2002-264410	A1	20021004	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-805341, filed on 13 Mar 2001, ABANDONED			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000			
NUMBER OF CLAIMS:	24			
EXEMPLARY CLAIM:	1			
LINE COUNT:	2410			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula ##STR1##

alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:96100 USPATFULL  
TITLE: Retinoid-related receptor function regulating agent  
INVENTOR(S): Sugiyama, Yasuo, Kawanishi, JAPAN  
Momose, Yu, Takarazuka, JAPAN  
Kimura, Hiroyuki, Sakai, JAPAN  
Sakamoto, Junichi, Toyonaka, JAPAN  
Odaka, Hiroyuki, Kobe, JAPAN  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, JAPAN  
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6545009	B1	20030408	<--
	WO 2000001679		20000113	<--
APPLICATION INFO.:	US 2000-720644		20001228	(9)
	WO 1999-JP3520		19990630	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-186698	19980701
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Tsang, Cecilia	
ASSISTANT EXAMINER:	Sackey, Ebenezer	
LEGAL REPRESENTATIVE:	Cha, Mark, Ramesh, Elaine	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2740	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 1,3-Azole derivatives, pharmaceutical compositions thereof and methods for regulating the function of retinoid-related receptors with 1,3-azole derivatives are disclosed. Such regulation may be useful for preventing or treating diabetes, preventing or treating hyperlipidemia,

preventing or treating impaired glucose tolerance (IGT) or for preventing transition from impaired glucose tolerance to diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:251945 USPATFULL  
TITLE: C-aryl glucoside SGLT2 inhibitors and method  
INVENTOR(S): Ellsworth, Bruce, Princeton, NJ, UNITED STATES  
Washburn, William N., Titusville, NJ, UNITED STATES  
Sher, Philip M., Plainsboro, NJ, UNITED STATES  
Wu, Gang, Princeton, NJ, UNITED STATES  
Meng, Wei, Pennington, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002137903	A1	20020926	<--
	US 6515117	B2	20030204	
APPLICATION INFO.:	US 2002-151436	A1	20020520	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-679027, filed on 4 Oct 2000, GRANTED, Pat. No. US 6414126			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-194615P	20000405 (60)
	US 1999-158773P	19991012 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1148	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An SGLT2 inhibiting compound is provided having the formula ##STR1##

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:160855 USPATFULL  
TITLE: C-aryl glucoside SGLT2 inhibitors and method  
INVENTOR(S): Ellsworth, Bruce, Princeton, NJ, United States  
Washburn, William N., Titusville, NJ, United States  
Sher, Philip M., Plainsboro, NJ, United States  
Wu, Gang, Princeton, NJ, United States  
Meng, Wei, Pennington, NJ, United States  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6414126	B1	20020702	<--
APPLICATION INFO.:	US 2000-679027		20001004	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-194615P	20000405 (60)
	US 1999-158773P	19991012 (60)



DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Gitomer, Ralph  
 ASSISTANT EXAMINER: Khare, Devesh  
 LEGAL REPRESENTATIVE: Provoost, Jonathan N.  
 NUMBER OF CLAIMS: 30  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
 LINE COUNT: 2425  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB SGLT2 inhibiting compounds are provided having the formula ##STR1##

where

R.sup.1, R.sup.2, and R.sup.2a are independently hydrogen, OH, OR.sup.5, lower alkyl, CF.sub.3, OCHF.sub.2, OCF.sub.3, SR.sup.5i or halogen, or two of R.sup.1, R.sup.2 and R.sup.2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle;

R.sup.3 and R.sup.4 are independently hydrogen, OH, OR.sup.5a, OAryl, OCH.sub.2Aryl, lower alkyl, cycloalkyl, CF.sub.3, --OCHF.sub.2, --OCF.sub.3, halogen, --CN, --CO.sub.2R.sup.5b, --CO.sub.2H, --COR.sup.6b, --CH(OH)R.sup.6c, --CH(OR.sup.5h)R.sup.6d, --CONR.sup.6R.sup.6a, --NHCOR.sup.5c, --NHSO.sub.2R.sup.5d, --NHSO.sub.2Aryl, Aryl, --SR.sup.5e, --SOR.sup.5f, --SO.sub.2R.sup.5g, --SO.sub.2Aryl, or a five, six or seven membered heterocycle, or R.sup.3 and R.sup.4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle;

R.sup.5, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.5d, R.sup.5e, R.sup.5f, R.sup.5g, R.sup.5h and R.sup.5i are independently lower alkyl;

R.sup.6, R.sup.6a, R.sup.6b, R.sup.6c and R.sup.6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R.sup.6 and R.sup.6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle;

A is O, S, NH, or (CH.sub.2).sub.n where n is 0-3.

A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:265968 USPATFULL  
 TITLE: Oxyiminoalkanoic acid derivatives  
 INVENTOR(S): Momose, Yu, Hyogo, JAPAN  
 Odaka, Hiroyuki, Hyogo, JAPAN  
 Imoto, Hiroshi, Shiga, JAPAN  
 Kimura, Hiroyuki, Osaka, JAPAN  
 Sakamoto, Junichi, Osaka, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003186985	A1	20031002	<--
	US 6924300	B2	20050802	
APPLICATION INFO.:	US 2002-331056	A1	20021227	(10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-714699, filed on 16 Nov 2000, GRANTED, Pat. No. US 6495581 Division of Ser. No. US 1999-423854, filed on 15 Nov 1999, GRANTED, Pat. No.			

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-127921	19980511
	JP 1998-127922	19980511
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6054	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB To provide a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

A compound represented by the formula: ##STR1##

wherein R.sup.1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, --CO--, --CH(OH)-- or a group represented by --NR.sup.6-- wherein R.sup.6 is a hydrogen atom or an optionally substituted alkyl group; n is an integer of 1 to 3; Y is an oxygen atom, a sulfur atom, --SO--, --SO.sub.2-- or a group represented by --NR.sup.7-- wherein R.sup.7 is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R.sup.2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R.sup.3 is a hydroxy group, OR.sup.8 (R.sup.8 is an optionally substituted hydrocarbon group.) or NR.sup.9R.sup.10 (R.sup.9 and R.sup.10 are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group or R.sup.9 and R.sup.10 combine together to form a ring); R.sup.4 and R.sup.5 are the same or different groups which are selected from a hydrogen atom or an optionally substituted hydrocarbon group wherein R.sup.4 may form a ring with R.sup.2; provided that when R.sup.1 is a ethoxymethyl, a C.sub.1-3 alkyl, phenyl or p-methoxyphenyl and q=m=0, R.sup.3 is NR.sup.9R.sup.10; and provided that O-[2-chloro-4-(2-quinolylmethoxy)phenylmethyl]oxime and a methylpyruvate of [2-chloro-4-(2-quinolylmethoxy)phenylmethyl]-2-iminoxypropionic acid are excluded; or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:106793 USPATFULL  
TITLE: Method of treatment  
INVENTOR(S): Shahinfar, Shahnaz, Newton Square, PA, UNITED STATES  
Zhang, Zhongxin, Blue Bell, PA, UNITED STATES  
Brenner, Barry M., Weston, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003073705	A1	20030417	<--
APPLICATION INFO.:	US 2002-143415	A1	20020510	(10)

NUMBER	DATE
--------	------

-----  
PRIORITY INFORMATION: US 2001-290839P 20010514 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907  
NUMBER OF CLAIMS: 32  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 6 Drawing Page(s)  
LINE COUNT: 1200

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This disclosure relates to a method of preventing end stage renal disease using an angiotensin II antagonist in patients with impaired renal function. Angiotensin II antagonists such as candesartan cilexetil, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, 2-butyl-4-chloro-1-[(2'-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazolecarboxylic acid and 3-(2'-(tetrazol-5-yl)-1,1'-biphen-4-yl)methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine, or pharmaceutically acceptable salts thereof are useful.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 22 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2001:97948 USPATFULL  
TITLE: Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity  
INVENTOR(S): Momose, Yu, Takarazuka, Japan  
Odaka, Hiroyuki, Kobe, Japan  
Imoto, Hiroshi, Kusatsu, Japan  
Kimura, Hiroyuki, Sakai, Japan  
Sakamoto, Junichi, Toyonaka, Japan  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan  
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6251926	B1	20010626	<--

	WO 9958510	19991118	<--
APPLICATION INFO.:	US 1999-423854	19991115	(9)
	WO 1999-JP2407	19990510	
		19991115	PCT 371 date
		19991115	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-127921	19980511
	JP 1998-127922	19980511
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Powers, Fiona T.	
ASSISTANT EXAMINER:	Wright, Sonya	
LEGAL REPRESENTATIVE:	Riesen, Philippe Y.	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5841	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:332756 USPATFULL  
 TITLE: Oxyiminoalkanoic acid derivatives  
 INVENTOR(S): Momose, Yu, Takarazuka, JAPAN  
 Odaka, Hiroyuki, Kobe, JAPAN  
 Imoto, Hiroshi, Kusatsu, JAPAN  
 Kimura, Hiroyuki, Sakai, JAPAN  
 Sakamoto, Junichi, Toyonaka, JAPAN  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, JAPAN  
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495581	B1	20021217
APPLICATION INFO.:	US 2000-714699		20001116 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 423854, now patented, Pat. No. US 6251926		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-127921	19980511
	JP 1998-127922	19980511
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	McKane, Joseph K.	
ASSISTANT EXAMINER:	Wright, Sonya	
LEGAL REPRESENTATIVE:	Chao, Mark, Ramesh, Elaine M.	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	5850	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound represented by the formula: ##STR1##

wherein R<sup>sup.1</sup> is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; X is a bond, --CO--, --CH(OH)-- or a group represented by --NR<sup>sup.6</sup>-- wherein R<sup>sup.6</sup> is a hydrogen atom or an optionally substituted alkyl group; n is an integer

of 1 to 3; Y is an oxygen atom, a sulfur atom, --SO--, --SO.sub.2-- or a group represented by --NR.sup.7-- wherein R.sup.7 is a hydrogen atom or an optionally alkyl group; ring A is a benzene ring optionally having additional one to three substituents; p is an integer of 1 to 8; R.sup.2 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; q is an integer of 0 to 6; m is 0 or 1; R.sup.3 is a hydroxy group, OR.sup.8 (R.sup.8 is an optionally substituted hydrocarbon group.) or NR.sup.9R.sup.10 (R.sup.9 and R.sup.10 are the same or different groups which are selected from a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group or R.sup.9 and R.sup.10 combine together to form a ring); R.sup.4 and R.sup.5 are the same or different groups which are selected from a hydrogen atom or an optionally substituted hydrocarbon group wherein R.sup.4 may form a ring with R.sup.2; provided that when R.sup.1 is a ethoxymethyl, a C.sub.1-3 alkyl, phenyl or p-methoxyphenyl and q=m=0, R.sup.3 is NR.sup.9R.sup.10; and provided that O-[2-chloro-4-(2-quinolylmethoxy)phenylmethyl]oxime and a methyl pyruvate of [2-chloro-4-(2-quinolylmethoxy)phenylmethyl]-2-iminoxypropionic acid are excluded; or a salt thereof which has excellent hypoglycemic and hypolipidemic actions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:283219 USPATFULL

TITLE: Heterocyclic containing biphenyl aP2 inhibitors and method

INVENTOR(S): Robl, Jeffrey A., Newtown, PA, UNITED STATES  
Magnin, David R., Hamilton, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003199563	A1	20031023	<--
	US 6927227	B2	20050809	
APPLICATION INFO.:	US 2002-321137	A1	20021217	(10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-519079, filed on 6 Mar 2000, GRANTED, Pat. No. US 6548529			

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-127745P	19990405 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3547	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB aP2 inhibiting compounds are provided having the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X-Z and ##STR2##

are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:226410 USPATFULL  
 TITLE: Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors  
 INVENTOR(S): Anderson, Craig, Devonport/Auckland, NEW ZEALAND  
 Yusuf, Salim, Carlisle, CANADA  
 Sleight, Peter, Wheatley, Oxfordshire, UNITED KINGDOM  
 Hilbrich, Lutz, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF


	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003158223	A1	20030821	<--
APPLICATION INFO.:	US 2002-79703	A1	20020220	(10)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877			
NUMBER OF CLAIMS:	10			
EXEMPLARY CLAIM:	1			
LINE COUNT:	366			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method of treatment of dementia and/or regression of cognitive function, comprising co-administration of effective amounts of an Angiotensin II antagonist and an Angiotensin I Converting Enzyme inhibitor, pharmaceutical compositions containing an Angiotensin II antagonist together with an ACE inhibitor and the use of an Angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
 (pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors)  
 RN 144701-48-4 USPATFULL  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 26 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:172321 USPATFULL  
 TITLE: Tetrahydropyrimidone inhibitors of fatty acid binding protein and method  
 INVENTOR(S): Sulsky, Richard, West Trenton, NJ, UNITED STATES



Robl, Jeffrey A., Newtown, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002091078	A1	20020711	<--
	US 6649622	B2	20031118	
APPLICATION INFO.:	US 2001-771310	A1	20010126	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-178598P	20000128 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3597	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	aP2 inhibiting compounds are provided having the formula ##STR1##	

wherein A, B, X, and Y are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:149184 USPATFULL  
TITLE: Pyridone inhibitors of fatty acid binding protein and method  
INVENTOR(S): Sulsky, Richard, West Trenton, NJ, UNITED STATES  
Robl, Jeffrey A., Newtown, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002077340	A1	20020620	<--
	US 6670380	B2	20031230	
APPLICATION INFO.:	US 2001-989212	A1	20011120	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-252014P	20001120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1335	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds are provided having the formula ##STR1##	

wherein A, Q, and X are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such compounds alone or in combination with other antidiabetic agents such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:888552 CAPLUS

DOCUMENT NUMBER: 137:380012

TITLE: Method of treatment for prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function

INVENTOR(S): Shahinfar, Shahnaz; Brenner, Barry M.; Zhang, Zhongxin

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092081	A1	20021121	WO 2002-US14919	20020510 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003073705	A1	20030417	US 2002-143415	20020510 <--
CA 2445913	A1	20031029	CA 2002-2445913	20020510 <--
EP 1389105	A1	20040218	EP 2002-731759	20020510
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005501815	T	20050120	JP 2002-588998	20020510
PRIORITY APPLN. INFO.:			US 2001-290839P	P 20010514
			WO 2002-US14919	W 20020510

AB This disclosure relates to a method of preventing end stage renal disease using an angiotensin II antagonist in patients with impaired renal function. Angiotensin II antagonists such as candesartan cilexetil, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan, 2-butyl-4-chloro-1-(((2'-tetrazol-5-yl)biphenyl-4-yl)methyl)imidazolecarboxylic acid and 3-(2'-(tetrazol-5-yl)-1,1'-biphen-4-yl)methyl-5,7-dimethyl-2-ethyl-3H-imidazo[4, -b]pyridine, or pharmaceutically acceptable salts thereof are useful.


IT 144701-48-4, Telmisartan

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prevention of end stage renal disease using an angiotensin II antagonist in patients with impaired renal function)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 113 USPTF on STN  
 ACCESSION NUMBER: 2003:226419 USPTF  
 TITLE: Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method  
 INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
 Zhang, Hao, Belle Mead, NJ, UNITED STATES  
 Hariharan, Narayanan, Richboro, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158232	A1	20030821
	US 6967212	B2	20051122
APPLICATION INFO.:	US 2002-294525	A1	20021114 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-153454, filed on 22 May 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-294380P	20010530 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	3975	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N; R<sup>sup.2a</sup>, R<sup>sup.2b</sup>, R<sup>sup.2c</sup>, X<sup>sub.1</sup> to X<sup>sub.7</sup>, R<sup>sup.1</sup>, R<sup>sup.2</sup>, R<sup>sup.3</sup>, R<sup>sup.3a</sup>, R<sup>sup.4</sup>, A, Y, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents. The present invention further provides a method for treating obesity and dyslipidemia in mammals including humans through simultaneous inhibition of peroxisome proliferator activated receptor-γ (PPARγ) and stimulation of peroxisome proliferator activated receptor-α (PPARα).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 30 OF 113 USPTF on STN

ACCESSION NUMBER: 2003:134647 USPATFULL  
TITLE: Substituted azole acid derivatives useful as  
antidiabetic and antiobesity agents and method  
INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
Zhang, Hao, Belle Mead, NJ, UNITED STATES  
Hariharan, Narayanan, Richboro, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003092736	A1	20030515	<--
APPLICATION INFO.:	US 2002-153454	A1	20020522	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-294380P	20010530 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	3412	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds are provided which have the structure ##STR1##	

wherein Q is C or N; R.sup.2a, R.sup.2b, R.sup.2c, X.sub.1 to X.sub.7,  
R.sup.1, R.sup.2, R.sup.3, R.sup.3a, R.sup.4, A, Y, m, and n are as  
defined herein, which compounds are useful as antidiabetic,  
hypolipidemic, and antiobesity agents. The present invention further  
provides a method for treating obesity and dyslipidemia in mammals  
including humans through simultaneous inhibition of peroxisome  
proliferator activated receptor- $\gamma$  (PPAR $\gamma$ ) and stimulation of  
peroxisome proliferator activated receptor- $\alpha$  (PPAR $\alpha$ ).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:102390 USPATFULL  
TITLE: Heterocyclic containing biphenyl aP2 inhibitors and  
method  
INVENTOR(S): Robl, Jeffrey A., Newtown, PA, United States  
Sulsky, Richard B., West Trenton, NJ, United States  
Magnin, David R., Hamilton, NJ, United States  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United  
States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6548529	B1	20030415	<--
APPLICATION INFO.:	US 2000-519079		20000306	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-127745P	19990405 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	McKane, Joseph K.	
ASSISTANT EXAMINER:	Shameem, Golam M M	
LEGAL REPRESENTATIVE:	Hermenau, Ronald S., Kilcoyne, John, Rodney, Burton	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	3405	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB aP2 inhibiting compounds are provided having the formula ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X-Z and ##STR2##

are as described herein.

A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:428761 CAPLUS

DOCUMENT NUMBER: 137:11000

TITLE: Pharmaceutical compositions containing angiotensin receptor blockers for treating sexual dysfunction

INVENTOR(S): Sahota, Pritam Singh

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma. GmbH

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043807	A2	20020606	WO 2001-EP13976	20011129 <--
WO 2002043807	A3	20030814		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW			
RW:	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR			
CA 2430924	A1	20020606	CA 2001-2430924	20011129 <--
AU 2002026365	A5	20020611	AU 2002-26365	20011129 <--
EP 1353727	A2	20031022	EP 2001-995680	20011129 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004514703	T	20040520	JP 2002-545776	20011129
US 2002107236	A1	20020808	US 2001-8445	20011203 <--
US 2004087484	A1	20040506	US 2003-433189	20030624
PRIORITY APPLN. INFO.:			US 2000-250540P	P 20001201
			WO 2001-EP13976	W 20011129

AB The present invention relates to methods of treating sexual dysfunction associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an HMG-CoA reductase inhibitor. A film-coated tablet contained valsartan 8.00, microcryst. cellulose 54.00, crospovidone 20.00, colloidal silica 1.50, magnesium stearate 4.5, and Diolack pale red 00F34899 7.00 mg.


IT 144701-48-4, Telmisartan

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. containing angiotensin receptor blockers for treating sexual dysfunction)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 33 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:790344 CAPLUS  
 DOCUMENT NUMBER: 133:340269  
 TITLE: Preventives/remedies/progression inhibitors for  
 simplex retinopathy or preproliferating retinopathy  
 INVENTOR(S): Nakagawa, Shizue; Nagisa, Yasutaka; Ikeda, Hitoshi  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066161	A1	20001109	WO 2000-JP2766	20000427 <--
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2371554	A1	20001109	CA 2000-2371554	20000427 <--
BR 2000010084	A	20020115	BR 2000-10084	20000427 <--
EP 1197223	A1	20020417	EP 2000-921056	20000427 <--
EP 1197223	B1	20050216		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 514855	A	20040130	NZ 2000-514855	20000427
AU 774799	B2	20040708	AU 2000-41434	20000427
RU 2239454	C2	20041110	RU 2001-132073	20000427
AT 289204	T	20050315	AT 2000-921056	20000427
PT 1197223	T	20050429	PT 2000-921056	20000427
ES 2233362	T3	20050616	ES 2000-921056	20000427
JP 2001010975	A	20010116	JP 2000-134243	20000428 <--
US 7064141	B1	20060620	US 2001-958740	20011016
ZA 2001008527	A	20021017	ZA 2001-8527	20011017 <--
NO 2001005257	A	20011026	NO 2001-5257	20011026 <--



US 2006189669 A1 20060824 US 2006-406345 20060419  
 PRIORITY APPLN. INFO.: JP 1999-121498 A 19990428  
 WO 2000-JP2766 W 20000427  
 US 2001-958740 A3 20011016

OTHER SOURCE(S): MARPAT 133:340269


AB Disclosed are drugs which contain a compound having an angiotensin II antagonism or its salt and are useful in, for example, preventing or treating simplex retinopathy or preproliferating retinopathy by inhibiting the progression thereof. Administration of candesartan cilexetil to diabetes model rats inhibited the production of VEGF and improved retinal elec. potentials. Formulations for capsules, tablets, and ophthalmic suspensions containing the invention compds. are also provided.

IT 144701-48-4, Telmisartan  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(angiotensin II antagonists for treatment of retinopathy)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 34 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:113449 USPATFULL  
 TITLE: Methods for tissue protection using highly effective inhibition of the renin-angiotensin system  
 INVENTOR(S): Weinberg, Marc S., Seekonk, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003078190	A1	20030424	<--
APPLICATION INFO.:	US 2002-155824	A1	20020524	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293835P	20010525 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211	
NUMBER OF CLAIMS:	133	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	3074	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and pharmaceutical compositions are provided for protecting tissue of a subject from the effects of angiotensin II. The methods involve administering to subjects angiotensin receptor blockers (ARB), either by themselves at doses beyond those recommended or effective for the management of hypertension, or in combination with angiotensin-converting enzyme inhibitors (ACEI). The pharmaceutical compositions include both an ARB and an ACEI and are formulated in certain preferred embodiments for once-daily oral administration. The methods and pharmaceutical compositions are useful for the treatment of proteinuria, chronic or congestive heart failure, aneurysms, and vascular tissue hypertrophy.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan 144701-48-4D, Telmisartan, prodrug derivs.

(renin-angiotensin system inhibition for protecting tissue from effects of angiotensin II)


RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 35 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2001:36849 USPATFULL  
 TITLE: Method for reducing mortality with an angiotensin II antagonist  
 INVENTOR(S): Beere, Polly A., Lahaska, PA, United States  
 Chang, Paul I., Doylestown, PA, United States  
 Pitt, Bertram, Ann Arbor, MI, United States  
 Rucinska, Eva J., Blue Bell, PA, United States  
 Segal, Robert, Gwynedd Valley, PA, United States  
 Sharma, Divakar, Hatfield, PA, United States  
 Snaveley, Duane B., Chalfont, PA, United States  
 PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6201002	B1	20010313	<--
APPLICATION INFO.:	US 1998-3159		19980106	(9)


	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-34927P	19970110 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Krass, Frederick	
LEGAL REPRESENTATIVE:	Camara, Valerie J., Daniel, Mark R.	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	2373	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Angiotensin II receptor antagonists are useful in reducing and preventing mortality and sudden cardiac death in symptomatic heart failure patients. Losartan potassium has been shown to reduce mortality and sudden cardiac death in this patient population. Additionally, losartan potassium has been shown to reduce the need for hospitalization of symptomatic heart failure patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
 (angiotensin II antagonists to treat symptomatic heart failure)  
 RN 144701-48-4 USPATFULL  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 36 OF 113 MEDLINE on STN  
 ACCESSION NUMBER: 2002652897 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 12411451  
 TITLE: Angiotensin blockade prevents type 2 diabetes by  
 formation of fat cells.  
 AUTHOR: Sharma Arya M; Janke Jurgan; Gorzelniak Kerstin; Engeli  
 Stefan; Luft Friedrich C  
 CORPORATE SOURCE: HELIOS Klinikum Berlin, Franz Volhard Clinic-Charite,  
 Humboldt University of Berlin, and Max Delbruck Center for  
 Molecular Medicine, Berlin, Germany..  
 sharma@ccc.mcmaster.ca  
 SOURCE: Hypertension, (2002 Nov) Vol. 40, No. 5, pp.  
 609-11.  
 Journal code: 7906255. E-ISSN: 1524-4563.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 (RESEARCH SUPPORT, NON-U.S. GOV'T)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200211  
 ENTRY DATE: Entered STN: 5 Nov 2002  
 Last Updated on STN: 11 Dec 2002  
 Entered Medline: 8 Nov 2002

AB Obesity is the prime risk factor for the development of type 2  
 diabetes. Recent clinical trials have shown that blockade of the  
 renin-angiotensin system, either by inhibiting the angiotensin-converting  
 enzyme or blocking the angiotensin type 1 receptor, may substantially  
 lower the risk for type 2 diabetes. The mechanism underlying  
 this effect is unknown. Based on our recent observation that angiotensin  
 II markedly inhibits adipogenic differentiation of human adipocytes via  
 the angiotensin type I receptor and that expression of angiotensin  
 II-forming enzymes in adipose tissue is inversely correlated with insulin  
 sensitivity, we propose the hypothesis that blockade of the  
 renin-angiotensin system prevents diabetes by promoting the  
 recruitment and differentiation of adipocytes. Increased formation of  
 adipocytes would counteract the ectopic deposition of lipids in other  
 tissues (muscle, liver, pancreas), thereby improving insulin sensitivity  
 and preventing the development of type 2 diabetes.

L6 ANSWER 37 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:122803 CAPLUS  
 DOCUMENT NUMBER: 142:219083  
 TITLE: Preparation of phosphorus-containing rapamycin  
 derivatives for use in pharmaceutical compositions as  
 immunosuppressive and anticancer agents  
 INVENTOR(S): Metcalf, Chester A., III; Rozamus, Leonard W.; Wang,  
 Yihan; Berstein, David L.  
 PATENT ASSIGNEE(S): Ariad Gene Therapeutics, Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S.  
 Ser. No. 635,054.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005032825	A1	20050210	US 2004-862149	20040604
US 7091213	B2	20060815		
US 2003220297	A1	20031127	US 2003-357152	20030203 <--
US 2004073024	A1	20040415	US 2003-635054	20030806
US 2006264405	A1	20061123	US 2006-429582	20060505


US 2006264456  
PRIORITY APPLN. INFO.:

A1 20061123

US 2006-494418	20060727
US 2002-353252P	P 20020201
US 2002-426928P	P 20021115
US 2002-428383P	P 20021122
US 2002-433930P	P 20021217
US 2003-357152	A2 20030203
US 2003-635054	A2 20030806
US 2003-486367P	P 20030711
US 2004-862149	A2 20040604
US 2004-889163	B2 20040712
US 2005-711859P	P 20050826

OTHER SOURCE(S):  
GI

CASREACT 142:219083; MARPAT 142:219083




AB Rapamycin derivs. containing phosphorus moiety, such as I [A = O, S, NR<sub>2</sub>, absent; Q = V, OV, SV, NR<sub>2</sub>, absent; V = aliphatic, heteroaliph., aryl, heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR<sub>2</sub>VA; J = P(:K)(YR<sub>5</sub>)<sub>2</sub>, P(YR<sub>5</sub>)<sub>2</sub>, P(:K)(YR<sub>5</sub>)GR<sub>6</sub>; K = O, S; Y = O, S, NR<sub>2</sub>, bond; R<sub>2</sub>, R<sub>5</sub> = aliphatic, heteroaliph., aryl, heteroaryl, H; R<sub>6</sub> = PK(YR<sub>5</sub>)YR<sub>5</sub>, SO<sub>2</sub>YR<sub>5</sub>, C(O)YR<sub>5</sub>; G = O, S, NR<sub>2</sub>, (M)X; M = (un)substituted methylene, alkyl, alkylene; X = 1-6], and pharmaceutically acceptable derivs. thereof, were prepared for therapeutic use as immunosuppressive and anticancer agents. These rapamycin derivs. are useful for treatment of graft vs. host disease, lupus, rheumatoid arthritis, diabetes mellitus, myasthenia gravis, multiple sclerosis, psoriasis, dermatitis, eczema, seborrhea, inflammatory bowel disease, pulmonary inflammation, ocular uveitis; adult T-cell leukemia, lymphoma, fungal infections, hyperproliferative restenosis, graft vascular atherosclerosis, coronary artery disease, cerebrovascular disease, arteriosclerosis, atherosclerosis, nonatheromatous arteriosclerosis, or vascular wall damage from cellular events leading toward immune mediated vascular damage, stroke or multi-infarct dementia. Thus, I [A-QJ = OP(O)(OBu)Me] was prepared by reacting rapamycin with methylphosphonic dichloride and n-butanol using 3,5-lutidine in CH<sub>2</sub>Cl<sub>2</sub> under a nitrogen atmosphere. Binding affinity of the rapamycin phosphorus derivs. for human FKBP-12 protein was assayed, dosages for restenosis prevention were discussed.

IT 144701-48-4, Telmisartan

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of phosphorus-containing rapamycin derivs. for use in pharmaceutical compns. as immunosuppressive and anticancer agents)

RN 144701-48-4 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 38 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:157602 CAPLUS  
 DOCUMENT NUMBER: 136:205430  
 TITLE: Pharmaceutical compositions containing AT-receptor antagonist or insulin secretion enhancers  
 INVENTOR(S): Allison, Malcolm; Gatlin, Marjorie Regan  
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Novartis Pharma. GmbH  
 SOURCE: PCT Int. Appl., 24 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002015933	A2	20020228	WO 2001-EP9587	20010820 <--
WO 2002015933	A3	20030814		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001087698	A5	20020304	AU 2001-87698	20010820 <--
EP 1351683	A2	20031015	EP 2001-967289	20010820 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004514654	T	20040520	JP 2002-520854	20010820
US 2004034065	A1	20040219	US 2003-362340	20030616
US 2006089389	A1	20060427	US 2005-295928	20051207
US 2006281790	A1	20061214	US 2006-508353	20060823



PRIORITY APPLN. INFO.:


US 2000-643641 A 20000822  
 US 2000-327553P P 20000822  
 WO 2001-EP9587 W 20010820  
 US 2003-362340 B1 20030616  
 US 2005-295928 B1 20051207

AB A pharmaceutical composition comprises as active ingredients an AT1-receptor antagonist or a salt, an insulin secretion enhancer or a its salt or an insulin sensitizer or its salt. Thus, tablets contained Starlix DS 60, lactose monohydrate 141.5, microcryst. cellulose 71, Povidone-K30 12, and Croscarmellose sodium 18.4, colloidal SiO2 6.4, Mg stearate 5.7, and Opadry 9 mg.

IT 144701-48-4, Telmisartan  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical comps. containing AT-receptor antagonist or insulin secretion enhancers)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 39 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2001:762798 CAPLUS  
 DOCUMENT NUMBER: 135:308910  
 TITLE: Pharmaceutical compositions containing an aldosterone synthase inhibitor and an AT1-receptor antagonist  
 INVENTOR(S): Steele, Ronald Edward  
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.  
 SOURCE: PCT Int. Appl., 25 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001076574	A2	20011018	WO 2001-EP4116	20010410 <--
WO 2001076574	A3	20020425		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,

VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2405895	A1	20011018	CA 2001-2405895	20010410 <--
BR 2001010079	A	20021231	BR 2001-10079	20010410 <--
EP 1282410	A2	20030212	EP 2001-940317	20010410 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003530343	T	20031014	JP 2001-574092	20010410 <--
NZ 521855	A	20041029	NZ 2001-521855	20010410
NZ 534086	A	20060831	NZ 2001-534086	20010410
US 2003083342	A1	20030501	US 2002-149107	20020827 <--
IN 2002CN01650	A	20050128	IN 2002-CN1650	20021008
NO 2002004920	A	20021127	NO 2002-4920	20021011 <--
ZA 2002008204	A	20031014	ZA 2002-8204	20021011 <--
US 2004204444	A1	20041014	US 2004-826106	20040415
US 2005059697	A1	20050317	US 2004-940544	20040914
US 2006122217	A1	20060608	US 2005-291008	20051130

PRIORITY APPLN. INFO.:

US 2000-196742P	P	20000412
NZ 2001-521855	A1	20010410
WO 2001-EP4116	W	20010410
US 2002-149107	A3	20020827
US 2004-940544	B1	20040914

AB The invention relates to a pharmaceutical composition, of (i) an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof either alone or in combination with (ii) an AT1-receptor antagonist combined with a diuretic, or in each case, a pharmaceutically acceptable salt thereof and (iii) a pharmaceutically acceptable carrier. A pharmaceutical composition comprising an aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof is used for the prevention of, delay of progression of, and treatment of a disease or condition selected from the group consisting of hypertension, congestive heart failure, renal failure, especially chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery, atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, hypothyroidism, myocardial infarction, etc. For example, a hard gelatin capsules were prepared containing valsartan 80.0 mg, microcryst. cellulose 110.0 mg, Polyvidone K30 45.2 mg, sodium lauryl sulfate 1.2 mg, crospovidone 26.0 mg, and magnesium stearate 2.6 mg by a granulation method.


IT 144701-48-4, Telmisartan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral compns. containing aldosterone synthase inhibitor and AT1-receptor antagonist for therapeutic uses)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 40 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:188513 USPATFULL  
 TITLE: Substituted acid derivatives useful as antidiabetic and  
 antiobesity agents and method  
 INVENTOR(S): Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
 Jeon, Yoon T., Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003130306	A1	20030710	<--
	US 6673815	B2	20040106	
APPLICATION INFO.:	US 2002-289053	A1	20021106	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333022P	20011106 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1699	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds are provided which have the structure ##STR1##	

wherein Q is C or N, X.sub.1 is CH or N and, A, E, M, G, X.sub.2,  
 X.sub.3, X.sub.4, R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c,  
 R.sup.3, Y, x, m, and n are as defined herein, which compounds are  
 useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:134608 USPATFULL  
 TITLE: Conformationally constrained analogs useful as  
 antidiabetic and antiobesity agents and method  
 INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
 Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
 Wang, Wei, Princeton, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003092697	A1	20030515	<--

APPLICATION INFO.: US 7105556 B2 20060912  
US 2002-153342 A1 20020522 (10)

NUMBER DATE  
-----  
PRIORITY INFORMATION: US 2001-294505P 20010530 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Stephen B. Davis, Bristol-Myers Squibb Company, Patent  
Department, P.O. Box 4000, Princeton, NJ, 08543-4000  
NUMBER OF CLAIMS: 34  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2127  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, X.sub.1 is C or N, and R.sup.1, R.sup.2, R.sup.2a,  
R.sup.2b, R.sup.2c, R.sup.3, Y, A, m, n, X.sub.2, X.sub.3 and X.sub.4  
are as defined herein, which compounds are useful as antidiabetic,  
hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


L6 ANSWER 42 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:757520 CAPLUS  
DOCUMENT NUMBER: 139:255390  
TITLE: Method of treatment and prophylaxis of neuropathic  
condition  
INVENTOR(S): Smith, Maree Therese; Brown, Lindsay  
PATENT ASSIGNEE(S): The University of Queensland, Australia  
SOURCE: PCT Int. Appl., 87 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003077912	A1	20030925	WO 2003-AU336	20030320 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,				
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003209851	A1	20030929	AU 2003-209851	20030320 <--
US 2003199424	A1	20031023	US 2003-393056	20030320 <--
PRIORITY APPLN. INFO.:			US 2002-365858P	P 20020320
			WO 2003-AU336	W 20030320

AB The invention is involves the use of angiotensin II receptor 1 (AT1  
receptor) antagonists for the treatment, prophylaxis, reversal and/or  
symptomatic relief of a neuropathic condition, especially a peripheral  
neuropathic condition such as painful diabetic neuropathy, in vertebrate  
animals and particularly in human subjects. The invention also discloses  
the use of AT1 receptor antagonists for preventing, attenuating or  
reversing the development of reduced opioid sensitivity, and more  
particularly reduced opioid analgesic sensitivity, in individuals and  
especially  
in individuals having, or at risk of developing, a neuropathic condition.

IT 144701-48-4, Telmisartan  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (method of treatment and prophylaxis of neuropathic condition)  
 RN 144701-48-4 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-  
 benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 43 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:390959 CAPLUS  
 DOCUMENT NUMBER: 133:12837  
 TITLE: Clinical pharmacokinetics of angiotensin II (AT1)  
 receptor blockers in hypertension  
 AUTHOR(S): Israili, Z. H.  
 CORPORATE SOURCE: Emory University School of Medicine, Atlanta, GA,  
 30303, USA  
 SOURCE: Journal of Human Hypertension (2000),  
 14(Suppl. 1), S73-S86  
 CODEN: JHHYEN; ISSN: 0950-9240  
 PUBLISHER: Nature Publishing Group  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English  
 AB A review with 174 refs. Angiotensin II receptor blockers (ARBs) represent  
 a new class of effective and well tolerated orally active antihypertensive  
 agents. Recent clin. trials have shown the added benefits of ARBs in  
 hypertensive patients (reduction in left ventricular hypertrophy, improvement  
 in diastolic function, decrease in ventricular arrhythmias, reduction in  
 microalbuminuria, and improvement in renal function), and cardioprotective  
 effect in patients with heart failure. Several large long-term studies  
 are in progress to assess the beneficial effects of ARBs on cardiac  
 hypertrophy, renal function, and cardiovascular and cerebrovascular  
 morbidity and mortality in hypertensive patients with or without  
 diabetes mellitus, and the value of these drugs in patients with  
 heart disease and diabetic nephropathy. The ARBs specifically block the  
 interaction of angiotensin II at the AT<sub>1</sub> receptor, thereby relaxing smooth  
 muscle, increasing salt and water excretion, reducing plasma volume, and  
 decreasing cellular hypertrophy. These agents exert their blood  
 pressure-lowering effect mainly by reducing peripheral vascular resistance  
 usually without a rise in heart rate. Most of the com. available ARBs  
 control blood pressure for 24 h after once daily dosing. Sustained  
 efficacy of blood pressure control, without any evidence of tachyphylaxis,



has been demonstrated after long-term administration (3 yr) of some of the ARBs. The efficacy of ARBs is similar to that of thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors or calcium channel blockers in patients with similar degree of hypertension. Higher daily doses, dietary salt restriction, and concomitant diuretic or ACE inhibitor administration amplify the antihypertensive effect of ARBs. The ARBs have a low incidence of adverse effects (headache, upper respiratory infection, back pain, muscle cramps, fatigue and dizziness), even in the elderly patients. After the approval of losartan, five other ARBs (candesartan cilexetil, eprosartan, irbesartan, telmisartan, and valsartan) and three combinations with hydrochlorothiazide (irbesartan, losartan and valsartan) have been approved as antihypertensive agents, and some 28 compds. are in various stages of development. The ARBs are non-peptide compds. with varied structures; some (candesartan, losartan, irbesartan, and valsartan) have a common tetrazolo-biphenyl structure. Except for irbesartan, all active ARBs have a carboxylic acid group. Candesartan cilexetil is a prodrug, while losartan has a metabolite (EXP3174) which is more active than the parent drug. No other metabolites of ARBs contribute significantly to the antihypertensive effect. The variation in the mol. structure of the ARBs results in differences in the binding affinity to the receptor and pharmacokinetic profiles. The differences observed in lipid solubility, absorption/distribution, plasma protein binding, bioavailability, biotransformation, plasma half-life, and systemic elimination influence the time of onset, duration of action, and efficacy of the ARBs. On the basis of the daily mg dose, the anti-hypertensive potency of the ARBs follows the sequence: candesartan cilexetil > telmisartan losartan > irbesartan valsartan > eprosartan. After oral administration, the ARBs are rapidly absorbed (time for peak plasma levels = 0.5-4 h) but they have a wide range of bioavailability (from a low of 13% for eprosartan to a high of 60-80% for irbesartan); food does not influence the bioavailability, except for valsartan (a reduction of 40-50%) and eprosartan (increase). A limited dose-peak plasma levels/areas under the plasma level-time curve proportionality is observed for some of the ARBs. Most of these drugs have high plasma protein binding (95-100%); irbesartan has the lowest binding among the group (90%). The steady-state vols. of distribution vary from a low of 9 L (candesartan) to a high of 500 L (telmisartan). Plasma elimination half-life is short for candesartan cilexetil and losartan (1-4 h), intermediate for eprosartan and valsartan (5-10 h), and longer for candesartan, irbesartan and telmisartan (11-38 h); the active metabolite of losartan has a longer half-life than for the parent drug. The drugs and their active metabolites do not accumulate to a significant extent after repeated dosing, except for telmisartan (100%). Most of the orally administered dose of ARBs is excreted via bile into the feces; from 2% (telmisartan) to 33% (candesartan) of the oral dose is excreted in the urine. In most cases, changes in pharmacokinetic parameters due to aging, mild to moderate renal disease and heart failure do not require dosage modification; dosage has to be individualized for eprosartan, losartan, telmisartan and valsartan in patients with hepatic disease. In general, pharmacokinetic drug-drug interactions are rare, with the exception of combination of digoxin and telmisartan. The ARBs are an important treatment option for hypertension, being relatively safe and efficacious. The beneficial effects of the ARB therapy go beyond blood pressure control. They may prove to have beneficial hemodynamic and neurohormonal effects in heart failure and provide renoprotection in diabetic nephropathy.

REFERENCE COUNT: 189 THERE ARE 189 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 44 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:141004 USPATFULL  
 TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method



INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
Chen, Sean, Princeton, NJ, UNITED STATES  
Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003096846	A1	20030522	<--
	US 6653314	B2	20031125	
APPLICATION INFO.:	US 2002-80981	A1	20020222	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-812960, filed on 20 Mar 2001, GRANTED, Pat. No. US 6414002			
	Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5718	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds are provided which have the structure ##STR1##	

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 45 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:100110 USPATFULL  
TITLE: Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions  
INVENTOR(S): Kosoglou, Teddy, Jamison, PA, UNITED STATES  
Ress, Rudyard J., Flemington, NJ, UNITED STATES  
Strony, John T., Lebanon, NJ, UNITED STATES  
Veltri, Enrico P., Princeton, NJ, UNITED STATES  
Hauer, William, Warren, NJ, UNITED STATES  
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003069221	A1	20030410	<--
APPLICATION INFO.:	US 2002-57339	A1	20020125	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-323842P	20010921 (60)
	US 2001-264396P	20010126 (60)
	US 2001-264600P	20010126 (60)
	US 2001-264275P	20010126 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	

NUMBER OF CLAIMS: 49  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3423

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 46 OF 113 MEDLINE on STN  
ACCESSION NUMBER: 2003255815 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 12781906  
TITLE: The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.  
AUTHOR: Unger Thomas  
CORPORATE SOURCE: Institute of Pharmacology and Toxicology, Charite Hospital, Humboldt University at Berlin, Berlin, Germany.. Thomas.unger@charite.de  
SOURCE: The American journal of cardiology, (2003 May 22) Vol. 91, No. 10A, pp. 28G-34G. Ref: 52 Journal code: 0207277. ISSN: 0002-9149.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) General Review; (REVIEW)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 200307  
ENTRY DATE: Entered STN: 4 Jun 2003  
Last Updated on STN: 10 Jul 2003  
Entered Medline: 9 Jul 2003

AB The renin-angiotensin system evolved to maintain volume homeostasis and blood pressure and to prevent ischemia during acute volume loss. But in the present age, these mechanisms are redundant, and the clinical significance of angiotensin II results from its pathologic effects, which are mediated by the angiotensin II type 1 (AT(1)) receptor. Activation of AT(1) receptors has been linked to pathologic processes that contribute to atherosclerosis and ischemic events, including oxidative stress, inflammatory processes, low-density lipoprotein cholesterol trafficking, and prothrombotic states. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) program will compare the efficacy of the angiotensin II receptor blocker (ARB) telmisartan, the angiotensin-converting enzyme (ACE) inhibitor ramipril, and combination therapy with telmisartan plus ramipril for reducing cardiovascular risk. The ARB telmisartan is distinguished by its long duration of action, which compares favorably with some other ARBs and conventional antihypertensives. Ramipril was shown in the Heart Outcomes Prevention Evaluation (HOPE) study to reduce the risk for myocardial infarction (MI) and other cardiovascular events in patients at high risk for cardiovascular events but without heart failure or a low ejection fraction. The ONTARGET program consists of 2 randomized, double-blind, multicenter international trials: a principal trial, ONTARGET, and a parallel trial, Telmisartan Randomized Assessment Study in ACE-I Intolerant Patients with Cardiovascular Disease (TRANSCEND). The treatment arms for the principal ONTARGET study are telmisartan 80 mg, ramipril 10 mg, and combination therapy with telmisartan 80 mg plus ramipril 10 mg; for the parallel study TRANSCEND, the treatment arms are telmisartan 80 mg and placebo. Both trials will assess cardiovascular outcomes in patients at high risk using the same criteria as that of the HOPE study, with a single exception: the TRANSCEND trial will enroll patients who do not tolerate

ACE inhibitor treatment. The primary end points in both ONTARGET and TRANSCEND are death caused by cardiovascular disease, acute MI, stroke, and hospitalization because of congestive heart failure. The secondary end points include newly diagnosed heart failure, revascularization, new-onset type 2 diabetes mellitus, nephropathy, cognitive decrease and dementia, and newly diagnosed atrial fibrillation; these will be used for hypothesis generation.

L6 ANSWER 47 OF 113 MEDLINE on STN  
ACCESSION NUMBER: 2002274881 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 12015188  
TITLE: Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.  
AUTHOR: Rippin J; Bain S C; Barnett A H  
CORPORATE SOURCE: Department of Medicine, University of Birmingham, Birmingham B9 5SS, UK. (DETAIL study).  
SOURCE: Journal of diabetes and its complications, (2002 May-Jun) Vol. 16, No. 3, pp. 195-200.  
Journal code: 9204583. ISSN: 1056-8727.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(MULTICENTER STUDY)  
(RANDOMIZED CONTROLLED TRIAL)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200210  
ENTRY DATE: Entered STN: 17 May 2002  
Last Updated on STN: 8 Oct 2002  
Entered Medline: 4 Oct 2002

AB The DETAIL (diabetics exposed to telmisartan and enalapril) study will compare the long-term renal outcome of treatment with the angiotensin II receptor antagonist (ARA) telmisartan versus the angiotensin-converting enzyme (ACE) inhibitor enalapril in patients with mild-to-moderate hypertension and diabetic nephropathy. In short-term clinical studies, ACE inhibitors reduce microalbuminuria and, in the longer term, they are superior to conventional therapies in maintaining normal renal function. ARAs also appear to be renoprotective in diabetic animals. In this double-blind, parallel-group study, 252 patients with Type 2 diabetes and concurrent hypertension (mean seated systolic blood pressure  $\leq$  180 mm Hg, on treatment seated diastolic blood pressure  $\leq$  95 mm Hg) have been randomised to once-daily telmisartan 40 mg or enalapril 10 mg; doses are mandatorily titrated to 80 and 20 mg once daily, respectively, after 4 weeks. The primary endpoint will be the change from baseline in glomerular filtration rate (GFR) after 5 years of therapy, using the iohexol method and central laboratory analysis. The secondary endpoints to be evaluated will be: changes in GFR in relation to baseline after 1-4 years of therapy; percentage changes in albumin excretion rate after 1-5 years; and incidences of end-stage renal disease, cardiovascular events, all-cause mortality, and adverse events. The planned date for the completion of the study is 2005.

L6 ANSWER 48 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:203196 CAPLUS  
DOCUMENT NUMBER: 138:215317  
TITLE: Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin  
INVENTOR(S): Liang, Matthew H.; Manson, Joann E.  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 14 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003049314	A1	20030313	US 2001-942084	20010828 <--
US 6576256	B2	20030610		


PRIORITY APPLN. INFO.: US 2001-942084 20010828

AB Methods and compns. are provided for reducing the risk of cardiovascular events in individuals who are at elevated cardiovascular risk, including individuals who have systemic lupus erythematosus. The methods comprise administering a combination of: a cholesterol-lowering agent, such as an HMG CoA reductase inhibitor; an inhibitor of the renin-angiotensin system, such as an ACE inhibitor; aspirin; and optionally one or more of vitamin B6, vitamin B12, and folic acid. Pharmaceutical formulations combining all the active agents in unit-dose form for once-daily dosing are provided. Tablets containing pravastatin 40 mg, ramipril 10 mg, aspirin (in enteric coated granules) 81 mg, Vitamin B6 50 mg, Vitamin B12 1 mg, folic acid 3 mg, calcium carbonate 50 mg, magnesium oxide 25 mg, magnesium carbonate 25 mg, microcryst. cellulose 25 mg, lactose 25 mg, and magnesium stearate 1 mg are used to treat subjects at elevated cardiac risk.

IT 144701-48-4, Telmisartan  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (as renin-angiotensin system inhibitor; treatment of patients at elevated cardiovascular risk with combination of cholesterol-lowering agent, inhibitor of renin-angiotensin system, and aspirin)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 49 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:574955 CAPLUS  
 DOCUMENT NUMBER: 137:129903  
 TITLE: Combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions  
 INVENTOR(S): Kosoglou, Teddy; Ress, Rudyard Joseph; Strony, John; Veltri, Enrico P.; Hauer, William  
 PATENT ASSIGNEE(S): Schering Corporation, USA  
 SOURCE: PCT Int. Appl., 105 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 12  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002058731	A2	20020801	WO 2002-US1196	20020125 <--
WO 2002058731	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2434436	A1	20020801	CA 2002-2434436	20020125 <--
CA 2562982	A1	20020801	CA 2002-2562982	20020125 <--
CA 2563051	A1	20020801	CA 2002-2563051	20020125 <--
US 2003069221	A1	20030410	US 2002-57339	20020125 <--
EP 1385548	A2	20040204	EP 2002-707500	20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002006644	A	20040225	BR 2002-6644	20020125
HU 200303923	A2	20040301	HU 2003-3923	20020125
EP 1413331	A2	20040428	EP 2004-161	20020125
EP 1413331	A3	20040630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517919	T	20040617	JP 2002-559065	20020125
CN 1582168	A	20050216	CN 2002-804219	20020125
EP 1541175	A2	20050615	EP 2005-3029	20020125
EP 1541175	A3	20060412		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1671650	A1	20060621	EP 2006-5831	20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1915429	A	20070221	CN 2006-10126233	20020125
ZA 2003005692	A	20041025	ZA 2003-5692	20030723
ZA 2003005694	A	20041025	ZA 2003-5694	20030723
ZA 2003005693	A	20050209	ZA 2003-5693	20030723
IN 2003CN01150	A	20050422	IN 2003-CN1150	20030724
NO 2003003358	A	20030912	NO 2003-3358	20030725 <--
US 2004097482	A1	20040520	US 2003-639900	20030813
US 2005153952	A1	20050714	US 2004-998400	20041129
US 2006199793	A1	20060907	US 2005-158429	20050622
PRIORITY APPLN. INFO.:			US 2001-264275P	P 20010126
			US 2001-264396P	P 20010126
			US 2001-264600P	P 20010126
			US 2001-323842P	P 20010921
			US 2001-323839P	P 20010921
			CA 2002-2434682	A3 20020125
			CN 2002-807208	A3 20020125
			EP 2002-705933	A3 20020125
			EP 2002-707500	A3 20020125
			EP 2002-714773	A3 20020125
			US 2002-57323	A3 20020125
			US 2002-57646	A1 20020125
			WO 2002-US1196	W 20020125
			US 2002-136968	A3 20020501

OTHER SOURCE(S):

MARPAT 137:129903



GI




AB The present invention provides compns., therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols. Tablets were prepared containing cardiovascular agents which can be coadministered with formulations containing, e.g., I. The preparation of I was given.

IT 144701-48-4, Telmisartan

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combinations of azetidinone sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 50 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:127720 USPATFULL

TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method

INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
Chen, Sean, Princeton, NJ, UNITED STATES  
Zhang, Hao, Belle Mead, NJ, UNITED STATES



	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087935	A1	20030508
	US 6727271	B2	20040427
APPLICATION INFO.:	US 2002-81075	A1	20020222 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5712	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds are provided which have the structure ##STR1##	

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 51 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:100164 USPATFULL  
 TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method  
 INVENTOR(S): Cheng, Peter T., Princeton, NJ, UNITED STATES  
 Devasthale, Pratik, Plainsboro, NJ, UNITED STATES  
 Jeon, Yoon, Belle Mead, NJ, UNITED STATES  
 Chen, Sean, Princeton, NJ, UNITED STATES  
 Zhang, Hao, Belle Mead, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069275	A1	20030410
	US 6919358	B2	20050719
APPLICATION INFO.:	US 2002-80965	A1	20020222 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-812960, filed on 20 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5710	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds are provided which have the structure ##STR1##	

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic,

hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 52 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:708455 CAPLUS

DOCUMENT NUMBER: 138:378867

TITLE: Angiotensin II Receptor Antagonists and  
Angiotensin-Converting Enzyme Inhibitors Lower In  
Vitro the Formation of Advanced Glycation End  
Products: Biochemical Mechanisms

AUTHOR(S): Miyata, Toshio; van Ypersele de Strihou, Charles;  
Ueda, Yasuhiko; Ichimori, Kohji; Inagi, Reiko; Onogi,  
Hiroshi; Ishikawa, Naoyoshi; Nangaku, Masaomi;  
Kurokawa, Kiyoshi

CORPORATE SOURCE: Institute of Medical Sciences and Department of  
Medicine, Tokai University School of Medicine,  
Kanagawa, Japan

SOURCE: Journal of the American Society of Nephrology (  
2002), 13(10), 2478-2487  
CODEN: JASNEU; ISSN: 1046-6673

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The implication of advanced glycation end products (AGE) in the  
pathogenesis of atherosclerosis and of diabetic and uremic complications  
has stimulated a search for AGE inhibitors. This study evaluates the AGE  
inhibitory potential of several well-tolerated hypotensive drugs.  
Olmesartan, an angiotensin II type 1 receptor (AIIR) antagonist, as well  
as temocaprilat, an angiotensin-converting enzyme (ACE) inhibitor, unlike  
nifedipine, a calcium blocker, inhibit in vitro the formation of two AGE,  
pentosidine and N $\epsilon$ -carboxymethyllysine (CML), during incubation of  
nonuremic diabetic, nondiabetic uremic, or diabetic uremic plasma or of  
BSA fortified with arabinose. This effect is shared by all tested AIIR  
antagonists and ACE inhibitors. On an equimolar basis, they are more  
efficient than aminoguanidine or pyridoxamine. Unlike the latter two  
comps., they do not trap reactive carbonyl precursors for AGE, but impact  
on the production of reactive carbonyl precursors for AGE by chelating  
transition metals and inhibiting various oxidative steps, including  
carbon-centered and hydroxyl radicals, at both the pre- and post-Amadori  
steps. Their effect is paralleled by a lowered production of reactive  
carbonyl precursors. Finally, they do not bind pyridoxal, unlike  
aminoguanidine. Altogether, this study demonstrates for the first time  
that widely used hypotensive agents, AIIR antagonists and ACE inhibitors,  
significantly attenuate AGE production. This study provides a new framework  
for the assessment of families of AGE-lowering comps. according to their  
mechanisms of action.


IT 144701-48-4, Telmisartan

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL  
(Biological study)

(angiotensin II receptor antagonists and angiotensin-converting enzyme  
inhibitors lower formation of advanced glycation end products and  
mechanisms therein)

RN 144701-48-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-  
benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 53 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:160755 USPATFULL  
 TITLE: Substituted acid derivatives useful as antidiabetic and antiobesity agents and method  
 INVENTOR(S): Cheng, Peter T., Princeton, NJ, United States  
 Devasthale, Pratik, Plainsboro, NJ, United States  
 Jeon, Yoon, Belle Mead, NJ, United States  
 Chen, Sean, Princeton, NJ, United States  
 Zhang, Hao, Belle Mead, NJ, United States  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6414002	B1	20020702
APPLICATION INFO.:	US 2001-812960		20010320 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-664598, filed on 18 Sep 2000		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-155400P	19990922 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Higel, Floyd D.	
ASSISTANT EXAMINER:	Sackey, Ebenezer	
LEGAL REPRESENTATIVE:	Burton Rodney	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	5133	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Compounds are provided which have the structure ##STR1##

wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 54 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:759924 CAPLUS  
 DOCUMENT NUMBER: 139:316442  
 TITLE: New definitions in cardiovascular risk management: is it time for angiotensin II receptor blockers to become first-line medication?  
 AUTHOR(S): Jennings, G.  
 CORPORATE SOURCE: Baker Heart Research Institute, Melbourne, Australia  
 SOURCE: European Heart Journal Supplements (2003), 5(Suppl. F), F3-F11  
 CODEN: EHJSFT; ISSN: 1520-765X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English  
 AB A review. The risk for coronary heart disease (CHD) increases with the number of risk factors. Thus, the clin. focus in prevention of CHD should be on patients with multiple risk factors. Both hypertension and a history of myocardial infarction are acknowledged risk factors for heart failure - the most severe form of CHD - but hypertension is more common. Anal. of data from the Framingham Heart Study shows that hypertension is associated with a greater population-attributable risk for heart failure. Angiotensin II, acting via the angiotensin II type 1 receptor, has been implicated in pathol. associated with ischemic heart disease and heart failure. Data on the efficacy of angiotensin-converting enzyme inhibitors in reducing cardiovascular events are comprehensive, with benefits demonstrated for patients with multiple risk factors, target organ damage, acute myocardial infarction and heart failure. Several recent trials have shown that angiotensin II receptor blockers reduce the progression of nephropathy in patients with type 2 diabetes mellitus. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Trial Program will provide a large body of data on the efficacy of the angiotensin II receptor Mocker telmisartan in lowering cardiovascular morbidity and mortality in patients with multiple risk factors.  
 IT 144701-48-4, Telmisartan  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (role of angiotensin II receptor blockers in cardiovascular risk management)  
 RN 144701-48-4 CAPLUS  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 58      THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 55 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:166611 USPATFULL  
 TITLE: Combinations  
 INVENTOR(S): Cohen, David Saul, New Providence, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003114469	A1	20030619	<--
APPLICATION INFO.:	US 2002-231427	A1	20020828	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-325485P	20010927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080	

NUMBER OF CLAIMS: 9  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 2636  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a pharmaceutical composition,  
 comprising

(a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable  
 salt thereof and

(b) at least one of the active ingredients selected from the group  
 consisting of

- (i) an anti-diabetic agent;
- (ii) HMG-Co-A reductase inhibitors;
- (iii) an anti-hypertensive agent; and
- (iv) a serotonin reuptake inhibitor (SSRI)

or, in each case, or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier. The pharmaceutical composition  
 may be employed for the treatment of sexual dysfunction, hyperglycemia,  
 hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia,  
 diabetes, insulin resistance, impaired glucose metabolism,  
 conditions of impaired glucose tolerance (IGT), conditions of impaired  
 fasting plasma glucose, obesity, diabetic retinopathy, diabetic  
 nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X,  
 erectile dysfunction, coronary heart disease, hypertension, especially  
 ISH, angina pectoris, myocardial infarction, stroke, vascular  
 restenosis, endothelial dysfunction, impaired vascular compliance,  
 congestive heart failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 56 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:266021 USPATFULL  
 TITLE: Fibrinogen-lowering agents  
 INVENTOR(S): Imura, Yoshimi, Toyono-gun, JAPAN  
 Hirakata, Masao, Kobe-shi, JAPAN

NUMBER	KIND	DATE
-----		

PATENT INFORMATION:	US 2003187038	A1	20031002	<--
APPLICATION INFO.:	US 2003-344719	A1	20030214 (10)	
	WO 2001-JP7239		20010824	


	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	JP 2000-260881	20000825
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1512	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We offer a fibrinogen-lowering agent comprising a compound having an angiotensin II antagonistic activity, a prodrug thereof, or a salt thereof. Because of having an excellent effect of lowering fibrinogen, the above fibrinogen-lowering agent is useful as a prophylactic or therapeutic agent for various diseases caused by hyperfibrionogenemia, etc.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(fibrinogen lowering agents containing angiotensin II antagonists)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 57 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:201442 USPATFULL  
TITLE: Combinations  
INVENTOR(S): Cohen, David Saul, New Providence, NJ, UNITED STATES

	NUMBER	KIND	DATE	
	-----	-----	-----	
PATENT INFORMATION:	US 2003139429	A1	20030724	<--
	US 7019010	B2	20060328	
APPLICATION INFO.:	US 2002-236651	A1	20020906 (10)	

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-325485P	20010927 (60)



DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK  
DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ,  
07936-1080

NUMBER OF CLAIMS: 10  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1304

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a pharmaceutical composition,  
comprising

(a) a phosphodiesterase 5 inhibitor or a pharmaceutically acceptable  
salt thereof and

(b) at least one of the active ingredients selected from the group  
consisting of

(i) an anti-diabetic agent;

(ii) HMG-Co-A reductase inhibitors;

(iii) an anti-hypertensive agent; and

(iv) a serotonin reuptake inhibitor (SSRI)

or, in each case, or a pharmaceutically acceptable salt thereof and a  
pharmaceutically acceptable carrier. The pharmaceutical composition may  
be employed for the treatment of sexual dysfunction, hyperglycemia,  
hyperinsulinaemia, hyperlipidaemia, hypertriglyceridemia,  
diabetes, insulin resistance, impaired glucose metabolism,  
conditions of impaired glucose tolerance (IGT), conditions of impaired  
fasting plasma glucose, obesity, diabetic retinopathy, diabetic  
nephropathy, glomerulosclerosis, diabetic neuropathy, syndrome X,  
erectile dysfunction, coronary heart disease, hypertension, especially  
ISH, angina pectoris, myocardial infarction, stroke, vascular  
restenosis, endothelial dysfunction, impaired vascular compliance,  
congestive heart failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 58 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:120858 USPATFULL  
TITLE: Combination of organic compounds  
INVENTOR(S): Steele, Ronald Edward, Long Valley, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003083342	A1	20030501	<--
APPLICATION INFO.:	US 2002-149107	A1	20020827	(10)
	WO 2001-EP4116		20010410	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK			
	DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ,			
	07936-1080			
NUMBER OF CLAIMS:	10			
EXEMPLARY CLAIM:	1			
LINE COUNT:	726			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a pharmaceutical composition, of (i) an  
aldosterone synthase inhibitor or a pharmaceutically acceptable salt  
thereof either alone or in combination with (ii) an AT.sub.1-receptor  
antagonist combined with a diuretic, or in each case, a pharmaceutically

acceptable salt thereof and (iii) a pharmaceutically acceptable carrier.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(oral compns. containing aldosterone synthase inhibitor and AT1-receptor antagonist for therapeutic uses)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 59 OF 113

USPATFULL on STN

ACCESSION NUMBER:

2001:173610 USPATFULL

TITLE:

Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist

INVENTOR(S):

Segal, Robert, Gwynedd Valley, PA, United States  
Robinson, Paul J., Hertfordshire, United Kingdom  
Deckelbaum, Lawrence I., Gladwyne, PA, United States

PATENT ASSIGNEE(S):

Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6300356	B1	20011009	<--
	WO 9943210		19990902	<--
APPLICATION INFO.:	US 2000-601938		20000810	(9)
	WO 1999-US3828		19990222	
			20000810	PCT 371 date
			20000810	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1998-8937	19980427
	US 1998-75915P	19980225 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Krass, Frederick	
LEGAL REPRESENTATIVE:	Camara, Valerie J., Daniel, Mark R.	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	1520	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Angiotensin II receptor antagonists are useful for decreasing QT dispersion or inhibiting the progression of QT prolongation in patients. Also disclosed is a method for monitoring the reduction in the risk of experiencing an adverse cardiac event, such as sudden cardiac death, myocardial infarction or arrhythmias, using QT dispersion in patients treated with a therapeutically effective amount of an angiotensin II antagonist.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(angiotensin II receptor antagonists for decreasing QT dispersion or inhibiting progression of QT prolongation in humans)

RN 144701-48-4 USPTAFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 60 OF 113 MEDLINE on STN

ACCESSION NUMBER: 2002104848 MEDLINE

DOCUMENT NUMBER: PubMed ID: 11835907

TITLE: From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.

AUTHOR: Yusuf Salim

CORPORATE SOURCE: Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.. yusufs@mcmaster.ca

SOURCE: The American journal of cardiology, (2002 Jan 24)  
Vol. 89, No. 2A, pp. 18A-25A; discussion 25A-26A.  
Journal code: 0207277. ISSN: 0002-9149.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
(META-ANALYSIS)

LANGUAGE: English

FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals

ENTRY MONTH: 200202

ENTRY DATE: Entered STN: 12 Feb 2002

Last Updated on STN: 23 Feb 2002

Entered Medline: 22 Feb 2002

AB The Heart Outcomes Prevention Evaluation (HOPE) study conclusively demonstrated that ramipril, an angiotensin-converting enzyme (ACE) inhibitor, reduces the risk of cardiovascular death, myocardial infarction (MI), and death in patients at risk for cardiovascular events but without heart failure. The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE) substudy demonstrated that ramipril also reduced atherosclerosis. These results

suggest that the renin-angiotensin system (RAS) has a more important role in the development and progression of atherosclerosis than previously believed, and they indicate the need for further clinical studies to define the range of benefits available from modifying the RAS. Achieving maximum benefit may require treatment with both an ACE inhibitor and an angiotensin II type-1 receptor blocker (ARB). The Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) study indicated that combining an ACE inhibitor with an ARB decreased blood pressure and improved the ejection fraction more than treatment with either drug alone in patients with congestive heart failure. The Valsartan in Heart Failure Trial (Val-HeFT) showed that the combination of an ACE inhibitor and an ARB reduced hospitalization for heart failure in patients with congestive heart failure by 27.5%, although no decrease in all-cause mortality was observed. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) is a large, long-term study (23,400 patients, 5.5 years). It will compare the benefits of ACE inhibitor treatment, ARB treatment, and treatment with an ACE inhibitor and ARB together, in a study population with established coronary artery disease, stroke, peripheral vascular disease, or diabetes with end-organ damage. Patients with congestive heart failure will be excluded. In a parallel study, patients unable to tolerate an ACE inhibitor will be randomized to receive telmisartan or placebo (the Telmisartan Randomized Assessment Study in ACE-I Intolerant Patients with Cardiovascular Disease [TRANSCEND]). The primary endpoint for both trials is a composite of cardiovascular death, MI, stroke, and hospitalization for heart failure. Secondary endpoints will investigate reductions in the development of diabetes mellitus, nephropathy, dementia, and atrial fibrillation. These 2 trials are expected to provide new insights into the optimal treatment of patients at high risk of complications from atherosclerosis.

L6 ANSWER 61 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2003:709669 CAPLUS  
 DOCUMENT NUMBER: 140:1129  
 TITLE: Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation  
 AUTHOR(S): Yamagishi, S.; Amano, S.; Inagaki, Y.; Okamoto, T.; Inoue, H.; Takeuchi, M.; Choei, H.; Sasaki, N.; Kikuchi, S.  
 CORPORATE SOURCE: Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Kurume, 830-0011, Japan  
 SOURCE: Drugs under Experimental and Clinical Research (2003), 29(2), 75-80  
 CODEN: DECRDP; ISSN: 0378-6501  
 PUBLISHER: Bioscience Ediprint Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The renin-angiotensin system has been implicated in the development and progression of atherosclerosis, thereby contributing to adverse cardiovascular events. However, its role in diabetic retinopathy remains to be elucidated. Since pericyte loss and dysfunction have been considered as one of the characteristic changes of the early phase of diabetic retinopathy, we investigated the effects of angiotensin II (Ang II) on the growth and function of bovine cultured retinal pericytes. Ang II stimulated intracellular reactive oxygen species (ROS) generation in pericytes in a dose-dependent manner. Telmisartan, a newly developed Ang II type 1 receptor antagonist, completely inhibited ROS generation in pericytes induced by Ang II. Ang II decreased DNA synthesis in pericytes, which was significantly prevented by an antioxidant N-acetylcysteine. Furthermore, telmisartan or N-acetylcysteine were found to completely inhibit the Ang II-induced upregulation of

vascular endothelial growth factor mRNA levels in pericytes. The present results suggest that Ang II-type 1 receptor interaction could induce pericyte loss and dysfunction through intracellular ROS generation, thus being involved in the development and progression of diabetic retinopathy.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 62 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2005:33212 USPATFULL  
TITLE: Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof  
INVENTOR(S): Ojima, Mami, Amagasaki, JAPAN  
Kitayoshi, Takahito, Suita, JAPAN  
Miyamoto, Masaomi, Takarazuka, JAPAN  
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Osaka, JAPAN  
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6852743	B1	20050208	
	WO 2001005428		20010125	<--
APPLICATION INFO.:	US 2002-31398		20020118	(10)
	WO 2000-JP4830		20000719	
			20020118	PCT 371 date


	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-205877	19990721
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Powers, Fiona T.	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack, L.L.P.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1291	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided an agent for preventing the recurrence of cerebrovascular disorder and an agent for ameliorating troubles following cerebrovascular disorder and inhibiting the progress thereof which contain a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(preventives for recurrence of cerebrovascular failure containing benzimidazoles as angiotensin II antagonists)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 63 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:289188 USPATFULL  
 TITLE: Activator of PPAR delta  
 INVENTOR(S): Chao, Esther Yu-Hsuan, Durham, NC, UNITED STATES  
 Haffner, Curt Dale, Durham, NC, UNITED STATES  
 Lambert, Millard Hurst, III, Durham, NC, UNITED STATES  
 Maloney, Patrick Reed, Durham, NC, UNITED STATES  
 Sierra, Michael Lawrence, Les Ulis, FRANCE  
 Sternbach, Daniel David, Durham, NC, UNITED STATES  
 Sznajdman, Marcos Luis, Durham, NC, UNITED STATES  
 Willson, Timothy Mark, Durham, NC, UNITED STATES  
 Xu, Huaqiang Eric, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003203947	A1	20031030 <--
	US 6723740	B2	20040420
APPLICATION INFO.:	US 2003-383011	A1	20030306 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-18935, filed on 19 Dec 2001, PENDING A 371 of International Ser. No. WO 2000-EP5720, filed on 22 Jun 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-14977	19990625
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1942	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Compounds of Formula (I) are disclosed. These compounds include selective activators of human PPAR delta.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 64 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:127094 USPATFULL  
 TITLE: Methods for identifying novel multimeric agents that modulate receptors  
 INVENTOR(S): Christensen, Burton G., Alamo, CA, UNITED STATES



Griffin, John H., Atherton, CA, UNITED STATES  
Jenkins, Thomas E., La Honda, CA, UNITED STATES  
Judice, J. Kevin, El Granada, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003087306	A1	20030508	<--
APPLICATION INFO.:	US 2001-15534	A1	20011213	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-493462, filed on 28 Jan 2000, ABANDONED Continuation of Ser. No. US 1999-327904, filed on 8 Jun 1999, ABANDONED			

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92938P	19980715 (60)
	US 1998-88466P	19980608 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THERAVANCE, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	52 Drawing Page(s)	
LINE COUNT:	8387	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological processes/functions thereof. Each of the ligands is covalently attached to a linker or linkers which may be the same or different to provide for the multi-binding compound. The linker is selected such that the multi-binding compound so constructed demonstrates increased modulation or disruption of the biological processes/functions of the cell. Also disclosed is a method for identifying such novel multi-binding compounds which bind cellular receptors and a method for generating a mixture of such novel multi-binding compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 65 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2004:72635 USPATFULL  
TITLE: Activators of PPAR delta  
INVENTOR(S): Chao, Esther Yu-Hsuan, Durham, NC, United States  
Haffner, Curt Dale, Durham, NC, United States  
Lambert, III, Millard Hurst, Durham, NC, United States  
Maloney, Patrick Reed, Durham, NC, United States  
Sierra, Michael Lawrence, Les Ulis, FRANCE  
Sternbach, Daniel David, Durham, NC, United States  
Sznajdman, Marcos Luis, Durham, NC, United States  
Willson, Timothy Mark, Durham, NC, United States  
Xu, Huaqiang Eric, Durham, NC, United States  
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6710063	B1	20040323	
	WO 2001000603		20010104	<--
APPLICATION INFO.:	US 2001-18935		20011219	(10)
	WO 2000-EP5720		20000622	

NUMBER	DATE
-----	

PRIORITY INFORMATION: GB 1999-14977 19990625  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Rotman, Alan L.  
ASSISTANT EXAMINER: Shameem, Golam M. M.  
LEGAL REPRESENTATIVE: Brink, Robert H.  
NUMBER OF CLAIMS: 20  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
LINE COUNT: 2021  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compounds of Formula (1) are disclosed. These compounds include selective activators of human PPAR delta. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 66 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:306948 USPATFULL  
TITLE: Composition and method for treating hypertension  
INVENTOR(S): Stokes, Gordon, St Leonards, AUSTRALIA  
PATENT ASSIGNEE(S): Northern Sydney Area Health Service (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003216384	A1	20031120	<--
APPLICATION INFO.:	US 2002-255447	A1	20020925	(10)


	NUMBER	DATE
PRIORITY INFORMATION:	AU 2002-2369	20020516
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	902	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a composition for the treatment and/or prevention of hypertension, said composition comprising an synergistic anti-hypertensive combination of a therapeutically effective amount of at least one angiotensin II inhibitor, and a therapeutically effective amount of at least one nitric oxide donor; said composition optionally further comprising a pharmaceutically acceptable carrier, diluent and/or adjuvant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(angiotensin II inhibitor-nitric oxide donor synergistic combination for treating hypertension)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 67 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:312692 USPATFULL  
 TITLE: Phosphorus-containing compounds and uses thereof  
 INVENTOR(S): Berstein, David L., Waban, MA, UNITED STATES  
 Metcalf, Chester A., III, Needham, MA, UNITED STATES  
 Rozamus, Leonard W., Bedford, MA, UNITED STATES  
 Wang, Yihan, Newton, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003220297	A1	20031127	<--
APPLICATION INFO.:	US 2003-357152	A1	20030203	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-353252P	20020201 (60)
	US 2002-426928P	20021115 (60)
	US 2002-428383P	20021122 (60)
	US 2002-433930P	20021217 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: David L. Berstein, ARIAD Gene Therapeutics, Inc., 26  
 Landsdowne Street, Cambridge, MA, 02139-4234  
 NUMBER OF CLAIMS: 39  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 3696

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention concerns a new family of phosphorus-containing compounds containing a moiety JQA--in which:

A is absent or is --O--, --S-- or --NR.sup.2--;

Q is absent or (if A is --O--, --S-- or --NR.sup.2--) Q may be --V--, --OV--, --SV--, or --NR.sup.2V--, where V is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, such that J is linked to the cyclohexyl ring directly, through A or through VA, OVA, SVA or NR.sup.2VA; ##STR1##

K is O or S;

each occurrence of Y is independently --O--, --S--, --NR.sup.2--, or a chemical bond linking a R.sup.5 moiety to P;

and the other variables are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 68 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:199127 USPATFULL  
TITLE: Methods of treating sexual dysfunction associated with hypertension  
INVENTOR(S): Sahota, Pritam Singh, New Providence, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002107236	A1	20020808	<--
APPLICATION INFO.:	US 2001-8445	A1	20011203	(10)


	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-250540P	20001201 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	665	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods of treating SD associated with hypertension and another condition by administering a pharmaceutical combination of an angiotensin receptor blocker with either an anti-hypertensive drug or an HMG-CoA reductase inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(pharmaceutical compns. containing angiotensin receptor blockers for treating sexual dysfunction)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 69 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:759933 CAPLUS  
DOCUMENT NUMBER: 139:301175  
TITLE: PROGRESS beyond HOPE and LIFE: the ONTARGET trial

programme  
 AUTHOR(S): Sleight, P.  
 CORPORATE SOURCE: John Radcliffe Hospital, Oxford, UK  
 SOURCE: European Heart Journal Supplements (2003),  
 5(Suppl. F), F40-F47  
 CODEN: EHJSFT; ISSN: 1520-765X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English

AB A review. Large-scale cardiovascular trials traditionally have targeted  
 clin. hypertension, diabetes or survivors of myocardial  
 infarction, but the recent trend in such trials has been to consider the  
 treatment of high-risk individuals rather than specific diseases. This  
 allows the use of a much broader screening process to enroll patients.  
 Angiotensin-converting enzyme inhibitors and angiotensin II receptor  
 blockers (ARBs) act directly on the renin-angiotensin system to effect  
 blood pressure control. The Heart Outcomes Prevention Evaluation (HOPE)  
 and the Perindopril pROtection against REcurrent Stroke Study (PROGRESS)  
 showed that angiotensin-converting enzyme inhibitors (ramipril and  
 perindopril plus the diuretic indapamide), significantly decreased the  
 risk for stroke and other adverse cardiovascular outcomes. Both studies  
 showed benefits in patients with conventionally normal blood pressure.  
 The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial  
 showed that losartan, an ARB, could also significantly decrease the risk  
 of stroke to an extent greater than that predicted by the decrease in  
 blood pressure. The ONgoing Telmisartan Alone and in  
 combination with Ramipril Global Endpoint Trial (ONTARGET) Trial Program  
 is currently underway to study the effect of ramipril and the ARB  
 telmisartan, and a combination of the two agents in patients at  
 high risk of cardiovascular disease.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 70 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:99270 USPATFULL  
 TITLE: Sustained release preparations of physiologically  
 active compound hardly soluble in water and production  
 process and use of the same  
 INVENTOR(S): Kamei, Shigeru, Takarazuka-shi, JAPAN  
 Ojima, Mami, Amagasaki-shi, JAPAN  
 Kitayoshi, Takahito, Suita-shi, JAPAN  
 Igari, Yasutaka, Kobe-shi, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003068374	A1	20030410	<--
APPLICATION INFO.:	US 2002-204185	A1	20020819	(10)
	WO 2001-JP1191		20010220	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-48980	20000221
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2121	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sustained-release preparation containing a physiologically active  
 compound slightly soluble in water, a component obtained by treating  
 with water a polyvalent metal compound slightly soluble in water, and a  
 biodegradable polymer which are improved in the release-control and

stabilization of the physiologically active compound slightly soluble in water and can be produced by a process suitable for mass production.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(sustained-release compns. containing physiol. active compds. hardly-soluble in water, polyvalent metal compds., and biodegradable polymers)

RN 144701-48-4 USPATEFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 71 OF 113 USPATEFULL on STN

ACCESSION NUMBER: 2002:266305 USPATEFULL

TITLE: Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions

INVENTOR(S): Kosoglou, Teddy, Jamison, PA, UNITED STATES  
Ress, Rudyard J., Flemington, NJ, UNITED STATES  
Strony, John T., Lebanon, NJ, UNITED STATES  
Veltri, Enrico P., Princeton, NJ, UNITED STATES

PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002147184	A1	20021010	<--
APPLICATION INFO.:	US 2002-56680	A1	20020125	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-324123P	20010921 (60)
	US 2001-264396P	20010126 (60)
	US 2001-264600P	20010126 (60)
	US 2001-264275P	20010126 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530

NUMBER OF CLAIMS: 48

EXEMPLARY CLAIM: 1

LINE COUNT: 3296

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor; and



(b) at least one blood modifier, which can be useful for treating vascular conditions and lowering plasma levels of sterols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 72 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2006:154381 USPATFULL  
TITLE: Method for preventing, treating or inhibiting  
development of simple retinopathy and preproliferative  
retinopathy  
INVENTOR(S): Nakagawa, Shizue, Osaka, JAPAN  
Nagisa, Yasutaka, Higashiosaka, JAPAN  
Ikeda, Hitoshi, Higashiosaka, JAPAN  
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Osaka, JAPAN  
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 7064141	B1	20060620	
	WO 2000066161		20001109	<--
APPLICATION INFO.:	US 2000-958740		20000427	(9)
	WO 2000-JP2766		20000427	
			20011016	PCT 371 date


	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-121498	19990428
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Fay, Zohreh	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack, L.L.P.	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1057	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB To provide a pharmaceutical composition for preventing, treating or development-inhibiting simple retinopathy or preproliferative retinopathy, comprising a compound having angiotensin II antagonistic activity, or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(angiotensin II antagonists for treatment of retinopathy)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 73 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:173948 USPATFULL  
 TITLE: Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women  
 INVENTOR(S): Strony, John T., Lebanon, NJ, UNITED STATES  
 PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119796	A1	20030626
	US 7056906	B2	20060606
APPLICATION INFO.:	US 2002-247085	A1	20020919 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-166942, filed on 11 Jun 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-324118P	20010921 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	
NUMBER OF CLAIMS:	44	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2932	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, therapeutic combinations and methods including: (a) at least one hormone replacement therapy composition; and (b) at least one sterol absorption inhibitor which can be useful for treating vascular conditions in post-menopausal women and lowering plasma levels of sterols or 5 $\alpha$ -stanols.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 74 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:99262 USPATFULL  
 TITLE: Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin  
 INVENTOR(S): Chungi, Shubha, Sharon, MA, UNITED STATES  
 Iorio, Theodore L., Millis, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003068366	A1	20030410	<--
	US 6669955	B2	20031230	
APPLICATION INFO.:	US 2001-941948	A1	20010828	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025			
NUMBER OF CLAIMS:	59			
EXEMPLARY CLAIM:	1			
LINE COUNT:	1701			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An orally administrable pharmaceutical formulation is provided that combines, as active agents, a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, aspirin, and optionally at least one of vitamin B.sub.6, B.sub.12, and folate; the active agents are each present in a unit dose appropriate for once-daily dosing, and at least one of the active agents is contained in a dosage unit within the dosage form that physically separates it from the other active agents. The formulation is provided as a simple and convenient therapy to reduce the risk of cardiovascular events in individuals who are at elevated cardiovascular risk, including individuals who have systemic lupus erythematosus. The formulation is also therapeutic for individuals during or immediately following an occurrence of acute myocardial infarction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 75 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:330256 USPATFULL  
 TITLE: Use of inhibitors of the renin-angiotensin system  
 INVENTOR(S): Montgomery, Hugh Edward, London, UNITED KINGDOM  
 Martin, John Francis, London, UNITED KINGDOM  
 Erusalimsky, Jorge Daniel, London, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002187939	A1	20021212	<--
	US 7071183	B2	20060704	
APPLICATION INFO.:	US 2002-206659	A1	20020726	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-529628, filed on 15 Jun 2000, PENDING A 371 of International Ser. No. WO 1998-GB3122, filed on 19 Oct 1998, UNKNOWN			

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-22026	19971017
	GB 1998-10855	19980520
	US 1997-67819P	19971205 (60)
	US 1998-94902P	19980731 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SALIWANCIK LLOYD & SALIWANCIK, A PROFESSIONAL ASSOCIATION, 2421 N.W. 41ST STREET, SUITE A-1, GAINESVILLE, FL, 326066669	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1304	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been found that inhibitors of the renin-angiotensin system are useful for the treatment or prevention of conditions associated with

hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(renin-angiotensin system inhibitors for treatment or prevention of a condition associated with hypoxia or impaired metabolic function or efficiency or for enhancing metabolic function)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 76 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:120855 USPATFULL

TITLE: Compositions and methods for treating colorectal polyps and cancer

INVENTOR(S): Tamura, Masaaki, Nashville, TN, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003083339	A1	20030501	<--
APPLICATION INFO.:	US 2002-133056	A1	20020426	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-286621P	20010426 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JENKINS & WILSON, PA, 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	4380	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of decreasing a biological function of an AT.sub.2 receptor in a subject in need thereof is disclosed. The method includes administering an effective amount of a therapeutic agent to the subject to decrease a biological function of an AT.sub.2 receptor. Cancer

therapy, particularly colorectal cancer therapy, by the method is also disclosed.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(comps. and methods for treating colorectal polyps and cancer)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 77 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:113776 USPATFULL

TITLE: In vivo delivery methods and compositions

INVENTOR(S): Kensey, Kenneth, Malvern, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003078517	A1	20030424	<--
APPLICATION INFO.:	US 2001-839785	A1	20010420	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-819924, filed on 28 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, GRANTED, Pat. No. US 6322525 Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, GRANTED, Pat. No. US 6322524 Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, GRANTED, Pat. No. US 6019735			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212			
NUMBER OF CLAIMS:	36			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	19 Drawing Page(s)			
LINE COUNT:	2736			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood

viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(in vivo delivery methods and compns.)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 78 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:79112 USPATFULL  
 TITLE: Tnf-alpha inhibitors  
 INVENTOR(S): Ikeya, Kazuaki, Ikoma-gun, JAPAN  
 Kitayoshi, Takahito, Suita-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055039	A1	20030320
	US 6833381	B2	20041221
APPLICATION INFO.:	US 2002-203805	A1	20020814 (10)
	WO 2001-JP1069		20010215
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1230		


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB TNF- $\alpha$  inhibitors containing a heterocyclic compound having angiotensin II antagonistic activity which are useful as preventives/remedies for inflammatory diseases, etc.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



IT 144701-48-4, Telmisartan  
 (TNF- $\alpha$  inhibitors containing heterocyclic compds. having angiotensin  
 II antagonisms)  
 RN 144701-48-4 USPATFULL  
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-  
 benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 79 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:119847 USPATFULL  
 TITLE: In vivo delivery methods and compositions  
 INVENTOR(S): Kensey, Kenneth R., Malvern, PA, UNITED STATES

	NUMBER	KIND	DATE	
	-----	-----	-----	
PATENT INFORMATION:	US 2002061835	A1	20020523	<--
APPLICATION INFO.:	US 2001-828761	A1	20010409	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, PATENTED Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, PATENTED Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, PATENTED			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOV, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212			
NUMBER OF CLAIMS:	36			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	19 Drawing Page(s)			
LINE COUNT:	2173			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in

combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(methods for in vivo drug delivery based on monitoring blood flow parameters)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 80 OF 113

USPATFULL on STN

ACCESSION NUMBER:

2002:54986 USPATFULL

TITLE:

In vivo delivery methods and compositions

INVENTOR(S):

Kensey, Kenneth, Malvern, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002032149	A1	20020314	<--
APPLICATION INFO.:	US 2001-841389	A1	20010424	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-819924, filed on 28 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, GRANTED, Pat. No. US 6322525 Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, GRANTED, Pat. No. US 6322524 Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, GRANTED, Pat. No. US 6019735			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOW, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212			
NUMBER OF CLAIMS:	36			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	19 Drawing Page(s)			
LINE COUNT:	2747			
CAS INDEXING IS AVAILABLE FOR THIS PATENT.				

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(apparatus and methods for monitoring blood viscosity and other parameters in drug delivery for diagnostics and treatment)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 81 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2001:212586 USPATFULL  
TITLE: In vivo delivery methods and compositions  
INVENTOR(S): Kensey, Kenneth R., Malvern, PA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001044584	A1	20011122	<--
APPLICATION INFO.:	US 2001-819924	A1	20010328	(9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-727950, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-628401, filed on 1 Aug 2000, PENDING Continuation-in-part of Ser. No. US 2000-501856, filed on 10 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-439795, filed on 12 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1997-919906, filed on 28 Aug 1997, GRANTED, Pat. No. US 6019735			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	CAESAR, RIVISE, BERNSTEIN,, COHEN & POKOTILOV, LTD., 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET,			

PHILADELPHIA, PA, 19103-2212


NUMBER OF CLAIMS: 36  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 19 Drawing Page(s)  
LINE COUNT: 2120

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various methods are provided for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment, such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease in combination with administering to a living being at least one pharmaceutically acceptable agent. Agents pharmaceutically effective to regulate at least one of the aforementioned blood parameters are used to adjust distribution of a substance through the bloodstream.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(apparatus and methods for monitoring blood viscosity and other parameters in drug delivery for diagnostics and treatment)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 82 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2002:328709 CAPLUS  
DOCUMENT NUMBER: 137:345373  
TITLE: Angiotensin II receptor antagonists role in arterial hypertension  
AUTHOR(S): Hernandez-Hernandez, R.; Sosa-Canache, B.; Velasco, M.; Armas-Hernandez, M. J.; Armas-Padilla, M. C.; Cammarata, R.  
CORPORATE SOURCE: Clinical Pharmacology Unit, Center of Biomedical Research, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venez.  
SOURCE: Journal of Human Hypertension (2002), 16(Suppl. 1), S93-S99  
CODEN: JHHYEN; ISSN: 0950-9240

PUBLISHER: Nature Publishing Group  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Angiotensin II receptor blockers represent a class of effective and well tolerated orally active antihypertensive drugs. Activation of AT1 receptors leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone and promote growth of vascular and cardiac muscle. AT1 receptor blockers antagonize all those effects. Losartan was the first drug of this class marketed, shortly followed by valsartan, irbesartan, telmisartan, candesartan, eprosartan and others on current investigation. All these drugs have the common properties of blocking the AT1 receptor thereby relaxing vascular smooth muscle, increase salt excretion, decrease cellular hypertrophy and induce antihypertensive effect without modifying heart rate or cardiac output. Most of the AT1 receptor blockers in use controlled blood pressure during the 24 h with a once-daily dose, without evidence of producing tolerance to the antihypertensive effect and being with low incidence of side effects even at long term use. Monotherapy in mild-to-moderate hypertension controls blood pressure in 40 to 50% of these patients; when a low dose of thiazide diuretic is added, 60-70% of patients are controlled. The efficacy is similar to angiotensin-converting enzyme (ACE) inhibitors, diuretics, calcium antagonists and beta-blocking agents. AT1 receptor blockers are specially indicated in patients with hypertension who are being treated with ACE inhibitors and developed side effects such as, cough or angioedema. The final position in the antihypertensive therapy in this special population and other clin. situations, such as left ventricular hypertrophy, heart failure, diabetes mellitus and renal disease, has to be determined in large prospective clin. trials, some of which are now being conducted and seem promising.

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 83 OF 113 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:390956 CAPLUS

DOCUMENT NUMBER: 133:187

TITLE: Angiotensin II receptor antagonists in arterial hypertension

AUTHOR(S): Hernandez-Hernandez, R.; Velasco, M.; Armas-Hernandez, M. J.; Armas-Padilla, M. C.

CORPORATE SOURCE: Clinical Pharmacology Unit, Center of Biomedical Research, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venez.

SOURCE: Journal of Human Hypertension (2000), 14(Suppl. 1), S69-S72

CODEN: JHHYEN; ISSN: 0950-9240

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 34 refs. Angiotensin II receptor antagonists (AT-1) represent a new group of orally active antihypertensive agents. Activation on AT-1 receptor leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone with production of thirst, and promote growth of vascular and cardiac muscle; these effects are blocked by AT-1 antagonist agents. The first chemical useful, orally active AT-1 receptor antagonist was losartan, followed by other agents currently in clin. use, such as: valsartan, eprosartan, irbesartan, telmisartan, candesartan, and many others under investigation. AT-1 receptor antagonists are effective in reducing high blood pressure in hypertensive patients. Monotherapy in mild to moderate hypertension controls blood pressure in 40 to 50% of these patients; when a low dose of a thiazide diuretic is added, 60 to 70% of patients are controlled. The efficacy is similar to angiotensin-converting enzyme inhibitors,

diuretics, calcium antagonists and beta-blocking agents. Tolerability has been reported to be very good. AT-1 receptor antagonists would be a drug of choice in otherwise well-controlled hypertensive patients treated with angiotensin-converting enzyme inhibitors who developed cough or angioedema. The final position in the antihypertensive therapy in this special population and other clin. situations, such as left ventricular hypertrophy, heart failure, diabetes mellitus and renal disease, has to be determined in large prospective clin. trials, some of which are now being conducted.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 84 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:232558 USPATFULL  
TITLE: Aldosterone blocker therapy to prevent or treat inflammation-related disorders  
INVENTOR(S): Rocha, Ricardo, Gurnee, IL, UNITED STATES  
Zack, Marc, Evanston, IL, UNITED STATES  
McMahon, Ellen, Sunset Hills, MO, UNITED STATES  
Blasi, Eileen R., St. Louis, MO, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003162759	A1	20030828	<--
APPLICATION INFO.:	US 2001-916136	A1	20010726	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-221358P	20000727 (60)
	US 2001-261352P	20010112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006	
NUMBER OF CLAIMS:	71	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	55 Drawing Page(s)	
LINE COUNT:	5061	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Aldosterone blockers used for the treatment and prevention of inflammation are disclosed	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 85 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:173961 USPATFULL  
TITLE: Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors  
INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003119809	A1	20030626	<--
	US 7132415	B2	20061107	
APPLICATION INFO.:	US 2002-247095	A1	20020919	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-323942P	20010921 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ,	



07033-0530  
NUMBER OF CLAIMS: 23  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2722

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides therapeutic combinations and methods including at least one sterol or 5 $\alpha$ -stanol absorption inhibitor that can be useful for treating xanthomas.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 86 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2002:322441 USPATFULL  
TITLE: Haplotypes of the AGTR1 gene  
INVENTOR(S): Anastasio, Alison E., New Haven, CT, UNITED STATES  
Finkel, Kevin, Cheshire, CT, UNITED STATES  
Koshy, Beena, North Haven, CT, UNITED STATES  
Lee, Helen, Shelton, CT, UNITED STATES  
PATENT ASSIGNEE(S): Genaissance Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002182605	A1	20021205	<--
	US 6521747	B2	20030218	
APPLICATION INFO.:	US 2001-867915	A1	20010530	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-228542P	20000828 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENAISSANCE PHARMACEUTICALS, 5 SCIENCE PARK, NEW HAVEN, CT, 06511	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	2631	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel genetic variants of the Angiotensin Receptor 1 (AGTR1) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the AGTR1 gene. Compositions and methods for haplotyping and/or genotyping the AGTR1 gene in an individual are also disclosed. Polynucleotides defined by the sequence of the haplotypes disclosed herein are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 87 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2002:119917 USPATFULL  
TITLE: Ethers of 7-desmethyrapamycin  
INVENTOR(S): Zhu, Tianmin, Monroe, NY, UNITED STATES  
Enever, Robin, New City, NY, UNITED STATES  
PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061905	A1	20020523	<--
	US 6440991	B2	20020827	
APPLICATION INFO.:	US 2001-956322	A1	20010919	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-237469P	20001002 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation,  
Patent Law Department - 2B, Five Giralda Farms,  
Madison, NJ, 07940

NUMBER OF CLAIMS: 12  
EXEMPLARY CLAIM: 1  
LINE COUNT: 552

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides ethers of 7-desmethyrapamycin which are useful  
in inducing immunosuppression and in the treatment of transplantation  
rejection, autoimmune diseases, solid tumors, fungal infections, and  
vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 88 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:119916 USPATFULL  
TITLE: Hydroxyesters of 7-desmethyrapamycin  
INVENTOR(S): Zhu, Tianmin, Monroe, NY, UNITED STATES  
Enever, Robin, New City, NY, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061904	A1	20020523	<--
	US 6399626	B2	20020604	
APPLICATION INFO.:	US 2001-955685	A1	20010919	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-237470P	20001002 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	640	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides hydroxyesters of 7-desmethyrapamycin which are  
useful in inducing immunosuppression and in the treatment of  
transplantation rejection, autoimmune diseases, solid tumors, fungal  
infections, and vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 89 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:119915 USPATFULL  
TITLE: 1-oxorapamycins  
INVENTOR(S): Zhu, Tianmin, Monroe, NY, UNITED STATES  
PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ (U.S.  
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061903	A1	20020523	<--
	US 6399625	B2	20020604	
APPLICATION INFO.:	US 2001-954880	A1	20010918	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-235750P	20000927 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation,  
Patent Law Department - 2B, Five Giralda Farms,  
Madison, NJ, 07940  
NUMBER OF CLAIMS: 22  
EXEMPLARY CLAIM: 1  
LINE COUNT: 854

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides 1-oxorapamycins, which are useful in inducing immunosuppression, as a neurotrophic agent, and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 90 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:78778 USPATFULL  
TITLE: Use of angiotensin II receptor antagonists for treating acute myocardial infarction  
INVENTOR(S): Mann, Jessica M., Basel, SWITZERLAND  
Oddou, Pascale, Basel, SWITZERLAND  
Neuhart, Eric Michel, Mulhouse, FRANCE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002042436	A1	20020411	<--
	US 6544968	B2	20030408	
APPLICATION INFO.:	US 2001-915048	A1	20010725	(9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-EP525, filed on 24 Jan 2000, UNKNOWN			


	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-810061	19990126
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	627	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute MI and for the secondary prevention of acute MI.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan  
(angiotensin II receptor antagonists for treating acute myocardial infarction)  
RN 144701-48-4 USPATFULL  
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 91 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:17328 USPATFULL  
 TITLE: Dha-pharmaceutical agent conjugates of taxanes  
 INVENTOR(S): Shashoua, Victor, Brookline, MA, UNITED STATES  
 Swindell, Charles, Merion, PA, UNITED STATES  
 Webb, Nigel, Bryn Mawr, PA, UNITED STATES  
 Bradley, Matthews, Layton, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002010208	A1	20020124 <--
	US 6602902	B2	20030805
APPLICATION INFO.:	US 2001-846838	A1	20010501 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-135291, filed on 17 Aug 1998, ABANDONED Continuation of Ser. No. US 1996-651312, filed on 22 May 1996, GRANTED, Pat. No. US 5795909		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Edward R. Gates, Esq., Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Page(s)		
LINE COUNT:	2437		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 92 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2001:123317 USPATFULL  
 TITLE: Rapidly disintegrable solid preparation  
 INVENTOR(S): Shimizu, Toshihiro, Hyogo, Japan  
 Sugaya, Masae, Osaka, Japan  
 Nakano, Yoshinori, Hyogo, Japan

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001010825	A1	20010802 <--
	US 7070805	B2	20060704

APPLICATION INFO.: US 2001-800839 A1 20010307 (9)  
RELATED APPLN. INFO.: Division of Ser. No. US 1999-403429, filed on 20 Oct  
1999, PENDING A 371 of International Ser. No. WO  
1999-JP4015, filed on 27 Jul 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-213049	19980728
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TAKEDA PHARMACEUTICALS AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1509	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A rapidly disintegrable solid preparation which comprises (i) a  
pharmacologically active ingredient, (ii) a sugar and (iii) a  
low-substituted hydroxypropylcellulose having 5% by weight or more to  
less than 7% by weight of hydroxypropoxyl group. The rapidly  
disintegrable solid preparation has fast disintegrability, suitable  
strength and no roughness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 93 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2001:90260 USPATFULL  
TITLE: Fatty acid-pharmaceutical agent conjugates  
INVENTOR(S): Webb, Nigel L., Bryn Mawr, PA, United States  
Bradley, Matthews O., Laytonsville, MD, United States  
Swindell, Charles S., Merion, PA, United States  
Shashoua, Victor E., Brookline, MA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001002404	A1	20010531	<--
	US 6576636	B2	20030610	
APPLICATION INFO.:	US 2000-730450	A1	20001205	(9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210			
NUMBER OF CLAIMS:	12			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	14 Drawing Page(s)			
LINE COUNT:	2511			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty acids and pharmaceutical  
agents useful in treating noncentral nervous system conditions. Methods  
for selectively targeting pharmaceutical agents to desired tissues are  
provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 94 OF 113 MEDLINE on STN  
ACCESSION NUMBER: 2004085581 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 14974331  
TITLE: [Vascular patient with high infarction risk. Does the AT-1  
blocker protect as well as an ACE inhibitor?].  
Gefasspatient mit hohem Infarkttrisiko. Schutzt der  
AT1-Blocker so gut wie ein ACE-Hemmer?.

AUTHOR: Anonymous  
SOURCE: MMW Fortschritte der Medizin, (2003 Dec 18) Vol.  
145, No. 51-52, pp. 39.  
Journal code: 100893959. ISSN: 1438-3276.  
PUB. COUNTRY: Germany: Germany, Federal Republic of  
DOCUMENT TYPE: (COMPARATIVE STUDY)  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: German  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200404  
ENTRY DATE: Entered STN: 21 Feb 2004  
Last Updated on STN: 28 Apr 2004  
Entered Medline: 27 Apr 2004

L6 ANSWER 95 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:334719 USPATFULL  
TITLE: Oil-containing, orally administrable pharmaceutical  
composition for improved delivery of a therapeutic  
agent  
INVENTOR(S): Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES  
Patel, Mahesh V., Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003235595	A1	20031225	<--
APPLICATION INFO.:	US 2003-397969	A1	20030325	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 Continuation-in-part of Ser. No. US 2000-751968, filed on 29 Dec 2000, GRANTED, Pat. No. US 6458383 Continuation-in-part of Ser. No. US 1999-375636, filed on 17 Aug 1999, GRANTED, Pat. No. US 6309663			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025			
NUMBER OF CLAIMS:	110			
EXEMPLARY CLAIM:	1			
LINE COUNT:	3903			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to oral pharmaceutical compositions and  
methods for improved delivery of therapeutic agents, e.g.,  
lipid-regulating agents. Compositions of the present invention include a  
carrier, where the carrier contains a combination of a triglyceride and  
at least two surfactants, at least one of which is hydrophilic. Upon  
dilution with an aqueous medium, the composition forms a clear, aqueous  
dispersion. The invention also pertains to methods for treating lipid  
disorders such as hypercholesterolemia, hypertriglyceridemia, and mixed  
dyslipidemia by oral administration of the compositions provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 96 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:307001 USPATFULL  
TITLE: Thrombin receptor antagonists  
INVENTOR(S): Chackalamannil, Samuel, Califon, NJ, UNITED STATES  
Clasby, Martin C., Plainsboro, NJ, UNITED STATES  
Greenlee, William J., Teaneck, NJ, UNITED STATES  
Wang, Yuguang, North Brunswick, NJ, UNITED STATES  
Xia, Yan, Edison, NJ, UNITED STATES  
Veltri, Enrico P., Princeton, NJ, UNITED STATES  
Chelliah, Mariappan V., Edison, NJ, UNITED STATES



PATENT ASSIGNEE(S): SCHERING CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003216437	A1	20031120	<--
APPLICATION INFO.:	US 2003-412982	A1	20030414	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-373072P	20020416 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

LINE COUNT: 1651

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heterocyclic-substituted tricyclics of the formula ##STR1##

or a pharmaceutically acceptable salt thereof, wherein:

the dotted line represents an optional single bond;

represents an optional double bond;

n is 0-2;

Q is cycloalkyl, optionally substituted by R.sup.13 and R.sup.14;

R.sup.13 and R.sup.14 are independently selected from (C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.8)cycloalkyl, --OH, (C.sub.1-C.sub.6)alkoxy, R.sup.27-aryl(C.sub.1-C.sub.6)alkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen and haloalkyl; or

R.sup.13 and R.sup.14 together form a spirocyclic or a heterospirocyclic ring of 3-6 atoms;

Het is a mono- or bi-cyclic optionally substituted heteroaryl group; and

B is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 97 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:277178 USPATFULL

TITLE: PDE9 inhibitors for treating cardiovascular disorders

INVENTOR(S): DeNinno, Michael Paul, Gales Ferry, CT, UNITED STATES

Hughes, Bernadette, Sandwich, UNITED KINGDOM

Kemp, Mark Ian, Sandwich, UNITED KINGDOM

Palmer, Michael John, Sandwich, UNITED KINGDOM

Wood, Anthony, Sandwich, UNITED KINGDOM

PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 2003195205 A1 20031016 <--  
APPLICATION INFO.: US 2002-283514 A1 20021030 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-26395	20011102
	GB 2001-30695	20011221
	GB 2002-16761	20020718
	US 2002-350777P	20020122 (60)
	US 2002-399905P	20020730 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1888	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to PDE9 inhibitors for treating cardiovascular disorders. Preferred PDE9 inhibitors are compounds of formula I wherein R.sup.1 is H or C.sub.1-6 alkyl, wherein R.sup.1 is attached to either N.sup.1 or N.sup.2; R.sup.2 is C.sub.1-6 alkyl optionally substituted by hydroxy or alkoxy; C.sub.3-7 cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-membered heterocycle optionally substituted by alkyl, hydroxy or alkoxy; het1 or Ar.sup.1; R.sup.3 is C.sub.1-6 alkyl optionally substituted by 1 or 2 groups independently selected from: Ar.sup.2; C.sub.3-7cycloalkyl optionally substituted by C.sub.1-6alkyl; OAr.sup.2; SAr.sup.2; NHC(O)C.sub.1-6 alkyl; het.sup.2; xanthene; and naphthalene. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 98 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:238541 USPATFULL  
TITLE: Use of angiotensin II receptor antagonists for treating acute myocardial infarction  
INVENTOR(S): Mann, Jessica M., Basel, SWITZERLAND  
Oddou, Pascale, Basel, SWITZERLAND  
Neuhart, Eric Michel, Mulhouse, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166699	A1	20030904 <--
	US 6767905	B2	20040727
APPLICATION INFO.:	US 2003-376049	A1	20030227 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-915048, filed on 25 Jul 2001, GRANTED, Pat. No. US 6544968 Continuation of Ser. No. WO 2000-EP525, filed on 24 Jan 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-810061	19990126
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	626	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute MI and for the

secondary prevention of acute MI.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 144701-48-4, Telmisartan

(angiotensin II receptor antagonists for treating acute myocardial infarction)

RN 144701-48-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl[2,5'-bi-1H-benzimidazol]-3'-yl)methyl]- (CA INDEX NAME)



L6 ANSWER 99 OF 113 USPATFULL on STN

ACCESSION NUMBER: 2003:214427 USPATFULL

TITLE: Method of treating cardiovascular disease

INVENTOR(S): Azrolan, Neal I., Lawrenceville, NJ, UNITED STATES

Sehgal, Surendra N., Snohomish, WA, UNITED STATES

Adelman, Steven J., Doylestown, PA, UNITED STATES

PATENT ASSIGNEE(S): Wyeth, Madison, NJ (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003149070	A1	20030807	<--
	US 6670355	B2	20031230	
APPLICATION INFO.:	US 2002-313217	A1	20021206	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-880295, filed on 13 Jun 2001, ABANDONED			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-212117P	20000616 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WYETH, PATENT LAW GROUP, FIVE GIRALDA FARMS, MADISON, NJ, 07940	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
LINE COUNT:	574	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a method of treating or inhibiting cardiovascular, cerebral vascular, or peripheral vascular disease in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 100 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:173960 USPATFULL  
 TITLE: Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects  
 INVENTOR(S): LeBeaut, Alexandre P., Morristown, NJ, UNITED STATES  
 Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
 PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003119808	A1	20030626	<--
APPLICATION INFO.:	US 2002-246996	A1	20020919	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-324121P	20010921 (60)
	US 2002-351957P	20020125 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3092	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects associated with certain HMG-CoA reductase inhibitors by coadministration of at least one sterol or 5 $\alpha$ -stanol absorption inhibitor, pharmaceutically acceptable salts or solvates thereof, and at least one HMG-CoA reductase inhibitor, the latter being used sparingly in amounts insufficient to cause muscle degeneration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 101 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:173582 USPATFULL  
 TITLE: Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors  
 INVENTOR(S): Davis, Harry R., Berkeley Heights, NJ, UNITED STATES  
 Ress, Rudyard J., Flemington, NJ, UNITED STATES  
 Strony, John T., Lebanon, NJ, UNITED STATES  
 Veltri, Enrico P., Princeton, NJ, UNITED STATES  
 PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003119428	A1	20030626	<--
	US 7053080	B2	20060530	
APPLICATION INFO.:	US 2002-247397	A1	20020919	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-166942, filed on 11 Jun 2002, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-323840P	20010921 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530	

NUMBER OF CLAIMS: 35  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3027

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for the treatment of obesity using sterol or 5 $\alpha$ -stanol absorption inhibitors and compositions and therapeutic combinations including sterol or 5 $\alpha$ -stanol absorption inhibitors and at least one obesity control medication.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 102 OF 113 USPTF on STN  
ACCESSION NUMBER: 2003:110457 USPTF  
TITLE: Method and apparatus for dispensing inhalator medicament  
INVENTOR(S): Johnson, Keith A., Durham, NC, UNITED STATES  
Casper, Robert A., Sanford, NC, UNITED STATES  
Gardner, David L., Chapel Hill, NC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003075172	A1	20030424	<--
APPLICATION INFO.:	US 2002-267013	A1	20021008	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-344544P	20011019 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORRIS, BATEMAN, O'BRYANT & COMPAGNI, 136 SOUTH MAIN STREET, SUITE 700, SALT LAKE CITY, UT, 84101	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	846	

AB An apparatus and method for delivering a plurality of medication includes providing first and second medicament on a medicament pack in separate containers for preventing either medicament from interfering with the stability of the other. In accordance with the method, the medicaments are preferably delivered in a single inhalation.

L6 ANSWER 103 OF 113 USPTF on STN  
ACCESSION NUMBER: 2002:37867 USPTF  
TITLE: Methods for effecting neuroprotection  
INVENTOR(S): Ferguson, Alastair V., Kingston, CANADA  
Bains, Jaideep S., Calgary, CANADA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002022587	A1	20020221	<--
APPLICATION INFO.:	US 2001-817229	A1	20010327	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-192585P	20000328 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1199	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to methods for preventing damage to excitable cells following ischemic by administering to a patient who is undergoing or who has undergone an ischemic event an effective amount of a compound which increases a transient potassium (K<sup>sup.+</sup>) conductance in the excitable cells of the patient. The present invention also provides a method for screening for compounds which increase a transient K<sup>sup.+</sup> current in the excitable cells of a patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 104 OF 113 USPTAFULL on STN  
ACCESSION NUMBER: 2001:173168 USPTAFULL  
TITLE: Solid pharmaceutical preparation  
INVENTOR(S): Shimizu, Toshihiro, Itami, Japan  
Sugaya, Masae, Ikeda, Japan  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan  
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6299904	B1	20011009	<--
	WO 9853798		19981203	<--
APPLICATION INFO.:	US 1999-424434		19991123	(9)
	WO 1998-JP2298		19980526	
			19991123	PCT 371 date
			19991123	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-136724	19970527
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Fubara, Blessing	
LEGAL REPRESENTATIVE:	Chao, Mark, Ramesh, Elaine M.	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	679	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solid preparation which comprises (i) a pharmaceutically active ingredient, (ii) one or more water-soluble sugar alcohols selected from the group consisting of sorbitol, maltitol, reduced starch saccharide, xylitol, reduced palatinose and erythritol, and (iii) low-substituted hydroxypropylcellulose having hydroxypropoxyl group contents of 7.0 to 9.9 percent by weight; which exhibits excellent buccal disintegration and dissolution and also appropriate strength.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 105 OF 113 USPTAFULL on STN  
ACCESSION NUMBER: 2001:119057 USPTAFULL  
TITLE: Solid preparation  
INVENTOR(S): Toshihiro, Shimizu, Osaka, Japan  
Masae, Sugaya, Osaka, Japan

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001009678	A1	20010726	<--
	US 6586004	B2	20030701	
APPLICATION INFO.:	US 2001-800748	A1	20010307	(9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-424434, filed on 23 Nov 1999, PENDING A 371 of International Ser. No. WO 1998-JP2298, filed on 26 May 1998, UNKNOWN			



	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	JP 1997-136724	19970527
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TAKEDA PHARMACEUTICALS AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	705	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solid preparation which comprises (i) a pharmaceutically active ingredient, (ii) one or more water-soluble sugar alcohol selected from the group consisting of sorbitol, maltitol, reduced starch saccharide, xylitol, reduced palatinose and erythritol, and (iii) low-substituted hydroxypropylcellulose having hydroxypropoxyl group contents of 7.0 to 9.9 percent by weight; which exhibits excellent buccal disintegration and dissolution and also appropriate strength.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 106 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 1998:98932 USPATFULL  
 TITLE: DHA-pharmaceutical agent conjugates of taxanes  
 INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States  
 Swindell, Charles S., Merion, PA, United States  
 Webb, Nigel L., Bryn Mawr, PA, United States  
 Bradley, Matthews O., Laytonsville, MD, United States  
 PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States  
 (U.S. corporation)

	NUMBER	KIND	DATE	
	-----	-----	-----	
PATENT INFORMATION:	US 5795909		19980818	<--
APPLICATION INFO.:	US 1996-651312		19960522	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Jarvis, William R. A.			
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.			
NUMBER OF CLAIMS:	12			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)			
LINE COUNT:	2451			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 107 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2003:214415 USPATFULL  
 TITLE: Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders  
 INVENTOR(S): Eisert, Wolfgang, Hannover, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
	-----	-----	-----	
PATENT INFORMATION:	US 2003149058	A1	20030807	<--
APPLICATION INFO.:	US 2003-376072	A1	20030227	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-694610, filed on 23  
Oct 2000, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1999-991211210	19991022
	US 1999-167797P	19991129 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	456	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treatment of the human or non-human animal body for treating  
fibrin-dependent microcirculation disorders is disclosed, for example,  
microcirculation disorders caused by metabolic diseases, inflammatory  
reactions or autoimmune diseases; peripheral microcirculation disorders  
or microcirculation disorders associated with increased cell  
fragmentation comprising administering to a human or non-human animal  
body in need of such treatment an effective amount of a pharmaceutical  
composition containing a pyrimido-pyrimidine selected from dipyridamole,  
mopidamol and the pharmaceutically acceptable salts thereof, and the use  
of said pyrimido-pyrimidine for the manufacture of a corresponding  
pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 108 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2003:85867 USPATFULL  
TITLE: Oral delivery formulation  
INVENTOR(S): Compton, Bruce Jon, Lexington, MA, UNITED STATES  
Solari, Nancy E., West Newton, MA, UNITED STATES  
Flangan, Margaret A., Stow, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003059471	A1	20030327
APPLICATION INFO.:	US 2001-997277	A1	20011129 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-55560, filed on 6 Apr 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69501P	19971215 (60)
	US 1998-73867P	19980204 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Stephen J Gaudet, 68H Stiles Road, Salem, NH, 03079	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2950	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Flakes containing drugs and methods for forming and using such flakes  
are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 109 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2002:323094 USPATFULL  
TITLE: Dipeptide derivatives  
INVENTOR(S): Fink, Cynthia Anne, Lebanon, NJ, UNITED STATES

	NUMBER	KIND	DATE	
	-----	-----	-----	
PATENT INFORMATION:	US 2002183260	A1	20021205	<--
	US 6777443	B2	20040817	
APPLICATION INFO.:	US 2002-142693	A1	20020509	(10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2001-291088P	20010515 (60)
	US 2001-339575P	20011211 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1570	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Compounds of the formula ##STR1##	

wherein R, R.sub.1, COOR.sub.2, R.sub.3-R.sub.7, alk, and X have meaning as defined, such being useful as dual inhibitors of angiotensin converting enzyme and neutral endopeptidase, as well as inhibitors of endothelin converting enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 110 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:32538 USPATFULL  
 TITLE: Treatment for cardiovascular disease  
 INVENTOR(S): Kivlighn, Saluh, Doylestown, PA, UNITED STATES  
 Johnson, Richard, Bellaire, TX, UNITED STATES  
 Mazzali, Marilda, Houston, TX, UNITED STATES  
 PATENT ASSIGNEE(S): Merck & Co., Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
	-----	-----	-----	
PATENT INFORMATION:	US 2002019360	A1	20020214	<--
APPLICATION INFO.:	US 2001-892505	A1	20010628	(9)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2000-214825P	20000628 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	McDERMOTT, WILL & EMERY, 600 13th Street, N.W., Washington, DC, 20005-3096	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	1402	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	This invention relates to a method for treating and preventing hypertension by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment. Additionally, the scope of the invention includes a method of treating coronary heart disease by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 111 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2002:22499 USPATFULL  
 TITLE: Method of treating cardiovascular disease  
 INVENTOR(S): Azrolan, Neal I., Lawrenceville, NJ, UNITED STATES  
 Sehgal, Surendra N., Snohomish, WA, UNITED STATES  
 Adelman, Steven J., Doylestown, PA, UNITED STATES  
 PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ,  
 07054-0874 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002013335	A1	20020131	<--
APPLICATION INFO.:	US 2001-880295	A1	20010613	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-212117P	20000616 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	464	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a method of treating or inhibiting cardiovascular, cerebral vascular, or peripheral vascular disease in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 112 OF 113 USPATFULL on STN  
 ACCESSION NUMBER: 2001:48090 USPATFULL  
 TITLE: Method for reducing pericardial fibrosis and adhesion formation  
 INVENTOR(S): Spinale, Francis G., Charleston, SC, United States  
 de Gasparo, Marc, Rossemaison, Switzerland  
 PATENT ASSIGNEE(S): Novartis AG, Basel, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6211217	B1	20010403	<--
APPLICATION INFO.:	US 1999-270412		19990316	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Spivack, Phyllis G.			
LEGAL REPRESENTATIVE:	Ferraro, Gregory D.			
NUMBER OF CLAIMS:	10			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 3 Drawing Page(s)			
LINE COUNT:	1012			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods of reducing fibrosis and adhesion formation in a surgical patient wherein the AT.sub.1 receptor antagonist, the compound (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine (valsartan) of formula ##STR1##

or a salt thereof, in particular a pharmaceutically acceptable salt thereof, is administered to the patient. In particular, disclosed are methods of reducing pericardial fibrosis and pericardial adhesion formation which results from cardiac surgery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 113 OF 113 USPATFULL on STN  
ACCESSION NUMBER: 2001:21788 USPATFULL  
TITLE: Stabilized pharmaceutical preparation  
INVENTOR(S): Fukuta, Makoto, Nara, Japan  
Itoh, Hiroki, Suita, Japan  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan  
(non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6187340	B1	20010213	<--
APPLICATION INFO.:	US 1998-149122		19980909 (9)	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-245778	19970910
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Williamson, Michael A.	
LEGAL REPRESENTATIVE:	Wenderoth, Lind & Ponack, L.L.P.	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1140	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A stabilized pharmaceutical preparation which is coated with a coating agent comprising an agent for the protection from light, said agent being capable of producing free radicals when exposed to ultraviolet rays, and a free radical scavenger; which is stable to light, especially ultraviolet rays, or heat, and which has excellent storage-stability.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.